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Abstract 
Bax peptide 1c (FLIMGWTLD) and two of its derivatives, 15-mer cyclic peptide 
2c (FLRELIRTIMGWTLD), 13-mer cyclic peptide 3c (FLKSSKIMGWTLD) with 
their linear counterparts (1b, 2b, 3b) were prepared by a head−to−tail 
cyclisation strategy, purified (HPLC), characterised and identified (LCMS). 
Then the mass and concentration of the two derivatives (2c, 3c) with their linear 
counterparts (2b, 3b) were calculated. MS2 mass spectra were used as 
evidence of synthesis of the cyclic peptides from their linear counterparts. 
There was a clear difference between each of the two cyclic peptides and its 
linear counterpart’s mass spectra. A peak appeared for a fragment which has 
the two termini bonded together (Phe−Asp) in the cyclic peptide spectrum (1c, 
2c, 3c) that did not appear in the linear peptide spectrum (1b, 2b, 3b).  
The enzymatic degradation and kinetic study were undertaken for just the 
two derivatives (2c, 3c) with their linear counterparts (2b, 3b) using trypsin and 
chymotrypsin. Compound 1c and its linear counterpart (1b) were excluded from 
these two studies and the stability studies of the peptide in fetal calf serum 
(FCS) medium because the 9-mer cyclic peptide (1c) had very low solubility in 
HPLC solvents and was hydrolysed during storage in the freezer. 
Chymotrypsin cleaved the peptide bond between Trp and Thr but did not 
cleave the peptide bond between Phe and Asp in the 15-mer cyclic peptide (2c) 
and its linear counterpart (2b). Cyclisation of the linear peptide (2b) did not 
improve the stability of the peptide as the t½ of the cyclic peptide (2c) was less 
than the t½ of its linear counterpart (2b). 
Trypsin cleaved the peptide bond between Arg and Thr in the linear 
peptide (2b), while in the cyclic peptide (2c) the cleavage was between Arg and 
Thr in addition to Arg and Glu. Stability of the cyclic peptide (2c) did not improve 
significantly as the t½ of compound 2c increased slightly in comparison to the 
t½ of its linear counterpart (2b). 
The effect of chymotrypsin on the two peptides (3b, 3c) was the same. 
The peptide bond between Trp and Thr was hydrolysed in the two compounds 
(3b, 3c), while between Phe and Leu did not break. Cyclisation of the linear 
peptide (3b) did not improve the stability of the peptide because the t½ of the 
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cyclic peptide (3c) increased slightly in comparison to the t½ of its linear 
counterpart (3b). 
There was significant stability for the cyclic peptide (3c) against trypsin in 
comparison to its linear counterpart (3b). Compound 3c did not hydrolyse for 
30 min, while compound 3b was hydrolysed at the peptide bond between Lys 
and Ile in the first few minutes of the enzymatic hydrolysis.  
The stability of 15-mer cyclic compound (2c) was less than its linear 
counterpart (2b) in the medium of fetal calf serum (FCS) as the t½ of compound 
2c (120 h) was less than the t½ of compound 2b (165 h). In contrast, the stability 
of the 13-mer cyclic compound (3c) was more than its linear counterpart (3b) 
as indicated by the t½ of compound 3c (285 h) that was more than the t½ of 3b 
(110 h). 
  
   
 
vi 
 
Contents 
 Introduction ________________________________________________ 2 
 Motivation _______________________________________________ 2 
 Bax protein ______________________________________________ 3 
 Binding of epitopes with MHC complex and TCR (T cell receptor) ____ 4 
 Cyclic polypeptides in the medical field _________________________ 6 
 The various types of cyclic polypeptides ________________________ 8 
 Protecting groups in peptide synthesis ________________________ 10 
 Main chain protecting groups ____________________________ 11 
 Side chain protecting groups ____________________________ 15 
 Methods to synthesise polypeptides __________________________ 19 
 Cyclisation strategies of linear polypeptides ____________________ 23 
 Head to tail cyclisation _________________________________ 23 
 Side chain−to−side chain cyclisation ______________________ 29 
 Side chain−to−tail cyclisation ____________________________ 31 
 Important factors that affect the synthesis of cyclic polypeptides ____ 32 
 Internal factors _______________________________________ 32 
 External factors _______________________________________ 34 
 Amino acids ____________________________________________ 36 
 Resin _________________________________________________ 38 
 Coupling reagents _______________________________________ 39 
 Cyclic Peptide Synthesis ____________________________________ 44 
 Introduction _____________________________________________ 44 
 Result and discussion of peptide synthesis _____________________ 50 
 Synthesis of the 9-mer linear peptide allyl ester (1a) __________ 50 
 Synthesis of the 15-mer linear peptide allyl ester (2a) _________ 52 
 Synthesis of the 13-mer linear peptide allyl ester (3a) _________ 53 
   
 
vii 
 
 Synthesis of the 9-mer linear peptide (1b) as a precursor for the cyclic 
peptide (1c) ______________________________________________ 55 
 Synthesis of the 15-mer linear peptide (2b) as a precursor for the 
cyclic peptide (2c) _________________________________________ 57 
 Synthesis of the 13-mer linear peptide (3b) as a precursor for the 
cyclic peptide (3c) _________________________________________ 58 
 Results and discussion of cyclisation reaction __________________ 60 
 Synthesis of the 9-mer cyclic peptide (1c) __________________ 60 
 Synthesis of the 15-mer cyclic peptide (2c) _________________ 63 
 Synthesis of the 13-mer cyclic peptide (3c) _________________ 65 
 Synthesis of the linear peptide (2b, 3b) _______________________ 69 
 Synthesis of the 15-mer linear peptide (2b) _________________ 69 
 Synthesis of the 13-mer linear peptide (3b) _________________ 70 
 Results of calculation of the concentration of polypeptides ________ 72 
 Introduction __________________________________________ 72 
 The 9-mer cyclic polypeptide (1c) _________________________ 73 
 The 9-mer linear peptide (1b) ____________________________ 74 
 The 15-mer cyclic peptide (2c) ___________________________ 74 
 Results of peptide fragmentation _____________________________ 76 
 Introduction __________________________________________ 76 
 Comparison between fragmentation of the 9-mer cyclic peptide (1c) 
and its linear counterpart (1b) ________________________________ 80 
 Comparison between fragmentation of the 15-mer cyclic peptide (2c) 
and its linear counterpart (2b) ________________________________ 83 
 Comparison between fragmentation of the 13-mer cyclic (3c) peptide 
and its linear counterpart (3b) ________________________________ 87 
 Biological studies of the peptides ____________________________ 92 
 Introduction _____________________________________________ 92 
   
 
viii 
 
 Results and discussion of the study of enzymatic degradation of peptides
 __________________________________________________________ 92 
 Results of calculation of the concentration of trypsin and 
chymotrypsin _____________________________________________ 92 
 Results of the study of the activity of trypsin and chymotrypsin __ 94 
 Enzymatic degradation and kinetic study of the 15-mer linear peptide 
(2b) in the presence of chymotrypsin __________________________ 95 
 Enzymatic degradation and kinetic study of the 15-mer cyclic peptide 
(2c) in the presence of chymotrypsin and the comparison with its linear 
counterpart (2b) ___________________________________________ 99 
 Enzymatic degradation and kinetic study of the 15-mer linear peptide 
(2b) in the presence of trypsin _______________________________ 105 
 Enzymatic degradation and kinetic study of the 15-mer cyclic peptide 
(2c) in the presence of trypsin and the comparison with its linear 
counterpart (2b) __________________________________________ 110 
 Enzymatic degradation and kinetic study of the 13-mer linear peptide 
(3b) in the presence of chymotrypsin _________________________ 116 
 Enzymatic degradation and kinetic study of the 13-mer cyclic peptide 
(3c) in the presence of chymotrypsin and the comparison with its linear 
counterpart (3b) __________________________________________ 121 
 Enzymatic degradation and kinetic study of the 13-mer linear peptide 
(3b) in the presence of trypsin _______________________________ 126 
 Enzymatic degradation and kinetic study of the 13-mer cyclic 
peptide in the presence of trypsin and the comparison with its linear 
counterpart (3b) __________________________________________ 131 
 Stability of the peptides in fetal calf serum ____________________ 136 
 Introduction ____________________________________________ 136 
 Stability of the 15-mer linear peptide (2b) in 20% FCS ___________ 136 
 Stability of the 15-mer cyclic peptide (2c) in 20% FCS ___________ 139 
 Stability of the 13-mer linear peptide (3b) in 20% FCS ___________ 143 
 Stability of the 13-mer cyclic peptide (3c) in 20% FCS ___________ 145 
   
 
ix 
 
 Conclusion ______________________________________________ 151 
 Conclusion _____________________________________________ 151 
 Synthesis of peptides _________________________________ 151 
 Enzymatic degradation and kinetic study __________________ 155 
 Stability of the peptides (2b, 2c, 3b, 3c) in fetal calf serum (FCS)
 _______________________________________________________ 157 
 Future work ____________________________________________ 158 
 Methods _________________________________________________ 160 
 Analytical methods ______________________________________ 160 
 RP−HPLC __________________________________________ 160 
 LC−MS ____________________________________________ 160 
 Glass and plasticware _________________________________ 160 
 Chemicals __________________________________________ 161 
 Instruments _________________________________________ 161 
 Method to synthesise the cyclic peptide and their linear counterparts161 
 Method to synthesise the linear peptide allyl esters (1a, 2a, 3a) 161 
 Method to deprotect the allyl ester from the C−terminus ______ 162 
 Cyclisation of the linear peptide (1c, 2c, 3c) _______________ 163 
 Method to synthesise linear peptide (1b, 2b, 3b) ____________ 163 
 Cleavage of the cyclised peptide ________________________ 164 
 HPLC purification of the peptides ___________________________ 164 
 Fragmentation of the peptides ______________________________ 166 
 Preparation of the buffer solution ___________________________ 167 
 Calculating the concentration of the peptides (2b, 2c, 3b, 3c) _____ 167 
 The 13-mer cyclic peptide (3c) __________________________ 167 
 The 13-mer linear peptide (3b) __________________________ 167 
 The 15-mer cyclic peptide (2c) and its linear counterpart (2b) __ 168 
   
 
x 
 
 Calculation of the percentage yield of the peptides (2b, 2c, 3b, 3c)
 _______________________________________________________ 168 
 Calculation of the concentration of the enzymes ________________ 168 
 Preparation of the BSA solution ____________________________ 169 
 Checking the activity of the enzymes ________________________ 169 
 Activity of the chymotrypsin ____________________________ 169 
 Activity of the trypsin __________________________________ 169 
 Enzymatic degradation and kinetics for the hydrolysis of peptides _ 169 
 Enzymatic degradation and calculation of the t½ of 13-mer linear 
peptide (3b) in the presence of chymotrypsin ___________________ 169 
 Enzymatic degradation and calculation of the t½ of the 13-mer cyclic 
peptide (3c) in the presence of chymotrypsin ___________________ 170 
 Enzymatic degradation and calculation of the t½ of the 13-mer linear 
peptides (3b) in the presence of trypsin _______________________ 171 
 Enzymatic degradation and calculation of the t½ of the 13-mer cyclic 
peptide (3c) in the presence of trypsin ________________________ 171 
 Enzymatic degradation and calculation of the t½ of the 15-mer linear 
peptide (2b) in the presence of chymotrypsin ___________________ 171 
 Enzymatic degradation and calculation of the t½ of the 15-mer cyclic 
peptide (2c) in the presence of chymotrypsin ___________________ 172 
 Enzymatic degradation and calculation of the t½ of the 15-mer linear 
peptide (2b) in the presence of trypsin ________________________ 172 
 Enzymatic degradation and calculation of the t½ of the 15-mer cyclic 
peptide (2c) in the presence of trypsin ________________________ 173 
 General procedures to study the stability of the peptides (2b, 3b, 2c, 
3c) in fetal calf serum (FCS) __________________________________ 173 
 Preparation of 20% FCS solution _______________________ 173 
 Studying the stability of the 13-mer linear peptide (3b) in the 
presence of FCS _________________________________________ 173 
   
 
xi 
 
 Studying the stability of the 13-mer cyclic peptide (3c) in the 
presence of FCS _________________________________________ 174 
 Studying the stability of the 15-mer linear peptide (2b) in the 
presence of FCS _________________________________________ 174 
 Studying the stability of the 15-mer cyclic peptide (2c) in the 
presence of FCS _________________________________________ 175 
 General procedure to calculate the t½ of the peptides (2b, 2c, 3b, 
3c) in the presence of FCS _________________________________ 175 
 References ______________________________________________ 177 
 Appendix A ______________________________________________ 190 
 Appendix B ______________________________________________ 206 
 Appendix C ______________________________________________ 242 
 
  
   
 
xii 
 
List of Figures 
Figure 1.1: Structure of major histocompatibility complex class I (MHC).16 ......... 5 
Figure 1.2: A-homodetic cyclic peptide, B-heterodetic cyclic peptide, C-complex 
cyclic peptide, D-Cyclotides (Kalata B1). ............................................................. 9 
Figure 1.3: Structure of bactenecin (A), cyclosporin A (B), largamide (C). .........10 
Figure 1.4: Structure of Cbz (carbobenzoxy) protecting group. ..........................11 
Figure 1.5: Structure of Troc (A), Bpoc (B), Nps (C) protecting groups attached to 
an amino acid. ....................................................................................................12 
Figure 1.6: Dmab protecting group structure. ....................................................15 
Figure 1.7: Three types of arginine protecting group..........................................16 
Figure 1.8: Structure of Lys(ivDde)-OH (A) and Lys(Dde)-OH (B). .....................17 
Figure 1.9: Types of cysteine protecting group. .................................................18 
Figure 1.10: General structure of cyclic peptide via a lactam bond. ...................30 
Figure 1.11: General structure of cyclic peptide via a disulfide bond. .................30 
Figure 1.12: Formation of a cyclic structure by two serine residues that are 
esterified to a dicarboxylic acid. ..........................................................................31 
Figure 1.13: Types of additives to prevent racemisation. ...................................35 
Figure 1.14: L and D-isomers of amino acid. .....................................................37 
Figure 1.15: Types of coupling reagents. ...........................................................40 
Figure 2.1: Location of peptide IMGWTLDFL in the Bax protein (1F16) 
highlighted in yellow.171 ......................................................................................45 
Figure 2.2: Structure of compounds 1a, 2a and 3a. ...........................................47 
Figure 2.3: Sequences of 1c, 2c and 3c. ...........................................................48 
Figure 2.4: A = Structure of Fmoc-Asp (NovaSyn® TGA)-OAll. B = Structure of 
Fmoc-Trp(Boc)-Thr(psiMe, Mepro)-OH. .............................................................50 
Figure 2.5: HPLC chromatogram of 9-mer crude linear peptide allyl ester (1a). .51 
Figure 2.6: Total ion chromatogram of 9-mer purified linear peptide allyl ester 
(1a) ([M+H]+ m/z = 1135.5), collected peak at 22.53 min in Figure 2.5). .............51 
Figure 2.7: Structure of 9-mer linear peptide allyl ester (1a) in the +1 charge 
state (m/z = 1135.5). ..........................................................................................52 
Figure 2.8: HPLC chromatogram of 15-mer crude linear peptide allyl ester (2a).
 ...........................................................................................................................52 
Figure 2.9: Total ion chromatogram of 15-mer crude linear peptide allyl ester (2a) 
([M+2H]2+ m/z = 952.5). ......................................................................................53 
Figure 2.10: Structure of 15-mer linear peptide allyl ester (2a) in the +2 charge 
state (m/z = 952.5). ............................................................................................53 
   
 
xiii 
 
Figure 2.11: HPLC chromatogram of 13-mer crude linear peptide allyl ester (3a).
 ...........................................................................................................................54 
Figure 2.12: Total ion chromatogram of 13-mer crude linear peptide allyl ester 
(3a) ([M+3H]3+ m/z = 522.6). ...............................................................................54 
Figure 2.13: Structure of 13-mer linear peptide allyl ester (3a) in the +3 charge 
state (m/z = 522.6). ............................................................................................55 
Figure 2.14: HPLC chromatogram of 9-mer crude linear peptide (1b). ..............55 
Figure 2.15: Total ion chromatogram of 9-mer crude linear peptide (1b) ([M+H]+ 
m/z = 1095.6). ....................................................................................................56 
Figure 2.16: Structure of 9-mer linear peptide (1b) in the +1 charge state (m/z = 
1095.6). ..............................................................................................................56 
Figure 2.17: HPLC chromatogram of 15-mer purified linear peptide (2b). ..........57 
Figure 2.18: Total ion chromatogram of 15-mer purified linear peptide (2b) 
([M+3H]3+ m/z = 622.0). ......................................................................................57 
Figure 2.19: Structure of 15-mer linear peptide (2b) in the +3 charge state (m/z = 
622.0). ................................................................................................................58 
Figure 2.20: HPLC chromatogram of 13-mer crude linear peptide (3b)..............58 
Figure 2.21: Total ion chromatogram of 13-mer crude linear peptide (3b) 
([M+3H]3+ m/z = 509.3). ......................................................................................59 
Figure 2.22: Structure of 13-mer linear peptide (3b) in the +3 charge state (m/z = 
509.3). ................................................................................................................59 
Figure 2.23: HPLC chromatogram of 9-mer purified cyclic peptide (1c). ............61 
Figure 2.24: Total ion chromatogram of 9-mer purified cyclic peptide (1c) ([M−H]− 
m/z = 1075.5). ....................................................................................................62 
Figure 2.25: Structure of 9-mer cyclic peptide (1c) in the −1 charge state (m/z = 
1075.5). ..............................................................................................................62 
Figure 2.26: HPLC chromatogram of 15-mer purified cyclic peptide (2c). ..........64 
Figure 2.27: Total ion chromatogram of 15-mer purified cyclic peptide (2c) 
([M+2H]2+ m/z = 923.5). ......................................................................................64 
Figure 2.28: Structure of 15-mer cyclic peptide (2c) in the +2 charge state (m/z = 
923.5). ................................................................................................................65 
Figure 2.29: HPLC chromatogram of 13-mer purified cyclic peptide (3c). ..........66 
Figure 2.30: Total ion chromatogram of 13-mer purified cyclic peptide (3c) 
([M+2H]2+ m/z = 754.4). ......................................................................................67 
Figure 2.31: Structure of 13-mer cyclic peptide (3c) in the +2 charge state (m/z = 
754.4). ................................................................................................................67 
Figure 2.32: HPLC chromatogram of 15-mer purified linear peptide (2b). ..........69 
   
 
xiv 
 
Figure 2.33: Total ion chromatogram of 15-mer purified linear peptide (2b) 
([M+3H]3+ m/z = 622.0). ......................................................................................70 
Figure 2.34: HPLC chromatogram of 13-mer purified linear peptide (3b). ..........70 
Figure 2.35: Total ion chromatogram of 13-mer purified linear peptide (3b) 
([M+3H]3+ m/z = 509.5). ......................................................................................71 
Figure 2.36: HPLC chromatogram of 9-mer purified cyclic peptide (1c) after 15 
days’ storage in the freezer at −20 °C. ...............................................................73 
Figure 2.37: Total ion chromatogram of 9-mer purified cyclic peptide (1c) after 15 
days’ storage in the freezer at −20 °C, ([M+H]+ m/z = 1077.5). ...........................74 
Figure 2.38: MS2 mass spectrum of 9-mer cyclic peptide (1c) precursor (m/z = 
1077). .................................................................................................................80 
Figure 2.39: MS2 mass spectrum of 9-mer linear peptide (1b) precursor (m/z = 
1095.7). ..............................................................................................................82 
Figure 2.40: MS2 mass spectrum of 15-mer cyclic peptide (2c) precursor (m/z = 
924.0). ................................................................................................................84 
Figure 2.41: MS2 mass spectrum of 15-mer linear peptide (2b) precursor (m/z = 
933.0). ................................................................................................................86 
Figure 2.42: MS2 mass spectrum of purified 13-mer cyclic peptide (3c) precursor 
(m/z = 754.9). .....................................................................................................87 
Figure 2.43: MS2 mass spectrum of purified 13-mer linear peptide (3b) precursor 
(m/z = 509.6). .....................................................................................................89 
Figure 3.1: Calibration graph of the protein standard (BSA)...............................93 
Figure 3.2: HPLC chromatograms of the reaction between 25 µL of chymotrypsin 
(1.06 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 8.6 for 0 and 30 min. .....96 
Figure 3.3: Total ion chromatogram of 15-mer linear peptide (2b) in the presence 
of chymotrypsin at 10 °C and pH 8.6 for 20 min. ................................................97 
Figure 3.4: Suggested structure of peptide 2b1 (348.2 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 15-mer linear peptide (2b) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. .................................97 
Figure 3.5: Enzymatic hydrolysis of 15-mer linear peptide (2b) by chymotrypsin 
at 10 °C and pH 8.6. ...........................................................................................99 
Figure 3.6: HPLC chromatograms of the reaction between 25 µL of chymotrypsin 
(1.06 µM) and 250 µL of 2c (100 µM) at 10 °C and pH 8.6 at 0 and 20 min. ..... 100 
Figure 3.7: Total ion chromatogram of 15-mer cyclic peptide (2c) in the presence 
of chymotrypsin at 10 °C and pH 8.6 for 20 min. .............................................. 100 
Figure 3.8: Suggested structure of peptide (m/z = 923.5) in the +2 charge state 
produced from 15-mer cyclic peptide (2c) by trypsin catalysed hydrolysis of the 
   
 
xv 
 
peptide bond between Asp and Phe with elimination of one water molecule from 
one of the threonine residues. .......................................................................... 101 
Figure 3.9: Suggested structure of peptide 2c1 (m/z = 923.5,) in the +2 charge 
state produced from cyclic peptide (2c) by chymotrypsin catalysed hydrolysis of 
the peptide bond between Thr and Trp with elimination of a water molecule from 
one of the threonine residues. .......................................................................... 102 
Figure 3.10: Enzymatic hydrolysis of 15-mer cyclic peptide (2c) by chymotrypsin 
at 10 °C and pH 8.6. ......................................................................................... 104 
Figure 3.11: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 6.2 for 0, 8, 15 min. ..... 106 
Figure 3.12: Total ion chromatogram of 15-mer linear peptide (2b) in the 
presence of trypsin at 10 °C and pH 6.2 for 20 min. ......................................... 107 
Figure 3.13: Suggested structure of peptide 2b4 (936.4 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 15-mer linear peptide (2b) by trypsin at 
10 °C and pH 6.2 for 20 min. ............................................................................ 107 
Figure 3.14: Enzymatic hydrolysis of 15-mer linear peptide (2b) by trypsin at 10 
°C and pH 6.2. ................................................................................................. 109 
Figure 3.15: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 2c (100 µM) at 10 °C and the pH 6.2 for 0, 2, 30 min.111 
Figure 3.16: Total ion chromatogram of 15-mer cyclic peptide (2c) after its 
digestion by trypsin at 10 °C and pH 6.2 for 20 min. ......................................... 112 
Figure 3.17: Suggested structure of peptide 2c2 (676.9 m/z) in the +2 charge 
state produced by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the 
presence of trypsin where the peptide bonds between Arg and Thr, Arg and Glu 
were cleaved. ................................................................................................... 113 
Figure 3.18: Suggested structure of peptide 2c3 (m/z = 530.3) in the +1 charge 
state produced by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the 
presence of trypsin where the peptide bonds between Arg and Thr, Arg and Glu 
were cleaved. ................................................................................................... 114 
Figure 3.19: Structure of 15-mer linear peptide (2b) in the +3 charge state (m/z = 
622.0). .............................................................................................................. 114 
Figure 3.20: Enzymatic hydrolysis of 15-mer cyclic peptide (2c) by trypsin at 10 
°C and pH 6.2. ................................................................................................. 115 
Figure 3.21: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 13-mer linear peptide (3b) (200 µM) at 10 
°C and the pH 8.6 for 0, 4, 30 min. ................................................................... 117 
   
 
xvi 
 
Figure 3.22: Total ion chromatogram of 13-mer linear peptide (3b) after digestion 
by chymotrypsin at 10 °C and pH 8.6 for 20 min............................................... 118 
Figure 3.23: Suggested structure of peptide 3b1 (399.6 m/z) in the +3 charge 
state produced by enzymatic hydrolysis of 13-mer linear peptide (3b) in the 
presence of chymotrypsin where the peptide bond between Trp and Thr was 
cleaved............................................................................................................. 119 
Figure 3.24: Enzymatic hydrolysis of 13-mer linear peptide (3b) by chymotrypsin 
at 10 °C and pH 8.6. ......................................................................................... 121 
Figure 3.25: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 3c (200 µM) at 10 °C and pH 8.6 for 0, 4, 
20 min. ............................................................................................................. 122 
Figure 3.26: Total ion chromatogram of 13-mer cyclic peptide (3c) after its 
digestion with chymotrypsin at 10 °C and pH 8.6 for 20 min. ............................ 123 
Figure 3.27: Suggested structure of peptide 3c1 (763.4 m/z) in the +2 charge 
state produced by enzymatic hydrolysis of 3c in the presence of chymotrypsin 
where the peptide bond between Trp and Thr was cleaved. ............................. 123 
Figure 3.28: Enzymatic hydrolysis of 13-mer cyclic peptide (3c) in the presence 
of chymotrypsin at 10 °C and pH 8.6. ............................................................... 125 
Figure 3.29: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 3b (200 µM) at 10 °C and the pH 6.2 over 0, 8 and 20 
min. .................................................................................................................. 127 
Figure 3.30: Total ion chromatogram of 13-mer linear peptide (3b) during 
digestion by trypsin at 10 °C and pH 6.2 for 20 min. ......................................... 128 
Figure 3.31: Suggested structure of peptide 3b4 (835.4 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 3b in the presence of trypsin where 
the peptide bond between Lys and Ile was cleaved. ......................................... 128 
Figure 3.32: Suggested structure of peptide 3b3 (709.4 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 13-mer linear peptide (3b) in the 
presence of trypsin where the peptide bond between Lys and Ile was cleaved.
 ......................................................................................................................... 130 
Figure 3.33: Enzymatic hydrolysis of 13-mer linear peptide (3b) by trypsin at 10 
°C and pH 6.2. ................................................................................................. 131 
Figure 3.34: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 3c (200 µM) with an internal standard (IS) at 10 °C and 
the pH 6.2 for 0, 30 min. ................................................................................... 132 
Figure 3.35: Structure of 13-mer cyclic peptide (3c) in the +2 charge state (m/z = 
754.4). .............................................................................................................. 133 
   
 
xvii 
 
Figure 3.36: HPLC chromatograms of 13-mer cyclic peptide (3c) and its linear 
counterpart (3b) during their digestion with trypsin at 0, 20 min for 3b and 0, 30 
min for 3c. ........................................................................................................ 134 
Figure 4.1: Stability of 15-mer linear peptide (2b) in 20% FCS at 37 °C and pH 
7.4 (Replicate 1, 2, 3). ...................................................................................... 138 
Figure 4.2: Stability of 15-mer cyclic peptide (2c) in 20% FCS at 37 °C and pH 
7.4 (Replicate 1, 2, 3). ...................................................................................... 141 
Figure 4.3: Stability of 13-mer linear peptide (3b) in 20% FCS at 37 °C and pH 
7.4 (Replicates 1, 2, 3). .................................................................................... 144 
Figure 4.4: Stability of 13-mer cyclic peptide (3c) in 20% FCS at 37 °C and pH 
7.4 (Replicates 1, 2, 3). .................................................................................... 147 
 
  
   
 
xviii 
 
List of Schemes 
Scheme 1.1: The function of Bax in the apoptosis pathway. ............................... 3 
Scheme 1.2: N-protected dipeptide (benzoyl glycylglycine) formation. ...............11 
Scheme 1.3: Introduction of Fmoc group into an amino acid..............................12 
Scheme 1.4: Mechanism of Fmoc group removal by piperidine. ........................13 
Scheme 1.5: Introducing Boc protecting group to the N-terminus of the amino 
acid. ...................................................................................................................13 
Scheme 1.6: Mechanism of the Boc protecting group cleavage. ........................14 
Scheme 1.7: Protection of C-terminus as an allyl ester. .....................................14 
Scheme 1.8: Deprotection of allyl protecting group by palladium catalyst. .........15 
Scheme 1.9: Homoserine lactone formation after methionine alkylation. ...........17 
Scheme 1.10: β-elimination of protected cysteine at the C-terminus. .................18 
Scheme 1.11: α and β-peptide formation resulting from aspartimide formation. .19 
Scheme 1.12: Peptide bond formation reaction. ................................................19 
Scheme 1.13: Solution phase synthesis (SPS) fragment coupling method to 
synthesise a polypeptide. ...................................................................................20 
Scheme 1.14: General scheme for synthesis of polypeptide using the solid phase 
Fmoc strategy. ...................................................................................................21 
Scheme 1.15: Principle of native chemical ligation (NCL) reaction. ....................25 
Scheme 1.16: General mechanism of protein splicing by an intein. ...................27 
Scheme 1.17: Mechanism of the Staudinger ligation mediated by phosphinothiol.
 ...........................................................................................................................28 
Scheme 1.18: Click chemistry procedure. ..........................................................29 
Scheme 1.19: Cyclisation of the linear peptide via the radical addition of the thiol 
group in the cysteine to the alkene group. ..........................................................31 
Scheme 1.20: Amino acids categorised according to polarity. ...........................37 
Scheme 1.21: General scheme for the coupling reaction. ..................................39 
Scheme 1.22: Dicyclohexylurea formation using the reagent DCC. ...................41 
Scheme 1.23: Racemisation of a protected amino acid using DCC or DIC as a 
coupling reagent. ................................................................................................41 
Scheme 2.1: General procedure to synthesise of the cyclic peptide (1c) by the 
head to tail method. ............................................................................................47 
Scheme 2.2: Mechanism of peptide fragmentation using the CID method. ........77 
Scheme 2.3: Loss of ammonia from lysine-containing peptide forming a stable 
caprolactam derivative. ......................................................................................77 
   
 
xix 
 
Scheme 2.4: Caprolactam derivative formed from lysine without loss of ammonia.
 ...........................................................................................................................78 
Scheme 2.5: Loss of ammonia from arginine-containing peptide. ......................78 
Scheme 2.6: Caprolactam derivative formed by Arg side chain without loss of 
ammonia. ...........................................................................................................79 
Scheme 2.7: Loss of water from Ser-containing peptide. ...................................79 
Scheme 2.8: Formation of a stable cyclic anhydride from an Asp residue. .........79 
Scheme 2.9: Possible sites of cleaved peptide bonds during fragmentation of 9-
mer cyclic peptide (1c) by MS2 to result in the fragment of 946.6 m/z (b8, b8-H2O) 
which has a bond between F and D. ..................................................................82 
Scheme 2.10: Possible sites of cleaved peptide bonds in the 15-mer cyclic 
peptide (2c) during fragmentation by MS2 to produce the fragment of MH2-NH3 
(915.0 m/z) which has a bond between F and D. ................................................85 
Scheme 2.11: Possible sites of cleaved peptide bonds during fragmentation of 
13-mer cyclic peptide (3c) by MS2 to result in the fragment of 617.0 m/z (b5, y5) 
which has a bond between F and D. ..................................................................88 
Scheme 3.1: Site of the peptide bond in 15-mer linear peptide (2b) that is 
cleaved by chymotrypsin at 10 °C and pH 8.6 for 20 min. ..................................97 
Scheme 3.2: Site of the cleaved peptide bond in 15-mer cyclic peptide (2c) by 
chymotrypsin at 10 °C and pH 8.6 for 20 min. .................................................. 102 
Scheme 3.3: Site of the peptide bond in the 15-mer linear peptide (2b) that is 
cleaved by trypsin at 10 °C and pH 6.2 for 20 min. ........................................... 107 
Scheme 3.4: Sites of the peptide bonds in the 15-mer cyclic peptide (2c) that are 
cleaved by trypsin at 10 °C and pH 6.2 for 20 min. ........................................... 112 
Scheme 3.5: Site of the peptide bond (Trp−Thr) cleaved by chymotrypsin in the 
13-mer linear peptide (3b) at 10 °C and pH 8.6 for 20 min. .............................. 118 
Scheme 3.6: Site of the peptide bond (Trp−Thr) cleaved by chymotrypsin in the 
13-mer cyclic peptide (3c) at 10 °C and pH 8.6 for 20 min. .............................. 123 
Scheme 3.7: Site of the peptide bond (Lys−Ile) cleaved by trypsin in the 13-mer 
linear peptide (3b) at 10 °C and pH 6.2 for 20 min. .......................................... 128 
  
   
 
xx 
 
List of Tables 
Table 1.1: Name and structure of some common resin linkers. ..........................38 
Table 2.1: Attempts at cyclising 1b under different conditions. ...........................61 
Table 2.2: Comparison between the three cyclic peptides (1c, 2c, 3c). .............68 
Table 2.3: Properties of the two synthesised linear peptides (2b, 3b). ...............72 
Table 2.4: The value of concentration, weight, number of moles, and the 
percentage yield of the peptides (2b, 2c, 3b, 3c) in their stock solutions. ...........75 
Table 2.5: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 9-mer cyclic peptide (1c). (See Figure 2.38)
 ...........................................................................................................................81 
Table 2.6: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 9-mer linear peptide (1b). (See Figure 2.39).
 ...........................................................................................................................83 
Table 2.7: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 15-mer cyclic peptide (2c). (See Figure 2.40).
 ...........................................................................................................................84 
Table 2.8: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 15-mer linear peptide (2b). (See Figure 2.41).
 ...........................................................................................................................86 
Table 2.9: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 13-mer cyclic peptide (3c). (See Figure 2.42).
 ...........................................................................................................................87 
Table 2.10: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 13-mer linear peptide (3b). (See Figure 2.43).
 ...........................................................................................................................89 
Table 3.1: Absorbance at 595 nm for the different concentrations of standard 
protein (BSA) with Bradford reagent. ..................................................................93 
Table 3.2: Concentration of trypsin and chymotrypsin in 200 µL (C1) and the 
stock solution (C2) with the mean of C2. ..............................................................94 
Table 3.3: The comparison between theoretically calculated peaks and the 
observed CID fragments of precursor ion 348.1 m/z, (peptide 2b1) produced by 
hydrolysis of 15-mer linear peptide (2b) in the presence of chymotrypsin (See 
Figure B.6 in Appendix B). .................................................................................98 
Table 3.4: Areas of 15-mer linear peptide (2b) peaks in the HPLC 
chromatograms during its digestion with chymotrypsin at 10 °C and pH 8.6. ......98 
   
 
xxi 
 
Table 3.5: t½ of 15-mer linear peptide (2b) during incubation with chymotrypsin at 
10 °C and pH 8.6, including the rate constant (k min−1) and the standard error 
(SE). ...................................................................................................................99 
Table 3.6: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 924.0 m/z (peptide 2c1) produced 
by hydrolysis of 15-mer cyclic peptide (2c) by chymotrypsin (See Figure B.8 in 
Appendix B). .................................................................................................... 103 
Table 3.7: Areas of 15-mer cyclic peptide (2c) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. ........ 104 
Table 3.8: t½ of 15-mer cyclic peptide (2c) during incubation with chymotrypsin at 
10 °C and pH 8.6 including rate constant (k min−1) and the standard error (SE).
 ......................................................................................................................... 104 
Table 3.9: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 936.6 m/z (peptide 2b4) produced 
by trypsin digestion of 2b (Figure B.10 in Appendix B). .................................... 108 
Table 3.10: Areas of 15-mer linear peptide (2b) peaks in the HPLC 
chromatograms during trypsin digestion at 10 °C and pH 6.2. .......................... 109 
Table 3.11: t½ of 15-mer linear peptide (2b) in the presence of trypsin at 10 °C 
and pH 6.2, including the rate constant (k min−1) and the standard error (SE). . 109 
Table 3.12: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 676.6 m/z (peptide 2c2) produced 
by enzymatic hydrolysis of 2c in the presence of trypsin (See Figure B.12 in 
Appendix B). .................................................................................................... 113 
Table 3.13: Areas of 15-mer cyclic peptide (2c) peaks in the HPLC 
chromatograms during digestion with trypsin at 10 °C and pH 6.2. ................... 115 
Table 3.14: t½ of 15-mer cyclic peptide (2c) during digestion with trypsin at 10 °C 
and pH 6.2, including the value of rate the constant (k min−1) and the standard 
error (SE). ........................................................................................................ 116 
Table 3.15: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 399.6 m/z (peptide 3b1) produced 
by enzymatic hydrolysis of 13-mer linear peptide (3b) in the presence of 
chymotrypsin (See Figure B.16 in Appendix B). ............................................... 119 
Table 3.16: Areas of 13-mer linear peptide (3b) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. ........ 120 
Table 3.17: t½ of 13-mer linear peptide (3b) during digestion with chymotrypsin at 
10 °C and pH 8.6, including the value of the rate constant (k min−1) and the 
standard error (SE). ......................................................................................... 121 
   
 
xxii 
 
Table 3.18: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 763.5 m/z (peptide 3c1) produced 
by enzymatic hydrolysis of 3c in the presence of chymotrypsin (See Figure B.18 
in Appendix B). ................................................................................................. 124 
Table 3.19: Areas of 13-mer cyclic peptide (3c) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. ........ 125 
Table 3.20: t½ of 13-mer cyclic peptide (3c) during digestion with chymotrypsin at 
10 °C and pH 8.6, including value of rate constant (k min−1) and the standard 
error (SE). ........................................................................................................ 125 
Table 3.21: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 835.6 m/z (peptide 3b4) produced 
by enzymatic hydrolysis of 3b by trypsin (See Figure B.20 in Appendix B). ...... 129 
Table 3.22: Areas of 13-mer linear peptide (3b) peaks in the HPLC 
chromatograms during digestion with trypsin at 10 °C and pH 6.2. ................... 130 
Table 3.23: t½ of 13-mer linear peptide (3b) during digestion with trypsin at 10 °C 
and pH 6.2, including the value of the rate constant (k min−1) and the standard 
error (SE). ........................................................................................................ 131 
Table 3.24: The ratio of areas of 13-mer cyclic peptide (3c) peaks to areas of the 
internal standard peaks in the HPLC chromatograms during digestion with trypsin 
at 10 °C and pH 6.2. ......................................................................................... 132 
Table 4.1: HPLC peak areas for 15-mer linear peptide (2b) relative to the internal 
standard (IS) peak areas during incubation in 20% FCS at 37 °C and pH 7.4 for 0 
– 48 h. Three replicates. ................................................................................... 137 
Table 4.2: t½ of 15-mer linear peptide (2b) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. ....................................... 139 
Table 4.3: HPLC peak areas for 15-mer cyclic peptide (2c) relative to the internal 
standard (IS) during incubation in 20% FCS at 37 °C and pH 7.4 for 0 – 48 h. 
Three replicates. .............................................................................................. 139 
Table 4.4: t½ of 15-mer cyclic peptide (2c) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. ....................................... 142 
Table 4.5: HPLC peak areas for the 13-mer linear peptide (3b) relative to the 
internal standard (IS) during incubation in 20% FCS at 37 °C and pH 7.4 for 0 – 
48 h. Three replicates. ...................................................................................... 143 
Table 4.6: t½ of 13-mer linear peptide (3b) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. ....................................... 145 
   
 
xxiii 
 
Table 4.7: HPLC peak areas for 13-mer cyclic peptide (3c) relative to the internal 
standard (IS) during incubation in 20% FCS at 37 °C, and pH 7.4 for 0 – 48 h. 
Three replicates. .............................................................................................. 145 
Table 4.8: t½ of 13-mer cyclic peptide (3c) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. ....................................... 148 
Table 6.1: Names of the suppliers of glassware and plasticware. .................... 160 
Table 6.2: Names of the chemical suppliers. .................................................... 161 
Table 6.3: Suppliers of instruments. ................................................................. 161 
Table 6.4: HPLC method for purification of 9-mer cyclic peptide (1c), which has 
retention time 17.23 min. .................................................................................. 165 
Table 6.5: HPLC method for purification of 15-mer cyclic peptide (2c), which has 
retention time 12.29 min. .................................................................................. 165 
Table 6.6: HPLC method for the purification of 13-mer cyclic peptide (3c), which 
has retention time 14.49 min. ........................................................................... 166 
Table 6.7: Precursor ion m/z for the MS2 analysis which were obtained from MS 
scan. ................................................................................................................ 166 
Table 6.8: General HPLC method used to study the enzymatic degradation and 
t½ of 13-mer cyclic peptide (3c) and its linear counterpart (3b) in the presence of 
chymotrypsin and trypsin. ................................................................................. 170 
Table 6.9: General HPLC method used to study the enzymatic degradation and 
t½ of 15-mer cyclic peptide (2c) and its linear counterpart (2b) in the presence of 
chymotrypsin and trypsin. ................................................................................. 172 
Table 6.10: General HPLC method used to study the stability of 13-mer cyclic 
peptide (3c) and its linear counterpart (3b) in 20% FCS. .................................. 174 
Table 6.11: General HPLC method used to study the stability of 15-mer cyclic 
peptide (2c) and its linear counterpart (2b) in 20% FCS. .................................. 174 
 
  
   
 
xxiv 
 
Abbreviations 
Abs Absorbance 
Acm Acetamidomethyl 
Bax Bcl-2−associated X protein 
Boc tert−Butoxycarbonyl  
BSA Bovine serum albumin  
Cbz Carbobenzoxy  
DEPBT 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one 
DIPEA N,N-Diisopropylethylamine 
Dmab 4-{N-[1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)-3-
methylbutyl]-amino} benzyl alcohol 
DMPA 2,2-dimethoxy-2-phenylacetophenone 
DMSO Dimethyl sulfoxide  
ESI Electrospray ionisation 
FCS Fetal calf serum 
Fmoc Fluorenylmethoxycarbonyl  
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxide hexafluorophosphate 
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexaﬂuorophosphate 
HEPES 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid  
HLA Human leukocyte antigen 
HOAt 1-Hydroxy-7-azobenzotriazole 
HOBt 1-Hydroxybenzotriazole 
HODhbt 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine 
IS Internal standard  
LCMS Liquid chromatography mass spectrometry  
MALDI-TOF Matrix assisted laser desorption ionisation - time of flight 
MHC Major histocompatibility complex 
MOMP Mitochondrial outer membrane permeabilisation 
NIe Norleucine 
NMM N-methyl morpholine  
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
   
 
xxv 
 
PEG Polyethylene glycol 
PyBOP (Benzotriazol-1-yloxy) tripyrrolidinophosphonium 
hexafluorophosphate 
RCF Relative centrifugal force  
RP-HPLC Reversed phase - high performance liquid chromatography  
RPM Revolutions per minute  
RT  Retention time  
SE Standard error 
SPPS Solid phase peptide synthesis 
SPS Solution phase synthesis 
TAP Transporter associated with antigen processing 
TCR T cell receptor 
tBu tertiary-Butyl 
TCR T cell receptor 
TFA Trifluoroacetic acid  
Tmob Trimethoxybenzyl 
Trt Trityl 
UV Ultraviolet  
 
   
 
1 
 
 
 
 
 
Chapter 1 
 
   
 
2 
 
 Introduction 
 Motivation 
Bax, one of the essential proteins that belongs to the Bcl−2 family of proteins, 
has a size of 21 kDa and a short half−life in the cell. It plays a key role in 
programmed cell death (apoptosis) and, in particular, can work to promote 
apoptosis. Two types of mammalian Bcl−2 family members have been 
characterised:1  
a−Proapoptotic, e.g. Bax, which induce mitochondrial outer membrane 
permeabilisation (MOMP), releasing cytochrome c.  
b−Antiapoptotic, e.g. Bcl−2 and Bcl−XL, which serves as the guardian of the 
outer membrane by opposing the induction of MOMP. 
It has been observed that there is abnormal proteasomal degradation in 
cancer cells that has an adverse effect on the level of Bax, thus limiting 
apoptosis.2 It has been hypothesised that proteasomal degradation of Bax 
leads to the presence and binding of Bax−derived peptides to the human 
leukocyte antigen which in turn leads to the activation of CD8+ T cells.3 These 
then have the ability to kill a variety of human leukocyte antigen (HLA) 
matched−cancer cells, including primary tumour cells from chronic lymphocytic 
leukaemia (CLL).  
This study is concerned with the synthesis of a 9-mer cyclic Bax peptide 
(1c) with sequence FLIMGWTLD. This sequence is based upon cyclisation of 
a linear 9-mer, IMGWTLDFL, that had previously been identified as a potential 
tumour antigen originating from Bax136-144.3 Two derivatives of this sequence 
were also investigated. The first (2c) was a 15-mer cyclic peptide 
(FLRELIRTIMGWTLD) in which the immunogenic 9-mer is surrounded by 
additional flanking residues from the wild−type Bax sequence. The second, 
(3c), was a 13-mer cyclic peptide (FLKSSKIMGWTLD) where the additional 
residues were designed to provide a flexible and solubilising linker. 
In addition, the linear counterparts (1b, 2b, 3b) of these sequences were 
also investigated for comparison. Cyclic peptides are more highly ordered 
compounds than linear peptides in solution due to the constraints that 
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cyclisation places on their secondary structure. This is predicted to make them 
more resistant to enzymatic hydrolysis and proteolytic degradation in 
comparison to linear polypeptides, which have a poorly defined secondary 
structure.4 In this study, two Bax cyclic peptide derivatives (2c, 3c) were 
synthesised, resulting in cyclic peptides that are more soluble in aqueous 
solvents compatible with protease degradation assays and HPLC analysis. 
This allowed us to study their susceptibility to protease catalysed hydrolysis by 
performing an enzyme kinetic study, in addition to stability studies in serum.  
 Bax protein 
Bax protein plays a critical role in the cell suicide programme (apoptosis). Bax 
anchors into the outer mitochondrial membrane (OMM) through the 
hydrophobic C−terminus5 as a response, for instance, to DNA damage or 
growth factor deprivation, to release cytochrome c from the mitochondria. 
Cytochrome c in turn binds to a particular protein (Apaf−1) to form the 
apoptosome complex which controls the pathways of activation of caspases, 
enhancing the apoptosis process6 as in Scheme 1.1. Therefore, the presence 
of Bax is necessary and plays a significant role in repressing cancer 
development. Changes in the level of Bax are associated with more than one 
type of cancer cell. 
 
OMM = outer mitochondria membrane, frag. = fragmentation 
Scheme 1.1: The function of Bax in the apoptosis pathway. 
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In tissue samples of human prostate adenocarcinoma, it was found that 
there was a good correlation between an increase of Bax protein degradation, 
decreased levels of Bax protein and increased Gleason scores of prostate 
cancer.7 In addition, there were no significant changes in the level of Bcl−2 
protein. Moreover, using a proteasome inhibitor increased the level of 
ubiquitinated forms of Bax protein without influence on the presence of Bax 
mRNA. Therefore, manipulation of this pathway 
(ubiquitin/proteasome−mediated Bax degradation method) of cancer cell 
survival is a possible approach to targeting cancers in humans, particularly 
those with elevated Bcl−2 expression.7 
 Binding of epitopes with MHC complex and TCR (T cell 
receptor) 
T−cells are activated by foreign antigen (peptides), only when the antigen is 
displayed on the surface of antigen presenting cell (B−cells, dendritic cells, 
macrophage cells). The fragments of protein antigens are degraded to peptides 
inside antigen presenting cells. The antigenic peptides are then carried to the 
surface of the antigen presenting cell to bind in a deep cleft in the HLA of the 
complex of MHC class I proteins (major histocompatibility complex). Small 
peptides, typically 7−10 amino acids in length, are loaded into the complex in 
the endoplasmic reticulum. The complex is secreted to the cell surface which 
presents these peptides to T−cells expressing the CD8 receptor. CD8 is one of 
the accessory receptors of T−cells that is expressed on cytotoxic T−cells and 
binds to the MHC class I protein. The T−cell receptor of the T−cells recognises 
antigenic peptides and binding triggers a cascade of events which leads to the 
destruction of pathogens and infected cells.8 Therefore, peptides originating 
from the degradation of ubiquitinated−Bax could potentially serve as 
tumour−specific antigens of cancer cells.9, 10 
The response of the immune system to a specific antigen is different 
between individuals due to their different patterns of MHC genes. There are 
three main types (A−C) of HLA class I and many HLA class II genes in each 
human individual. A large range of polymorphism has been identified for MHC 
genes (800 variants for HLA class I and more than 500 for HLA class II). It has 
been estimated that the number of peptide sequences which have the ability to 
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bind to a particular HLA class I molecule reaches between 1000 to 10000 when 
just 9−10 mer peptides are considered as T cell epitopes.11 However, some 
peptides that are good binders to the MHC are not formed by processing of 
proteins and hence in reality are not presented by the MHC. Some peptides are 
presented by MHC molecules but do not stimulate the response system. 
Therefore, determining the sequences of the peptides that have an ability to 
bind MHC molecules and activate the immune system is a significant step for 
understanding the immune response with the goal to design and synthesise 
immunotherapies and peptide−based vaccines.12 Pathogens produce a large 
number of peptides. Therefore, diagnosis of candidate T cell epitopes needs 
theoretical screening accompanied by experimental validation. 
MHC class I complexes are noncovalently linked heterodimers13 with the 
heavy chain oriented with its N−terminal major portion on the outside of the cell. 
The extracellular portion of the heavy chain was classified into three parts; α1, 
α2, α3.14 The light chain is β2 microglobulin (β2 m).15 Therefore, the sequence 
differences in the MHC complex led to restricted recognition by T cells and 
binding of the peptide to the MHC varies and mainly clusters in the α1 and α2 
domains as in Figure (1.1). It was expected that these domains could include 
the part of the MHC class I molecule that binds to the both the peptide and 
TCR. It is concluded that the peptide−binding sites play a critical role in the 
prediction of which fragments will be antigenic or what conformation they would 
adopt when bound to a class I MHC molecule. 
 
Figure 1.1: Structure of major histocompatibility complex class I (MHC).16 
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It could be said that two generalisations can be made about the interaction 
of a peptide with an MHC class I molecule; firstly, binding of the peptide chain 
occurs at its ends.17, 18 This type of binding was considered as a universal 
peptide recognition element that is independent of MHC protein sequence. The 
second consideration is formation of hydrogen bonds from polymorphic MHC 
side chains to the peptide main chain and to peptide anchor side chains.  
Several methods have been designed for prediction of the epitopes within 
protein sequences that have an ability to bind a TCR then activate the immune 
system. One of these computational methods supposed that the non−polar face 
of amphipathic helical structures of antigenic peptides contacts the class I MHC 
molecules, while the polar face is solvent exposed or binds the TCR.19 Another 
method based on examination of the HLA−A2 structure, suggested that the 
antigenic peptides bind the MHC molecule from three faces leaving the fourth 
directed towards solvent or contacting the TCR.20 In addition, a search was 
performed for motifs within the primary sequence of a protein that have the 
ability to be T cell immunogens.21 By analysis of 57 T cell epitopes the authors 
found the motif was a charged residue or glycine, followed by two or three 
hydrophobic residues, ending with a polar residue or glycine. Although this 
consensus sequence was quite degenerate because several peptides known 
to be T cell epitopes do not contain it. 
Regarding the binding of the peptide to HLA−A2, using computational 
prediction to tether peptides into the HLA−A2 site, it has been suggested that 
the standard helical conformation of the peptide is a very close fit in the binding 
site thus small movements of side chains or opining up of the site by displacing 
the α−helices are potential requisites before binding or releasing a peptide in a 
helical conformation.22  
 Cyclic polypeptides in the medical field 
Living organisms have biochemical ‘tools’ to achieve their great number of 
physiological processes. Peptides are one of these powerful tools and play a 
crucial role throughout biology; for instance, they can act as hormones and are 
important factors in the nervous system as neurotransmitters.23 Therefore, the 
functional and structural characteristics of biologically active peptides are 
widely studied and are of considerable interest in biological or medicinal 
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chemistry research. Cyclic peptides are one of these bioactive compounds. 
Many naturally occurring cyclic peptides are used in medical treatment; for 
example, a cationic cyclopeptide named TD−34 has the ability to decrease the 
level of sugar in the blood stream,24 and vancomycin is a peptide−derived 
antibiotic.25 Cyclic peptides tend to be highly resistant to the process of 
hydrolysis in the human digestive tract, and this property makes them an 
attractive material for designers of protein−based drugs, as they may be used 
as scaffolds for the delivery of other proteins that would otherwise be 
destroyed.26 
Hundreds of cyclic peptides have been synthesised with different sizes of 
rings and types of building units (natural and unnatural amino acids, D or 
L−amino acids) giving a variety of conformations in solution. Many have also 
been investigated for their effectiveness against different diseases. For 
example, it was observed that the cyclic D−L−α−peptides, with six or eight 
residues have the ability to attack Gram positive and Gram−negative bacterial 
membranes, thus leading to rapid cell death.27 A cyclic peptide named C1 
containing D and L amino acids has the ability to reduce immune responses in 
models of arthritis and asthma.28 Finally, it has been observed that the cyclic 
peptide (SGWTWRMY) can inhibit the NADPH−dependent dimerisation of the 
C−terminal binding proteins (CtBPs) which regulate the maintenance of mitotic 
fidelity in breast cancer cells.29 
An important area of study of cyclic peptides in the field of medicine has 
been the search for a way to increase the half−life of peptides. This is 
considered a bottle neck in the development of new peptide drugs because 
endogenous proteases and peptidase degrade them before they can reach 
their target. Therefore, many attempts have been made to increase the stability 
and versatility of peptides.30 One of the strategies employed is the conversion 
of linear peptides to cyclic peptides. 
New findings demonstrate that cyclic decapeptides might represent novel 
anticancer agents, providing a new strategy for cancer therapy.31 Studying the 
cytotoxicity of a library of antibacterial cyclodecapeptides on human carcinoma 
cell lines, and their effects on apoptosis and cell signalling proteins in cultured 
human cervical carcinoma cells, led to this discovery. Some of these 
sequences displayed specificity to, and high cytotoxicity against, HeLa cells 
   
 
8 
 
while showing low hemolytic activity and low cytotoxicity to non−malignant 
fibroblasts. Importantly, they were also stable to proteases in human serum and 
were able to induce apoptosis. 
Inhibition of blood coagulation through anti−haemophilia Factor 
VIII−Factor IX interactions represents an attractive approach for the treatment 
and prevention of diseases caused by thrombosis. In this field, studies have 
indicated that the cyclic peptide analogues of the 558−565 sequence of the A2 
subunit of Factor VIII provided a starting point for the development of new 
anticoagulant agents. These analogues displayed efficient inhibition of the 
Factor VIIIa−Factor IXa interaction.32 
 The various types of cyclic polypeptides 
Cyclic polypeptides are polypeptide chains where the amino terminus and 
carboxyl terminus, and/or their equivalent side chain functionalities, are bonded 
together with a covalent bond, thereby producing a cyclic structure. Cyclic 
peptides can be found in nature in a number of different forms classified 
according to structural or physical characteristics.33, 34 Thus, there is more than 
one method to classify cyclic peptides, and categories include: 
A−Structure:  
1) Homodetic cyclic peptides: this type is formed from head−to−tail cyclisation 
(Figure 1.2, A), where the ring is formed of a normal peptide bond (α−carboxyl 
to α−amine).35, 36, 37 
2) Heterodetic cyclic peptides: a side chain is cyclised with another side chain 
or with one of the termini (head−to−side chain or side chain−to−tail). Here the 
bond is formed between the side chain functional group of the sequence and 
the N− or C−terminus (Figure 1.2, B).38  
3) Complex cyclic peptides: this is a hybrid cyclic peptide containing both 
homodetic and heterodetic bonding (side chain−to−side chain and head−to−tail 
cyclisation). In this case, bonds are formed between two side chains of amino 
acids e.g. disulfide bonds and thioethers, in addition to the head−to−tail bond 
(Figure 1.2, C).39, 40, 41 
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4) Cyclotides: these are polypeptides of size 2−8 kDa that contain more than 
one cycle in the structure, including multiple disulfide bonds, for example, 
Kalata B1, (Figure 1.2, D). These compounds are therefore multi−loop 
structures.42, 43 
 
A                                                              B 
        
C                                                     D 
Figure 1.2: A-homodetic cyclic peptide, B-heterodetic cyclic peptide, C-
complex cyclic peptide, D-Cyclotides (Kalata B1). 
 
B−Polarity: 
1) Polar cyclic polypeptides, i.e. cationic or anionic cyclic polypeptides, have 
more than one anionic residue, such as Glu, Asp in their structure or more than 
one cationic residue, such as Lys, Arg; for example, bactenecin (Figure 1.3, A) 
which functions as an antimicrobial compound.44, 45 
2) Non−polar cyclic polypeptides: most of the side chains in these polypeptides 
are lipophilic,46, 47 such as Leu and Val. Additionally, there is often a 
modification to the amide bond; for example, N−methylation in the compound 
cyclosporin A (Figure 1.3, B). The main function of this type of peptide is to 
penetrate cell membranes. 
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3) Mixed polarity cyclic polypeptides: these cyclic polypeptides have 
amphoteric properties; for example, largamide (Figure 1.3, C). This type also 
often has antimicrobial properties.48, 49 
 
 
Abu = L-α-aminobutyric acid, Bmt = (4R)−4[(E)-2-butenyl]-4,N-dimethyl-L-
threonine, Sar = Sarcosine  
 
Figure 1.3: Structure of bactenecin (A), cyclosporin A (B), largamide (C). 
 
 Protecting groups in peptide synthesis 
A requirement of protecting groups is that they are easy to attach to the target 
functional group. Also, they must be stable in a diverse array of reaction 
conditions. In addition to that, they must be easily and selectively removed at 
the end of the synthesis.50 
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 Main chain protecting groups 
 The α−amino protecting group 
The history of α−amino protecting groups dates back to 1882 when the first 
N−protected dipeptide (benzoyl glycylglycine)51 was synthesised as in Scheme 
1.2. Then, in 1901 the synthesis of a second N−protected dipeptide 
(glycylglycine) was published.52, 53 However, there was a problem during that 
period in that the synthesis involved a free active amino group in the amino 
acid. Therefore, a mixture of products would be produced.  
 
Scheme 1.2: N-protected dipeptide (benzoyl glycylglycine) formation. 
 
Consequently, amino protecting groups were investigated between 1930 
and 1960 and discovered to solve this problem. Some amino protecting groups 
are now in common use; one such example is the Cbz (carbobenzoxy) group 
as in Figure 1.4,54 which was then used as the N−protecting group in solid 
phase peptide synthesis (SPPS) launched by Merrifield in 1963.55  
 
Figure 1.4: Structure of Cbz (carbobenzoxy) 
protecting group. 
 
Various other protecting groups can also be used in solution phase 
synthesis (SPS) such as Troc (2, 2, 2−trichloroethoxycarbonyl), Bpoc 
(2−(4−biphenyl)−isopropoxy carbonyl) and Nps (2−nitrophenyl sulfenyl) as 
shown in Figure 1.5.50 
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Figure 1.5: Structure of Troc (A), Bpoc (B), Nps (C) protecting groups attached 
to an amino acid. 
 
Two main types of α−amino protecting groups used in the SPPS and SPS 
methods are Fmoc (fluorenylmethoxycarbonyl)56 and Boc 
(tert−butoxycarbonyl).54 The Fmoc group was launched as a protecting group 
for peptide synthesis in the 1970s.57 It has since become the most common 
protecting group used to block the α−amino group of every new incoming amino 
acid during the coupling reaction. The Fmoc group is stable under acidic 
conditions and a wide range of catalytic hydrogenation conditions.  
More than one method is used to tether the amino acid to a Fmoc group. 
The most frequently used of these methods is where the free amino acid reacts 
with a haloformate analogue of the Fmoc protecting group. 58 The reaction can 
be hampered by the presence of a free C−terminus. Therefore, two approaches 
are used to overcome this problem. Using a protecting group is the first 
technique and the second is using less reactive electrophiles in the reaction.50 
Scheme 1.3 is an example of how an amino acid is protected by the Fmoc 
group using the reagent Fmoc−chloroformate. 
 
Scheme 1.3: Introduction of Fmoc group into an amino acid. 
 
In the SPPS method, a piperidine reagent is used to remove the Fmoc 
group. This reagent also acts as a scavenger for the unstable dibenzofulvene 
intermediate compound, consequently converting it to a stable 
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fulvene−piperidine adduct. One of the standard conditions for removal of this 
protecting group is reaction with 20% piperidine−NMP for 18 min,59 as displayed 
in Scheme 1.4. 
 
Scheme 1.4: Mechanism of Fmoc group removal by piperidine. 
 
One of the popular methods of using the Fmoc protecting group is to rely 
on the combination of the Fmoc group for the N−terminus, and tert−butyl groups 
for the side chains. This strategy, denoted Fmoc/tert−butyl, is superior to the 
alternative Boc N−α−protection strategy because there is no accumulating loss 
of the side chain protection as a result of repetitive deblocking. Moreover, the 
presence of the Fmoc protecting group allows progress of the reaction to be 
followed using UV or fluorescence spectroscopy during automated peptide 
synthesis. 
Tert−butyloxycarbonyl (Boc)60 was one of the most common 
N−α−protecting groups. The N−terminus of the amino acid is attached to the 
Boc protecting group in a similar way to the Fmoc group.58 Scheme 1.5 
indicates the product of introducing a Boc group to the N−terminus of the amino 
acid. 
 
Scheme 1.5: Introducing Boc protecting group to the N-terminus of 
the amino acid. 
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Acids quickly remove the Boc protecting group; for example, TFA, as in 
Scheme 1.6, or 1 M trimethylsilyl chloride (TMS−Cl).61 The Boc group is stable 
under basic conditions and resistant to nucleophilic attack; in addition, it is 
unaffected by catalytic hydrogenation. Synthesis of polypeptides requires 
several deprotection cycles to remove the protecting group of the α−amine and 
thus, mild conditions are favoured to deprotect this protecting group without 
affecting the remaining protecting groups on the C−terminus or side chains. 
The main problem when employing Boc as the N−α protecting group is that 
undesired side chain deprotection can occur during repetitive deprotection of 
the group by acid at each coupling reaction step. In addition, using HF as the 
deprotection reagent for the peptide from the resin is dangerous and requires 
expensive laboratory apparatus. Hence the Fmoc strategy has gained in 
popularity over the Boc strategy. 
 
Scheme 1.6: Mechanism of the Boc protecting group cleavage. 
 
 C−terminal protecting group 
During solid phase synthesis of cyclic peptides, the resin support is commonly 
attached to an amino acid side chain or backbone nitrogen; therefore, 
protecting the C−terminus is very important.62 Many methods are used to 
protect the C−terminus, including as an allyl ester. To that end, allyl bromide is 
one of the most commonly used reagents for this reaction63 as shown in 
Scheme 1.7. 
 
Scheme 1.7: Protection of C-terminus as an allyl ester. 
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The palladium catalysed reaction of Pd(PPh3)4 in CHCl3, AcOH and NMM 
(N−methyl morpholine) can be used to remove the allyl ester protecting group 
from the C−terminus,64 as in Scheme 1.8.  
 
Scheme 1.8: Deprotection of allyl protecting group by palladium catalyst. 
 
The Dmab group seen in Figure 1.6 is another C-terminal protecting 
group. This group is removed by hydrazine.65, 66 In addition, trimethylsilyl ethyl 
ester is used as a carboxy protecting group which is removed under mild 
conditions by fluoride.67 
 
Figure 1.6: Dmab protecting group structure. 
 
 Side chain protecting groups 
The methods which are used to synthesise peptides need to be high yielding 
to prevent accumulation of products from undesired bond formation and other 
unwanted side reactions. Thus, an important factor that plays a significant role 
in the success of these techniques is careful control of the amino acids used in 
the growing peptide chain. Some of these amino acids have a reactive side 
chain functional group, for instance, lysine has an amino group in the side chain 
that is of similar reactivity to the N−terminus. Additionally, aspartic acid has a 
carboxyl group in the side chain similar to that of the C−terminus. Therefore, 
protecting groups are employed to block these side chain groups until the end 
of the synthesis. These groups must be stable during repeated exposure to the 
basic conditions of the α−N−deprotection step to prevent the reaction of these 
side groups; for example, in the coupling reaction.68 Thus an orthogonal 
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protection strategy is used to achieve this task, i.e. the Fmoc group is removed 
by basic conditions while acidic conditions remove side chain protecting 
groups. 
For arginine, there is a choice of more than one protecting group that can 
be used to block the guanidine side group during synthesis of polypeptides. 
The Mtr−protecting group (4−methoxy−2, 3, 6−trimethylbenzenesulfonyl) is one 
of these but requires extensive time for deprotection.69 The Pmc−protecting 
group (2, 2, 5, 7, 8−pentamethyl−chroman−6−sulfonyl) is another that is 
removed within a much shorter time span than the Mtr−protecting group.70 
Finally, the Pbf−protecting group 
(pentamethyl−2,3−dihydrobenzofuran−5−sulfonyl) is often considered the best 
and is strongly recommended because of the shorter deprotection reaction time 
required, near to two hours, and because it is easy to scavenge.71 Figure 1.7 
shows the three types of arginine protecting group. 
 
Figure 1.7: Three types of arginine protecting group. 
 
Some unscavenged protecting groups liberated by certain side chains in 
the deprotection of polypeptides lead to oxidation and alkylation of the indole 
ring of tryptophan.69 Using the Boc protecting group to block this indole group 
will minimise the likelihood of its destruction.50 
An unprotected methionine amino acid is employed in the Fmoc/t−Bu 
strategy. However, the thioether functionality of methionine has the potential 
for oxidation to the sulfoxide, or S−alkylation forms a homoserine lactone at the 
C−terminus,72 as shown in Scheme 1.9. Ethylmethylsulfide or thioanisole are 
used as scavengers to prevent formation of the lactone.73 
When synthesising polypeptides, the unprotected hydroxyl groups of 
serine may undergo dehydration or O−acylation. Thus, protection is more 
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essential in SPPS than SPS, since an excess of acylating agents is used in 
SPPS. Therefore, solution−phase synthesis with unprotected serine may be 
successful with selection of appropriate activating reagents.50 
 
Scheme 1.9: Homoserine lactone formation after methionine alkylation. 
 
The active side chain of lysine must also be blocked because it will be 
prone to acylation resulting in the formation of undesired branched peptides. 
More than one protecting group is available to protect the side chain of lysine; 
Boc is the common acid−labile choice. The ivDde protecting group (Figure 1.8) 
is cleaved by hydrazine and this group possesses higher orthogonality to Boc 
and Fmoc in comparison to the Dde protecting group.74  
 
Figure 1.8: Structure of Lys(ivDde)-OH (A) and Lys(Dde)-OH (B). 
 
One other amino acid which has a reactive side chain is cysteine, which 
contains a thiol −SH. Consequently, cysteine containing peptides must also be 
protected to prevent the acylation, alkylation or oxidation of the thiol group to 
disulfide by atmospheric oxygen. Disulfide linked dimers are formed by 
oxidation of the cysteine side chain thiols to connect two chains. A cyclic 
peptide can form if there is more than one cysteine residue in the same 
sequence. Usually, oxidations take place more rapidly at a higher pH. Thus, the 
use of a protecting group, such as trityl (Trt)75 or acetamidomethyl (Acm)76 or 
trimethoxybenzyl (Tmob)77 or S−phenylacetamidomethyl (Phacm)78 is 
recommended. These groups are shown in Figure 1.9.  
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Figure 1.9: Types of cysteine protecting group. 
 
Even a protected cysteine could react with piperidine in the Fmoc/t−Bu 
strategy. The C−terminal protected cysteine residue undergoes β−elimination 
then reacts with the piperidine, resulting in the piperidylalanine residue as in 
Scheme 1.10.50 
 
Scheme 1.10: β-elimination of protected cysteine at the C-terminus. 
 
Undesired branched peptides could be formed from the unprotected 
active side chains of glutamic or aspartic acid in the SPPS strategy. Therefore, 
a protecting group is needed to prevent this issue as well as minimising the 
formation of aspartimide, hydrolysis of which causes two products, one of them 
undesired79 as in Scheme 1.11. Pyroglutamate formation could also occur in 
the case of glutamic acid.80 t−Butyl is the most commonly used protecting group 
for Asp and Glu side chains in the Fmoc/t−Bu strategy. 
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β−peptide                                 α−peptide 
Scheme 1.11: α and β-peptide formation resulting from 
aspartimide formation. 
 
 Methods to synthesise polypeptides 
Two major chemical techniques are used to synthesise polypeptides: namely, 
SPPS (solid phase peptide synthesis), and SPS (solution phase synthesis).81 
Each technique has numerous advantages and disadvantages and the choice 
of one or the other depends on the properties of the resulting polypeptide 
combined with the quantity and quality required of the final product. The 
chemical synthesis of polypeptides requires a free amino group to react with 
the free carboxyl group of a second amino acid. Scheme 1.12 indicates the 
formation of an amide bond after activation of the carboxyl group. 
 
Scheme 1.12: Peptide bond formation reaction. 
 
The SPS technique is a classical method to synthesise polypeptides and 
has been widely used to form polypeptides since the pioneering research 
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performed by du Vigneaud in 1953.82 Unlike SPPS, the coupling of amino acids 
takes place in the solution phase, not on a solid support. This method is most 
useful for preparation of polymers containing repeats of short sequences (3−10 
amino acids). A long polypeptide chain can be formed by synthesising two short 
fragments as a first step, then coupling the two fragments.83 This means that 
fewer equivalents of starting material are used in creating the full sequence, as 
displayed in Scheme 1.13. The SPS method has been used to generate many 
different compounds since the original research. For instance, the peptide 
hormone oxytocin was synthesised by this method.84 
 
CO-X = activated form of C-terminal, W = C-terminal protection, Y = N-terminal 
protection,  = peptide fragment. 
Scheme 1.13: Solution phase synthesis (SPS) fragment coupling method 
to synthesise a polypeptide. 
 
Although SPS has its own positive attributes, for example being easy and 
inexpensive to scale up, there are also disadvantages to this approach.55 The 
first problem is that this method is tedious, laborious and slow. This is because 
the intermediate peptides need to be isolated after each amino acid addition. 
Typically, HPLC and mass spectrometry techniques are used to characterise 
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each fragment before continuing the synthesis of the chain. Thus, completion 
of the synthesis takes considerable time, and there is substantial labour 
involved. The second significant problem is the decreasing solubility of the 
growing polypeptide chain after each successful coupling step.  
Since the introduction of the Fmoc group and the work of Merrifield, the 
SPPS method has become more popular and is now the standard method of 
polypeptide synthesis.85 Furthermore, this approach can be used to synthesise 
other classes of polymer with a defined sequence, including oligosaccharides 
and oligonucleotides.86, 87  
The general procedure to synthesise polypeptides by the SPPS method 
on a resin consists of first binding an N−protected amino acid to the resin via 
the C−terminal carboxyl group. The carboxyl group of the second amino acid 
must then be activated to couple with the first resin−bound residue via its 
N−terminus once the protecting group is removed. The resin then needs to be 
filtered and washed to remove the excess reagents and any undesired waste 
products. The previous step is then repeated, the N−protecting group of the 
newly attached residue is removed by a deprotection reagent, followed by 
filtration and washing, and the addition of another activated amino acid. Finally, 
the processes of deprotection and coupling are repeated for each successive 
amino acid until the peptide sequence is complete. Typically, all the protecting 
groups for the reactive side chains of the amino acids are then removed. The 
peptide can then be cleaved from the resin after filtration and washing of the 
resin. This process is shown schematically in Scheme 1.14. 
 
Scheme 1.14: General scheme for synthesis of polypeptide using the solid 
phase Fmoc strategy. 
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SPPS has several advantages over SPS, one of these is that excess 
reagent can be used to ensure the reactions reach completion.55 Another is that 
purification of the product peptide is rapid after each step, requiring a simple 
filtration and washing of the resin to remove excess reagents and waste 
products. Washing the resin is made possible as the growing polypeptide chain 
is covalently attached to an insoluble solid polymeric support during the chain 
assembly.88 Additionally, the yield of desired products can be enhanced in 
otherwise poorly chemoselective reactions by attachment to an appropriate 
solid support.89 Moreover, many compounds can be prepared at one time, since 
every bead of resin can be considered as a single isolated system for the 
reaction. Another important advantage of the SPPS method is that it is highly 
amenable to automation through simple robotic fluid handling. Finally, pseudo 
dilution can be exploited to render a cyclisation reaction more efficient in this 
method90 and the final polypeptide can be detached from the polymer support 
and globally deprotected in one pot to simplify the work−up and isolation. 
However, despite these advantages, as with all techniques, there are several 
limitations to employing SPPS in the synthesis of polypeptides. 
The first problem is a potential incompatibility between the resin and the 
growing peptide chain91 leading to an incomplete reaction at each coupling step 
because of the aggregation of the peptide with the polymer of the resin. 
Consequently, resin−bound peptide side−products accumulate and, therefore, 
a complex mixture of products will be present upon cleavage from the resin. 
Furthermore, this method requires an excess of reagents and hence is 
wasteful. 
SPPS has since been developed for use under microwave irradiation, 
becoming the aptly named technique microwave−assisted SPPS.92 This 
approach is characterised as having limited racemisation and being high 
yielding. For this technique, both temperature and pressure are controlled over 
the course of the synthesis. Furthermore, Fmoc or Boc chemistry is compatible 
with this method, and it requires a much shorter cycle time in comparison to the 
traditional SPPS method for synthesising long polypeptides. 
The primary requirement in the SPPS method is that the solid support is 
stable under all conditions of the synthesis. It is believed that there is a lower 
tendency of peptides to aggregate, especially with low resin loading, because 
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intermolecular peptide−peptide interactions are more limited when attached to 
a polymer compared to freely moving molecules in solution.93 Avoidance of 
aggregation is an advantage of the SPPS technique. 
 Cyclisation strategies of linear polypeptides 
Cyclic polypeptides are conformationally constrained relative to their linear 
counterparts.94 Therefore, they are more resistant to enzymatic hydrolysis,95 
making them potentially more biologically active due to their increased 
likelihood of reaching the target under physiological conditions.96 In addition, 
cyclic polypeptides are more selective than their linear counterparts for binding 
to specific targets.97 Consequently, cyclic polypeptides have become attractive 
synthetic targets for medicinal and pharmaceutical chemistry.98 Nevertheless, 
new synthetic strategies for these types of cyclic compounds are critical, as the 
current cost to produce them is inhibiting their application in industry. Therefore, 
the development of novel methodologies for the cyclisation reaction is urgently 
required for these molecules to increase their commercial potential.99 
Importantly, the same strategies that are used to form a peptide bond can also 
be used to synthesise cyclic polypeptides. 
Depending on the functional groups in the linear compound, four different 
ways can be applied for cyclisation of the linear peptide,35, 38, 39 head−to−tail 
(C−terminus to N−terminus), head−to−side chain,100 side chain−to−tail or 
side−chain−to−side−chain101 (See Figure 1.2). Therefore, more than one 
strategy has been used to improve methods for the cyclisation of the linear 
polypeptide to obtain high yields in a short time, fewer side reactions and lower 
cost. 
 Head to tail cyclisation 
This method of cyclisation is one of the most important and has attracted the 
highest level of interest from chemists and pharmacologists over the last 30 
years.102 It has been observed that this strategy enhances biological activity by 
reducing flexibility and entropically increasing ligand binding affinity.103 Thus, 
this method has been most applied to synthesise cyclic polypeptides from their 
linear counterparts, with only water being lost during the formation of the 
connective peptide bond. Initial strategies to achieve this began with the 
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‘classical’ method, which is where the protected linear precursor is lactamised 
using high dilution in an organic solvent or under pseudo−dilution conditions on 
a solid support.81, 94  
The formation of this amide bond between the two termini of the same 
linear precursor, without the need for any additional new amino acid or chain, 
means the cyclic polypeptide has the same sequence as its linear counterpart. 
Therefore, a direct and reliable comparison between the properties of the cyclic 
polypeptide and its linear counterpart is possible; for example, their relative 
stability to enzymatic degradation. β−sheet mimic structures are also formed 
using the head−to−tail cyclisation strategy, the presence of which in the linear 
peptide can, in turn, enhance the macrocyclisation.81 Aspartic acid or glutamic 
acid is often used as the first amino acid in the sequence, both of which have 
two carboxyl groups. In this case, the side chain carboxyl group is bonded to 
the resin while the α−carboxyl group, which is used to bond with the α−amino 
group in the residue at the N−terminal, is protected with a temporary protecting 
group. 
The cyclisation is slow, particularly if there is no turn structure−inducing 
amino acid in the linear precursor, such as glycine, proline or any D−amino 
acids. This delay in cyclisation leaves the active intermediate linear polypeptide 
able to react for a long time, increasing the opportunity to epimerise at the 
C−terminal residue.104, 105 Furthermore the solubility of the protected peptide 
may become very low as its size increases. Therefore, synthesis of relatively 
large peptides by classical methods remains very difficult. Finally, it should be 
noted that there is no general, standard way to synthesise different peptides. 
The method used to synthesise a cyclic peptide depends on its properties, such 
as polarity and conformation, as well as the length and type of the sequence. 
To overcome the above issues, alternative methods to the classical 
methods (indirect peptide bond formation) have been devised to form cyclic 
polypeptides, with the aim of direct peptide bond formation using completed 
unprotected linear precursors in aqueous solution.106 These methods involve a 
process termed native chemical ligation (NCL),107 which is considered a 
significant way of overcoming some of the size limitations of the SPPS method. 
In this technique, the cyclisation reaction consists of two steps: the first 
segment, an unprotected linear peptide α−thioester108 is reacted 
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chemoselectively with the second segment containing an N−terminal Cys 
residue. This results in a thioester linked intermediate. In the second step, an 
intramolecular acyl migration occurs in the transient compound. This molecular 
rearrangement forms a native peptide bond at the site of ligation, without any 
need to change the conditions of the reaction. The final desired product is thus 
formed without any further manipulation. Scheme 1.15 shows the principle of 
this strategy, of which the synthesis of collagen protein is an example. This 
strategy is particularly useful for collagen as it is difficult to synthesise this type 
of protein by the classical method because of its large size.109 In this case, the 
SPPS method was used to prepare the cysteine and thioester peptide 
segments, then the polymerisation step between the two segments was 
undertaken using NCL under aqueous conditions to yield the polymer. Another 
example of NCL being used is in the synthesis of lipopeptide vaccine as 
treatment against group A streptococcal infection.110 
 
Scheme 1.15: Principle of native chemical ligation (NCL) reaction. 
 
The NCL method is characterised by high chemoselectivity, permitting 
coupling of the segments without protection of the reactive side chain groups. 
However, this approach also has some limitations.111 For example, the thioester 
peptide is usually prepared using Boc chemistry requiring repeated 
deprotections with TFA and an HF reaction for the cleavage of the thioester 
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peptide product from the resin. Synthesis of the thioester peptide is one of the 
obstructions that can limit the use of this method. Consequently, more than one 
ligation technique has been designed to form the peptide bond, each one 
having been used to synthesise a certain problematic protein. Solid phase 
ligation is another example of a chemical ligation method that was introduced 
to increase the activity of ligation of multiple segments.112 
The ligation of peptide hydrazides is an important strategy used to 
synthesise polypeptides and proteins.113 It is one of the more modern chemical 
methods and does not require protecting groups. In this example, a two−step 
reaction is used to ligate two unprotected peptides. Firstly, a peptide azide is 
produced after mixing two peptides (one of the peptides has C−terminal 
hydrazide and the other has N−terminal cysteine) with NaNO2 (an oxidant) 
under acidic conditions. The thiols are added as a second reactant, followed by 
adjusting the pH of the reaction, leading to the formation of the required 
product. 
The aforementioned strategies have encountered some difficulties when 
used for ligating a recombinant peptide to a synthetic peptide or labelled 
peptide which could not be converted into peptide thioesters. As a result, 
expressed protein ligation (EPL) is a synthetic strategy that has been 
investigated to overcome this problem by employing an intein (Scheme 1.16). 
Notably in this strategy, the labelled fragments (intein) have no negative effect 
on peptide synthesis. This method has been used to synthesise many different 
proteins; for example, the synthesis of Consensus tetratricopeptide repeat.114 
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Scheme 1.16: General mechanism of protein splicing by an 
intein. 
 
Another strategy, used as an alternative to NCL, is based on the 
Staudinger reaction.115 Scheme 1.17 indicates the mechanism of the 
Staudinger ligation by mediation of phosphinothiol.116 
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Scheme 1.17: Mechanism of the Staudinger ligation 
mediated by phosphinothiol. 
 
Several attempts have since been made to overcome the problems of the 
methods mentioned and in the past decade, a strategy involving click chemistry 
(CuAAC), i.e. copper azide alkyne cycloaddition,117 has emerged.118 In this 
method, triazole cyclic polypeptides are generated by an aliphatic azide at the 
N−terminus reacting with an alkyne in the C−terminus of the linear polypeptide. 
This occurs through a 1, 3−dipolar cycloaddition and is catalysed by copper(I) 
to form a 1, 2, 3−triazole. Scheme 1.18 indicates the strategy of this click 
reaction. 
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Scheme 1.18: Click chemistry procedure. 
 
The main advantages of the click reaction are that it is a fast and 
irreversible method, the ligation generates high yields with a simple isolation 
procedure for the resulting products. Importantly, the method is also wide in 
scope. The starting materials and reagents are also readily available, and any 
solvents needed such as water, are easily removed. Chemically, the conditions 
of the reaction are mild compared to other methods. These qualities have 
resulted in the click reaction becoming a meaningful strategy towards the 
synthesis of polypeptides and proteins. In some complex biological 
environments, the by−products must be non−toxic, particularly in an in 
vivo−system,119 therefore, the toxic copper catalyst can be considered a 
disadvantage of this strategy. 
 Side chain−to−side chain cyclisation 
Side chain−to−side chain cyclisation is one of the most common procedures 
used to synthesise cyclic polypeptides from their linear counterparts, to 
upgrade their biological activity, pharmacokinetic characteristics and proteolytic 
stability.120 In this case, a covalent attachment is formed between the side chain 
group on one amino acid residue and the side chain on another amino acid 
residue in the peptide. Therefore, there are many possibilities that form this 
type of tether. For example, cyclisation can occur via lactones (esters), lactams 
(amides), ethers, thioethers,121 ring closing metathesis122 or through the azide-
alkyne click reaction.123 Lactams have been the more widely used recently, with 
a side chain amino and a side chain carboxyl group being employed in this 
particular class.124 
Stabilised helical structures, formed by specific sequences of 
polypeptides and proteins, play an essential role in the conformations of these 
compounds in nature, as seen by their relative frequency of occurrence.125 
Therefore, many chemical methods use the side chains of reactive amino acids 
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to form cross-links that stabilise an α−helical segment of the peptide. An 
example of this strategy is a lactam cross-link between aspartate and lysine 
(Figure 1.10).126 
 
Figure 1.10: General structure of cyclic peptide via a lactam bond. 
 
A second important type of side chain−side chain bonding is a disulfide 
bridge. Disulfide bridges function naturally to strengthen the stability and 
conformational control of native peptides. This bond can also be used to protect 
protein−based therapeutics from fast enzymatic hydrolysis and to enhance the 
resistance of proteins from the effects of the environment during processes of 
chemical synthesis.127 Therefore, chemical cyclisation of polypeptides via an 
S−S bond is of high interest to chemists and pharmacologists. Figure 1.11 
indicates a polypeptide that has a cyclic structure formed by a disulfide bond. 
 
Figure 1.11: General structure of cyclic peptide via a disulfide bond. 
 
Another example of side chain−side chain bonding to form a cyclic 
structure is by cross-linking the side chains of two residues of serine with a 
dicarboxylic acid. This ring forming cyclisation procedure was used to prepare 
the new constrained PTH (parathyroid hormone) analogue128 as shown in 
Figure 1.12. 
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Figure 1.12: Formation of a cyclic structure by two serine residues that 
are esterified to a dicarboxylic acid. 
 
 Side chain−to−tail cyclisation 
The third important method of macrocyclisation is the side chain−to−tail 
strategy. An example of this type of bonding is through a cysteine thiol 
functionality. The process involves the radical addition of the thiol group in the 
cysteine at the N−terminus to the alkene group attached to the side amino 
group of a lysine residue at the C−terminus,129 as displayed in Scheme 1.19. 
 
Scheme 1.19: Cyclisation of the linear peptide via the radical addition of the 
thiol group in the cysteine to the alkene group. 
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 Important factors that affect the synthesis of cyclic 
polypeptides 
An organisation of the reactive ends of the linear polypeptide, into a narrow 
molecular space before ring closure via the head−to−tail method, can be 
considered an essential step to the success of the macrocyclisation of the linear 
polypeptide precursor. Therefore, factors affecting cyclic polypeptide formation 
have attracted the attention of some research groups. These factors can be 
classified into two types: 
 Internal factors 
The most important internal factor that controls the success of the cyclisation 
of the polypeptide is the resulting ring size,130, 131 in particular, through the 
head−to−tail method. Polypeptides consisting of more than seven amino acids 
in the linear precursor are often favoured to close the ring successfully. The 
cyclisation is typically straightforward: this length or more can supply the 
requirements of reactive orientation for both termini with little ring strain. 
However, problems are observed during cyclisation of fewer than seven residue 
linear polypeptides, yet it is possible to cyclise peptides of this length.104 The 
reason for the cyclisation difficulties is the absence of two crucial factors, 
hydrogen bonding and β−sheet structure, which both act as an accelerator to 
tether the residues of the sequence.132 
It has been found that the presence of D−amino acid residues in a 
sequence of L−amino acids accelerates the cyclisation reaction of the linear 
polypeptide precursor. Their ability to induce a turn structure results in higher 
yields for many types of polypeptide cyclisation.133 
The presence of a cis−amide bond in the middle of the linear polypeptide 
sequence can also result in a more efficient macrocyclisation. Thus, the 
presence of, N−methyl amino acids has a similar effect to a proline residue in 
the backbone of the peptide supporting the successful closure of the ring in 
high yields.134 On the other hand, a polypeptide which does not contain any 
D−residue in the sequence, and hence has no turn−inducing structure, is 
consequently tricky to cyclise. To combat this, the α−carbon of the C−terminal 
residue can be changed to the D−configuration.135 Other research groups have 
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found that incorporation of a small heterochiral unit of diproline, D−Pro−L−Pro, 
in the linear polypeptide sequence results in a particularly efficient rate of 
cyclisation because this unit increases the presence of β−turn structures.136 
In addition to the presence of proline in the sequence, glycine, when 
located in the middle of the sequence, also displays similar properties.137 
Glycine is a small residue and thus displays less steric hindrance, allowing for 
more bending of the linear peptide. In addition, it does not form side chain 
hydrogen bonds with neighbouring residues, leaving more degrees of freedom 
for the ends of the peptide to remain moving in the molecular space. 
Consequently, the likelihood of a ring−forming collision occurring is much 
higher. 
Positive effects on, and higher yields for, the cyclisation reaction have 
also been found for particular amino acids at the termini of the linear peptide; 
for example, having a glycine at the C−terminus and a proline or alanine at the 
N−terminus, and vice−versa. The probable cause for this advantage is the 
difference in the conformations for each sequence, with certain combinations 
being more suitable for ring closings. On the other hand, having large residues 
at the termini results in less macrocyclisation.138  
It has been found that using the amino acids serine, threonine or cysteine 
as protected oxazolidine/thiazolidine dipeptide derivatives in the SPPS 
techniques allows them to act as pseudo prolines, i.e. structural building blocks 
to prevent the aggregation and self−association of the linear polypeptide,139 
thus assisting the synthesis of short cyclic polypeptides without using 
turn−inducing factors.140 The presence of protected pseudoproline dipeptide 
derivatives temporarily induces the establishment of β−turn structures, 
enhancing the cyclisation reaction.141 
Some patterns have been found during the study into the effect of the size 
of the residue at the C−terminus or N−terminus on macrocyclisation efficiency. 
Linear polypeptides which have a small residue at the C−terminus have a 
greater ability to cyclise, and vice versa. With regards to the N−terminal residue, 
it has been found that the orientation of the side group of the N−terminus plays 
an important role in the success or failure of the cyclisation reaction.142 
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 External factors 
Multiple external factors play a significant role in the synthesis of polypeptides 
and their subsequent macrocyclisation. The first important factor is the choice 
of resin and how it swells, as there is often more than one type of resin with a 
particular property, such as high loaded resin or low loaded resin. Therefore, 
compatibility between the kind of peptide being produced and the properties of 
the resin is a key factor in the successful synthesis of the linear precursor of 
cyclic peptides. It has been observed that lower loaded resins are preferred for 
the synthesis of long peptide sequences, mainly due to increased accessibility 
to the α−amine when using resin loading of less than 0.4 mmol/g. This type of 
resin also reduces interactions between individual growing sequences 
preventing interchain aggregation.143 In addition, swelling of the resin prior to 
starting the synthesis must be performed in order to obtain the homogeneous 
presence of bound amino acids throughout the resin, resulting in a higher yield 
of the peptide.144 Using a low−loading resin, decreases the potential for 
dimerisation or cyclodimerisation side reactions which would reduce the 
yield.142, 145 
The second important factor is the choice of a coupling reagent, using 
high concentrations of the coupling reagent usually results in a high yield for 
the precursor peptide for the cyclisation reaction. It has also been observed 
that if not enough coupling reagent is added, the reaction may not reach 
completion, therefore, short, incomplete sequences are formed as a side 
product.146 
Activation of the carboxylic acid before the amide bond forming step 
sometimes leads to racemisation; therefore, including certain additives (Figure 
1.13) in the coupling reaction mixture is commonplace to overcome this 
problem; for example, adding HOBt (1−hydroxy benzotriazole) to a coupling 
reaction performed using PyBOP reagent.142 
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Figure 1.13: Types of additives to prevent racemisation. 
 
The third important factor is the choice of deprotection reagent. Multiple 
reagents can be used for this purpose. Cyclic secondary amines, e.g. piperidine 
and piperazine, are widely used as removal reagents for a 
9−Fluorenylmethoxycarbonyl (Fmoc) group. Optimisation of the concentration 
of the reagent, the number of times the molecule is subjected to the 
deprotection procedure, and the duration of reaction may support the coupling 
reactions,147 resulting in high quality and high yields of the linear peptide, thus 
affording more precursor to cyclise, giving a higher overall yield of cyclic 
peptide. 
A critical factor in the synthesis of both linear and cyclic polypeptides is 
the cleavage reagent used for removing the peptide and side protecting groups 
from the resin.69 The yield of the synthesis relies heavily on this step and the 
typical reagent for this cleavage when using the Fmoc protection method is 
TFA. Careful consideration of the TFA concentration and reaction time of the 
cleavage is important, as using too high a concentration could cleave the linker 
from the resin in addition to cleaving the peptide from the linker. The carbonium 
ion originating from the linker may react through alkylation with some side 
chains of the peptide, e.g. Trp or Cys, and consequentially, a side product is 
formed. In addition, leaving the reaction to occur for too long a time may result 
in the formation of the oxidised peptide. The addition of scavengers, such as 
ethanedithiol (EDT), triisopropyl silane (TIS), water and phenol, is essential to 
help prevent this problem.144, 148 
Finally, some other less obvious factors need to be considered in the 
synthesis of cyclic peptides, including the use of different metal ions as 
coordinators. These help to bend the peptide and reduce the distance between 
the two ends of the linear precursor before the cyclisation reaction. It has been 
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observed that lithium and cesium chloride are the best coordinators to obtain a 
high yield. However, solubility issues with the coupling reaction solvent can be 
a problem.138 Changing the time for which the mixture is heated during the 
coupling reaction could also increase the yield of the cyclic peptide.142, 143 In 
addition, increasing the number of times the coupling reaction is performed also 
affects the amount of the product. In the SPPS strategy, the number of 
occasions the resin bound peptide is washed after deprotection and coupling 
is important to remove excess quantities of reagents and side products. Finally, 
some cyclic peptides have poor solubility in certain solvents. Therefore, the 
purification of these cyclic peptides will be difficult. The choice of solvents are 
important factors for correct separation and purification of the peptide by high 
pressure liquid chromatography (HPLC). Meanwhile, trifluoroacetic acid (TFA) 
or formic acid is added to the solvents in a small percentage to boost the 
separation of the peptide, resulting in a higher yield.149 
 Amino acids 
Amino acids are organic compounds containing two functional groups, an 
amine, NH2, and a carboxyl, COOH, attached to the α−carbon atom in addition 
to a side group. Twenty common amino acids are the building units of proteins. 
They are classified according to the structure of the side group as seen in 
Scheme 1.20. 
The amino acids which contain nonpolar side chains, such as alkyl groups 
or aromatic groups, are called hydrophobic amino acids. Such examples 
include leucine or phenylalanine. The amino acids which have polar side 
chains, such as hydroxyl (OH), or sulfhydryl (SH), are called hydrophilic neutral 
amino acids; examples of these include serine or cysteine. Amino acids that 
have side chains such as a carboxylic acid (COOH) are hydrophilic acidic 
amino acids and include aspartic acid or glutamic acid. Finally, in addition, the 
amino acids which have side chains containing an amino group (RNH2) are 
called hydrophilic basic amino acids and include arginine and lysine. 
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Scheme 1.20: Amino acids categorised according to polarity. 
 
All the amino acids are optically active compounds as they have a 
α−chiral carbon except glycine which has a hydrogen atom as its side group. 
There are two isomers of amino acids, known as the L and D−isomers. The 
L−isomers are prevalent in living organisms (Figure 1.14). The L-isomer 
generally corresponds to an S configuration of the stereocentre, with cysteine 
being an important exception. 
 
Figure 1.14: L and D-isomers of amino acid. 
 
The sequence of amino acids in the peptide can be referred to by one or 
three letter abbreviations; for example, K or Lys for the amino acid lysine. 
Modified amino acids can also be found in some proteins; for instance, 
hydroxyproline or 5−hydroxylysine instead of proline or lysine respectively. 
Certain modifications in natural proteins help to boost their solubility, their 
stability, and their interaction with other proteins. Furthermore, the pKa of amino 
acids can be changed with modifications; for example, the pK3 of 
selenocysteine (5.3) is lower than that of cysteine (8.3).150 
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 Resin 
Resins or insoluble polymer supports are used in the SPPS strategy to enhance 
the synthesis of polypeptides in comparison to the classical SPS method. The 
possible functions of the resin are widely extended because the linkers that 
anchor the resin to the growing polypeptide chain consist of different chemical 
groups. The main physical properties of the resin are a spherically shaped 
particle with a diameter of between 35−135 µm. These days, the most 
commonly used resin is made of polystyrene cross−linked with 1% 
(divinylbenzene) DVB.151 After swelling and opening up of the porosity of the 
resin by an appropriate solvent, the reagents enter the beads to react with the 
resin. Swelling factors rely on the type of resin.152 Table 1.1 indicates some of 
the most common resin linkers for SPPS.153 Two types of resin can be used to 
synthesise polar substances, polyamines and polyethylene glycol (PEG).154 
The latter has been used to form long, complex peptides with different solvents, 
including water.155 
Table 1.1: Name and structure of some common resin linkers. 
Name Resin linker structure 
Wang 
 
Rink acid 
 
HMPB 
 
Rink amide 
 
Sulfonamide 
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  Coupling reagents 
One of the valuable reactions in organic synthesis and medicinal chemistry is 
amide bond formation. The amide bond has played a central role in the 
synthesis of drugs, especially for the creation of combinatorial libraries after the 
development of SPPS.156 The coupling reagents that can reduce the 
racemisation of amino acids have attracted the attention of those interested in 
this field.157 
The peptide bond formation reaction in the synthesis of peptides consists 
of two steps: the first is activation of the carboxyl of the new amino acid; the 
second step is acylation of the amino group. A reactive intermediate is formed 
in the first step following the reaction between the protected amino acid or 
peptide with the coupling reagent.  
Some of the variables that have a direct effect on the efficiency of the 
coupling reactions are, for example, the choice of solvent which is used to swell 
the resin, steric hindrance resulting from side chains and their protecting 
groups, and reactivity of the activated carboxylic group, as in Scheme 1.21. 
 
Scheme 1.21: General scheme for the coupling reaction. 
 
Racemisation could occur during poor coupling conditions which also may 
lead to forming unwanted products, such as truncated sequences.158 Repeat of 
the coupling reaction with fresh reagents may result in a higher yield.  
Different reagents have been prepared and used in the coupling reaction, 
for example, PyBOP, DEPBT, HATU, HABTU, DCC, DIC as in Figure 1.15.  
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Phosphonium reagents                 Uronium/guanidinium reagents 
 
 
Carbodiimide reagents 
 
Figure 1.15: Types of coupling reagents. 
 
DCC (dicyclohexylcarbodiimide) is one of the carbodiimide reagents; it 
was used during the first days of SPPS strategy. Use of this reagent is limited 
in the SPPS strategy because the dicyclohexylurea side product is poorly 
soluble in most solvents.159 (Scheme 1.22). Therefore, DIC 
(diisopropylcarbodiimide) is better than DCC in the SPPS method as the urea 
side product is soluble. DIC reagent was used to synthesis a cyclic 
undecapeptide, Wy−40,770 as an inhibitor for GH (growth hormone).160 
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Scheme 1.22: Dicyclohexylurea formation using the reagent DCC. 
 
Racemisation can occur resulting in epimers of the peptide, as in Scheme 
1.23. This issue can be avoided by the presence of additives such as HOBt 
(1−hydroxybenzotriazole) in the reaction mixture.161 
 
Scheme 1.23: Racemisation of a protected amino 
acid using DCC or DIC as a coupling reagent. 
 
Recently, highly popular coupling reagents have been acylphosphonium 
salts, such as PyBOP (Benzotriazole−1−yl−oxy−tris−pyrrolidinophosphonium 
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hexafluorophosphate),162 and acyluronium salts, such as TBTU 
(O−(Benzotriazol1−yl)−N,N,N',N'−tetramethyluronium tetrafluoroborate), 
HBTU (2−(1H−Benzotriazol−1−yl)−1,1,3,3−tetramethyluronium 
hexafluorophosphate).163 BOP 
(Benzotriazol−1−yl−oxy−tris−(dimethylamino)−phosphonium 
hexafluorophosphate) is one of the phosphonium reagents which was prepared 
as an alternative to carbodiimide reagents to minimise the problems that can 
occur with carbodiimide, such as racemisation or side reaction.164 Also, use of 
this reagent minimises asparagine or glutamine dehydration byproducts.165 One 
of the disadvantages of this reagent is that it generates a carcinogenic 
by−product, which is hexamethylphosphoramide (HMPA). The PyBOP reagent 
is more efficient than BOP, as the coupling reaction is fast to complete and the 
by−product is less hazardous. 
Uronium reagents, such as HBTU and TBTU, afford high coupling yields 
and fast reaction kinetics. Any excess of these reagents may lead to short 
sequences because they could react with free N−terminal of the peptide, 
forming a guanidine compound that blocks the elongation of the chain. Adding 
1−hydroxybenzotriazole as an additive to the reaction mixture will reduce 
racemisation.166 
DEPBT (3−(diethoxyphosphoryloxy)−1,2,3−benzotriazin−4(3H)−one) is 
an important coupling reagent in SPPS and SPS methods for synthesis of the 
polypeptides (linear and cyclic). It confers resistance to racemisation, and in 
addition, it is not necessary to protect the side chains of tyrosine, serine, 
threonine and histidine during the coupling reaction.167 
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Chapter 2 
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 Cyclic Peptide Synthesis 
 Introduction 
As a goal of this project was the synthesis of a cyclised tumour antigen peptide, 
an important consideration was the design of the peptide sequence. 
It has been found that many of the peptides that have the ability to bind 
HLA−A2 are composed of 9 amino acids with a Leu residue in position 2 of the 
sequence.168 It has been observed that the amino acid sequence of peptides is 
responsible for the conformation of the peptide in the HLA−A2 complex which 
thus presents the side chains that affect the binding of the complex to the T cell 
receptor (TCR). Also, the length of the bound peptide to HLA−A2 affects the 
orientation of the side chains of the residues giving different conformations for 
the complex that impact on recognition by the TCR.169 
Several algorithms have been developed for computational prediction of 
peptide epitopes and these are implemented in more than one software 
package (NetCTL, WAPP, SMM and EpiJen). The EpiJen server aims to select 
the true epitope that activates CD8+ T cells by modelling the processing of 
proteins to peptides, peptide transport and MHC binding.170 A proportion of non-
epitopes of the source protein are excluded in the first three steps (proteasome 
cleavage, TAP transport and MHC binding), leaving only 5% of peptides from 
the whole protein sequence. This small percentage has 85% of the true 
epitopes. 
In an experimental approach to epitope discovery, libraries of synthetic 9-
mer peptides derived from the Bax protein were screened at Cardiff University 
School of Medicine.2 Bax was chosen for investigation as it was hypothesised 
that degradation of Bax in tumours would lead to presentation by HLA class I 
of Bax-derived peptides on the cell surface. A peptide, IMGWTLDFL, derived 
from the Bax136−144 sequence was found to bind to HLA and then to activate 
CD8+ T−cells to recognise and kill a variety of HLA−matched cancer cells.2 The 
location of the antigenic peptide within the intact Bax protein is depicted in 
Figure 2.1. This peptide forms the basis of the work described in this thesis, 
where the goal is to increase its stability in serum while permitting uptake into 
cells followed by processing and display.  
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Figure 2.1: Location of peptide IMGWTLDFL in the Bax protein 
(1F16) highlighted in yellow.171  
 
The functions of the peptide residues are different; some of them contact 
the HLA, while others make contact with the TCR. The sequence of the Bax 
peptide IMGWTLDFL is terminated with the hydrophobic residues leucine and 
isoleucine, which play an important role in anchoring the peptide to the HLA. 
The residues in the interior of the sequence will contact the TCR. 
The cyclic peptide will no longer exhibit the helical structure found in the 
full length Bax protein and will not display any function of Bax. The 9-mer linear 
peptide could bind directly to the HLA−A2. However, it is likely that the cyclic 
peptides must be taken up by the cell and undergo processing (cleavage) inside 
the cell before binding to HLA−A2. Thus, the cyclic peptide must survive 
hydrolysis by extracellular proteases, so that it can be taken up by an antigen 
presenting cell (dendritic cell), processed by intracellular proteases in a similar 
way to Bax, to give the required fragment (9-mer) to be displayed on the MHC 
protein. 
Extending the original 9-mer sequence with a short linker comprising 
flanking residues from Bax or residues chosen for solubility or cell permeability 
was another possibility to create cyclic peptides that could be processed within 
cells to generate the epitope. One of the reasons for choosing a 15-mer 
polypeptide length was that it had been found that B−cells loaded with 15-mer 
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polypeptide libraries have the ability to activate T−cells against human 
papillomavirus (HPV)−associated tumour.172, 173  
For the purposes of synthesis of cyclic derivatives of this sequence, the 
terminal residues of IMGWTLDFL are not ideal as leucine lacks side chain 
functionality for resin-anchoring and the bulky side chains may slow the 
cyclisation reaction. To avoid these drawbacks, the sequence can be circularly 
permuted to place residues at the termini that are more conducive to cyclic 
peptide synthesis. 
The 9-mer linear peptide allyl ester 1a with sequence FLIMGWTLD was 
prepared along with its derivatives, the 15-mer linear peptide allyl ester 2a and 
13-mer linear peptide allyl ester 3a (Figure 2.2). The linear peptide allyl ester 
compounds (1a, 2a, 3a) were used as precursors for the synthesis of cyclic 
compounds 1c, 2c, and 3c respectively, starting with aspartic acid (D) and 
ending with phenylalanine (F). Therefore, the epitope sequence after 
cyclisation is still the same as the original. The purpose of this permutation is 
to shift the aspartic acid residue to the C−terminus so that it can be anchored 
to the resin through its side chain. Wang resin pre-loaded through the side 
chain of the allyl ester protected derivative of aspartate (Section 1.6.1.2) is 
commercially available for this purpose. Once deprotected with the aid of a 
Pd(PPh3)4 catalyst, the alpha carboxyl group of the aspartic acid residue at the 
C−terminus can be cyclised onto the amino group of the N−terminus to afford 
a cyclic peptide by a head−to−tail strategy (See Scheme 2.1). 
In addition, this permutation shifted the glycine residue into the middle of 
the peptide sequence, increasing the flexibility of the peptide and providing a 
greater chance for the termini of the peptide to be close together during the 
cyclisation reaction.136 
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1a (m/z = 1135.6) in the +1 charge state 
 
2a (m/z = 1904.1) in the +1 charge state 
 
3a (m/z = 1565.8) in the +1 charge state 
Figure 2.2: Structure of compounds 1a, 2a and 3a. 
 
 
Scheme 2.1: General procedure to synthesise of the cyclic peptide (1c) by the 
head to tail method. 
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 The importance of the epitope sequence for various aspects of 
immunotherapy 174, 175 and the poor physical properties of the 9-mer cyclic Bax 
peptide (very poor solubility in the HPLC and LCMS solvents) were the reasons 
to design and synthesise the two derivatives 2c and 3c (Figure 2.3) using the 
SPPS method. 
 
1c 
 
2c 
 
3c 
Figure 2.3: Sequences of 1c, 2c and 3c. 
 
The cyclic peptide derivative 2c included insertion of a fragment 
consisting of six amino acids, RELIRT, that flank the 9-mer epitope in the 
sequence of Bax (ELIRTIMGWTLDFLR). The flexibility arising from the greater 
length of the cyclic peptide (15-mer) enhances the chances of cyclic peptide 
formation.130, 131 This fragment has three polar amino acids, one glutamic acid 
and two arginine residues. Thus, this peptide has two positive charges from the 
side chains of arginine, and two negative charges from the side chains of 
glutamate and aspartate. The polarity is greater than that of cyclic Bax peptide 
(1c) which has a single negative charge and, consequently, water solubility was 
expected to be enhanced. The presence of this fragment gives an amphipathic 
property to the cyclic peptide, supporting the ability of the compound to cross a 
biological membrane to enter the target cell.176 In addition to that, this new 
fragment gives further synthetic options for forming a cyclic structure by linking 
the side chain of an Arg residue with the carboxyl group of the C−terminus (tail 
to side chain reaction) or linking the side chain of the Arg residue to the side 
chain of the Glu residue (side chain to side chain).38 Moreover, this fragment 
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introduced the option to bind the peptide with the resin by the Glu residue 
instead of the Asp residue which may influence the yield of the cyclisation 
reaction.  
The cyclic peptide 3c included insertion of a fragment consisting of the 
four amino acids KSSK. This polar fragment introduces two additional positive 
charges. Consequently, compound 3c is more hydrophilic than 1c and thus 
more soluble in water. In addition to that, the presence of the positively charged 
sequence KSSK will create an overall cationic charge state at physiological pH, 
thus increasing the chance of crossing the membrane of the target cell.177 
Moreover, this new fragment leads to further options for cyclisation by binding of 
a Lys side chain with the C−terminus of the peptide (side chain to tail).126 
Furthermore, lysine can provide other synthetic routes, thus, 13-mer linear 
peptide (3b) can be anchored to the resin through the side chain of Lys. The 
Ser residue was chosen as this has been applied in flexible hydrophilic linkers 
for fusion of protein domains such as multivalent antibodies.178 
Fmoc−Asp(NovaSyn® TGA)−OAll resin (Figure 2.4, A) with a low loading 
of 0.2 mmol/g, was used to synthesise the cyclic peptides (1c, 2c, 3c) and their 
linear counterparts (1b, 2b, 3b) by Fmoc methodology. The main reasons for 
using low loading resin is to increase the probability of intramolecular 
cyclisation and to reduce interactions between the individual growing 
sequences preventing interchain aggregation (intermolecular dimer 
formation).144 
In the synthesis of the linear peptide allyl ester (1a, 2a, 3a), 
Fmoc−Trp(Boc)−Thr(psiMe, Mepro)−OH (Figure 2.4, B) was used instead of 
Fmoc−Trp(Boc)−OH and Fmoc−Thr(t−Bu)−OH residues. This secondary 
amino acid surrogate can positively support the synthesis of the cyclic peptide 
as it induces a turn in the peptide chain which was intended to assist with the 
cyclisation reaction by bringing the termini of the peptide closer together. The 
secondary amino acid surrogates are like proline or N−alkylamino acids; they 
work to disrupt the formation of the secondary structures during synthesis of 
peptides.179 
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A 
 
B 
Figure 2.4: A = Structure of Fmoc-Asp (NovaSyn® TGA)-OAll. B = 
Structure of Fmoc-Trp(Boc)-Thr(psiMe, Mepro)-OH. 
  
 Result and discussion of peptide synthesis 
 Synthesis of the 9-mer linear peptide allyl ester (1a) 
Subsequent to an investigation of the linear peptide allyl ester (1a) by HPLC, 
as in Figure 2.5, the crude sample gave a strong peak at retention time of 22.53 
min; the peak width was less than one minute. It was eluted at a solvent 
composition containing more acetonitrile than water (41%:49% water to 
acetonitrile); this retention time is evidence that the peptide is a hydrophobic 
compound due to the presence in the sequence of more hydrophobic amino 
acids than hydrophilic. This peak was the target compound (1a).  
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Figure 2.5: HPLC chromatogram of 9-mer crude linear peptide allyl 
ester (1a). 
 
The LC−MS analysis for the collected peak at the retention time 22.53 
min in Figure 2.5 supported the HPLC result; the total ion chromatogram clearly 
showed a peak of 1135.8 m/z with the retention time of 11.0 min (Figure 2.6). 
This peak was consistent with the theoretically calculated value of 1135.5 m/z 
for the compound in the +1 charge state. 
 
Figure 2.6: Total ion chromatogram of 9-mer purified linear peptide allyl 
ester (1a) ([M+H]+ m/z = 1135.5), collected peak at 22.53 min in Figure 
2.5). 
 
The structure of this compound (1a) is presented in Figure 2.7. This result 
provided evidence that the coupling reactions were successful and that the 
linear peptide allyl ester compound (1a) was formed in its entirety. 
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Figure 2.7: Structure of 9-mer linear peptide allyl ester (1a) in the +1 
charge state (m/z = 1135.5). 
 
 Synthesis of the 15-mer linear peptide allyl ester (2a) 
The investigation of the 15-mer linear peptide allyl ester (2a) by HPLC, as in 
Figure 2.8, showed that the crude sample gave a high−intensity sharp peak 
without any overlap and less than 1 min width at the retention time of 17.84 
min. This peak was potentially compound 2a. 
 
Figure 2.8: HPLC chromatogram of 15-mer crude linear peptide allyl 
ester (2a). 
 
The mass spectrum of the same sample supported the HPLC result. The 
total ion chromatogram (Figure 2.9) distinctly showed a peak of 953.1 m/z at 
the retention time 11.9 min. This peak matches the theoretically calculated 
value of the target compound 2a (952.6 m/z) in the +2 charge state.  
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Figure 2.9: Total ion chromatogram of 15-mer crude linear peptide allyl 
ester (2a) ([M+2H]2+ m/z = 952.5). 
 
The structure of compound 2a is shown in Figure 2.10. This result is 
significant evidence of successful coupling reactions and that all the 15 
residues were bonded together to form the linear peptide allyl ester (2a). 
 
 
Figure 2.10: Structure of 15-mer linear peptide allyl ester (2a) in the +2 
charge state (m/z = 952.5).  
 
The other four peaks 981.1, 961.0, 993.0, 1001.0 m/z at 10.2, 10.9, 11.4, 
13.4 min respectively potentially represented: compound 2a still bonded with 
one or two side chain protecting groups on a threonine residue (t−Bu) and 
tryptophan residue (Boc); oxidation of the sulfur (S) to a sulfoxide (S=O) at the 
side chain of the methionine residue; or linear peptide allyl ester with one or 
more amino acid deletions.  
 Synthesis of the 13-mer linear peptide allyl ester (3a) 
Figure 2.11 shows the HPLC chromatogram of the crude sample of 13-mer 
linear peptide allyl ester (3a); the main result is a strong, sharp peak without 
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any overlap and less than 1 min width at the retention time 11.81 min. This 
peak was considered to be the target compound (3a).  
 
Figure 2.11: HPLC chromatogram of 13-mer crude linear peptide 
allyl ester (3a). 
 
The HPLC result was supported by the LC−MS analysis for the same 
sample; Figure 2.12 indicates the total ion chromatogram of the crude sample 
of compound 3a. The peak of 522.9 m/z at the retention time 10.0 min is 
consistent with the theoretically calculated value of 522.6 m/z for the target 
compound in the +3 charge state. 
 
Figure 2.12: Total ion chromatogram of 13-mer crude linear peptide allyl 
ester (3a) ([M+3H]3+ m/z = 522.6). 
 
The structure of 13-mer linear peptide allyl ester (3a), is illustrated in 
Figure 2.13. The mass spectrometry result is clear evidence of the success of 
all the coupling reactions.  
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Figure 2.13: Structure of 13-mer linear peptide allyl ester (3a) in the +3 
charge state (m/z = 522.6). 
 
The peak of 568.3 m/z at 13.3 min was possibly due to a side product in 
which compound 3a was still bonded to hydrophobic protecting groups. It 
potentially represented the same species that appeared at retention time 14.17 
min in the HPLC chromatogram (Figure 2.11) 
 Synthesis of the 9-mer linear peptide (1b) as a 
precursor for the cyclic peptide (1c) 
The data in Figure 2.14 show the HPLC chromatogram of a crude sample of 9-
mer linear peptide (1b). The main result is the intense peak at the retention time 
of 14.51 min. This peak was considered to be the target compound (1b).  
 
Figure 2.14: HPLC chromatogram of 9-mer crude linear peptide (1b). 
 
The result of the HPLC analysis was supported by LC-MS analysis of the 
same sample. As revealed in the total ion chromatogram of crude 1b (Figure 
2.15), the clear peak corresponding to 1095.7 m/z at retention time 10.5 min 
was evidence that the deprotection reaction of the allyl group using Pd(PPh3)4 
as a catalyst was successful. The observed peak (1095.7 m/z) was consistent 
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with the theoretically calculated value of 1095.6 m/z for the compound in the 
+1 charge state as in Figure 2.16.  
 
Figure 2.15: Total ion chromatogram of 9-mer crude linear peptide (1b) 
([M+H]+ m/z = 1095.6). 
 
 
 
Figure 2.16: Structure of 9-mer linear peptide (1b) in the +1 charge state 
(m/z = 1095.6). 
 
It is should be noted that the retention time of this peak (14.51 min) was 
indicative of the successful conversion of compound 1a to 1b because the 
retention time of the first compound (1a) was 22.53 min (Figure 2.5), which was 
expected due to the lower polarity because of the allyl group compared to the 
carboxylic acid of 1b. 
The low m/z peaks (288.2, 470.5, 338.4 m/z) at the retention times 12.6, 
19.2 and 22.4 min respectively are probably contamination originating from the 
column. 
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 Synthesis of the 15-mer linear peptide (2b) as a 
precursor for the cyclic peptide (2c) 
Figure 2.17 shows the HPLC chromatogram of the purified sample of 15-mer 
linear peptide (2b); the main apparent result is the strong sharp peak at the 
retention time 12.67 min. This peak was considered to be the target compound 
(2b) 
 
Figure 2.17: HPLC chromatogram of 15-mer purified linear peptide 
(2b). 
 
Mass spectral analysis for the same sample (Figure 2.18) supported the 
HPLC result. The single peak of 622.3 m/z at the retention time 10.8 min is 
consistent with the theoretically calculated value of 622.0 m/z for 2b in the +3 
charge state. 
 
Figure 2.18: Total ion chromatogram of 15-mer purified linear peptide (2b) 
([M+3H]3+ m/z = 622.0). 
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The structure of this peptide (2b) is in Figure 2.19. This result is evidence 
of the successful deprotection reaction of the allyl group by using Pd(PPh3)4 as 
a catalyst to form the linear peptide (2b).  
 
 
Figure 2.19: Structure of 15-mer linear peptide (2b) in the +3 charge state 
(m/z = 622.0). 
 
It is significant that the retention time of this peak (12.67 min) is less than 
the peak of 2a (17.84 min) as in Figure 2.8. This result was expected because 
the polarity of the compound 2a is less than compound 2b. The small peak at 
the retention time 14.09 min was potentially a contaminant from the column.  
 Synthesis of the 13-mer linear peptide (3b) as a 
precursor for the cyclic peptide (3c) 
As shown in Figure 2.20, the HPLC chromatogram of the crude sample for 13-
mer linear peptide (3b) displays a strong, sharp peak at the retention time 10.68 
min that was considered to be the linear peptide (3b).  
 
Figure 2.20: HPLC chromatogram of 13-mer crude linear peptide (3b). 
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The total ion chromatogram in Figure 2.21 for the same sample supports 
the HPLC result. The peak of 509.6 m/z at the retention time 8.9 min is 
consistent with the theoretically calculated value of 509.3 m/z for the linear 
peptide (3b) in the triply charged state. The structure of this compound (3b) is 
shown in Figure 2.22. 
 
Figure 2.21: Total ion chromatogram of 13-mer crude linear peptide (3b) 
([M+3H]3+ m/z = 509.3). 
 
 
 
Figure 2.22: Structure of 13-mer linear peptide (3b) in the +3 charge state 
(m/z = 509.3). 
 
This result is evidence of successful formation of the target compound 
(3b) by using Pd(PPh3)4 as a catalyst. The HPLC result reveals an important 
point that must be taken into account; the retention time of this compound (3b) 
is less than the retention time of 3a (11.81 min) as in Figure 2.11. This result is 
evidence that compound 3a was converted to 3b. The decrease in the retention 
time of 3b in comparison with compound 3a was expected, as the polarity of an 
allyl ester is less than a carboxylic acid.  
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 The peak of 514.9 m/z at the retention time 8.4 min is potentially 
compound 3b that has undergone oxidation, by atmospheric oxygen, of the 
sulfur in the side group of methionine to form a sulfoxide (S=O). The other two 
peaks 242.2, 304.3 m/z at 12.7, 16.8 min respectively are potentially due to 
contamination from the column. 
 Results and discussion of cyclisation reaction 
In the following three experiments, the resin-bound side chain protected linear 
peptides (1b, 2b, 3b) were used as precursors for the synthesis of the cyclic 
peptides (1c, 2c, 3c). 
 Synthesis of the 9-mer cyclic peptide (1c) 
Six attempts were conducted to convert the side chain protected 9-mer linear 
peptide (1b) to compound 1c as in Table 2.1. Three different reagents (PyBOP, 
HBTU, HATU) were used in the first four of these six attempts. At each one a 
different number of repeats (2, 3), reaction time (1, 2, 24, 48 h), temperature 
(20, 25 °C), speed of the shaker (100, 150 RPM) were tried. In addition, lithium 
ions were used as a coordinator to fold the peptide, but the reactions failed. 
The reason for this failure possibly resulted from the length of the 9-mer cyclic 
peptide (1c), for which the flexibility might have been insufficient to bring the 
termini close enough together to support the coupling reaction successfully. 
These three reagents with the different conditions were not adequate in 
overcoming this problem. The final two attempts (fifth and sixth) were 
successful, a different reagent (DEPBT) was used for the coupling reaction. It 
appears that the use of the DEPBT reagent with an initial reaction time of 2 h, 
followed by an overnight reaction with fresh reagent, at 20 °C, 100 RPM shaker, 
with or without lithium ions, resulted in a successful cyclisation reaction (Table 
2.1). 
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Table 2.1: Attempts at cyclising 1b under different conditions. 
No Reagent No of 
repeats 
Time (h) Temp 
(°C) 
RPM* MIǂ Result 
(LCMS) 
1 PyBOP 2 1
st (2), 2nd 
(overnight) 
25 100 Li+ Failed 
2 PyBOP 3 1
st (1), 2nd 
(2), 3rd (48) 
20 150 Li+ Failed 
3 HBTU 2 1
st (1), 2nd 
(overnight) 
25 100 Li+ Failed 
4 HATU 2 1
st (1), 2nd 
(overnight) 
25 100 Li+ Failed 
5 DEPBT 2 1
st (1), 2nd 
(overnight) 
20 100 Li+ Successful 
6 DEPBT 2 1
st (2), 2nd 
(overnight) 
20 100 No Successful 
ǂ MI = Metal ion, * RPM = shaker revolutions per min 
Although the cyclisation reaction of the Bax peptide (1b) succeeded twice 
by using the DEPBT reagent, the yield was very low (less than 0.5 mg, for both 
reactions combined). The solubility of the compound (1c) was very poor in 
HPLC solvents; therefore, a small amount (1−5 µL) of DMSO was always 
added for each sample that was analysed by HPLC or LCMS. 
The investigation of the sample of the purified cyclic peptide (1c), by 
HPLC, is given in Figure 2.23. The single strong, sharp peak without any 
overlap at the retention time 17.23 min was considered to be the 9-mer purified 
cyclic peptide (1c).  
 
Figure 2.23: HPLC chromatogram of 9-mer purified cyclic peptide (1c). 
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LCMS analysis of the same sample supported the HPLC result; as shown 
in Figure 2.24, the total ion chromatogram of compound 1c has a clear peak 
corresponding to 1075.8 m/z at the retention time 11.7 min that is consistent 
with the theoretically calculated value of 1075.5 m/z for 1c in the −1 charge 
state. The structure of this compound (1c) is in Figure 2.25. It was evident that 
the cyclisation reaction between the two termini of the linear peptide (1b) using 
DEPBT coupling reagent was successful. 
 
Figure 2.24: Total ion chromatogram of 9-mer purified cyclic peptide (1c) 
([M−H]− m/z = 1075.5). 
 
 
 
Figure 2.25: Structure of 9-mer cyclic peptide (1c) in the 
−1 charge state (m/z = 1075.5). 
 
It should be noted that the width of the cyclic peptide peak in HPLC 
chromatogram is less than 1 min, with no overlap with other peaks, and no 
shoulders; thus, the purity of this cyclic peptide (1c) was deemed to be 
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acceptable. The retention time of this peak is significant as an item of evidence 
for conversion of the linear compound (1b) to the cyclic compound (1c). The 
retention time of this peak (17.23 min) was higher than the peak of 1b (14.51 
min) as in Figure 2.14. This result was expected because the polarity of the 
cyclic compound (1c) is less than the linear compound (1b). The reason for the 
decrease of the polarity in the cyclic compound is bonding of the free polar 
termini of the peptide together.  
 Synthesis of the 15-mer cyclic peptide (2c) 
The 15-mer cyclic peptide synthesis was undertaken using the same method 
and conditions for the synthesis of the 9-mer cyclic peptide (1c) in entry five of 
Table 2.1. Two attempts were conducted to synthesise this cyclic compound; 
the first one failed during synthesis of the precursor (2a). In the second attempt, 
the on-resin cyclisation of protected 2b was successful. Therefore, it provided 
clear evidence that insertion of the RELIRT fragment in the Bax peptide 
sequence between isoleucine and leucine residues was a successful proposal 
to enhance the cyclisation reaction. 
The length and flexibility of the compound (15-mer) was potentially the 
reason for the precursor 2b adopting new conformations having the termini 
closer together than in compound 1b. Another possibility was hydrogen bonds 
between the side chains of the linker sequence pulling the termini of the peptide 
close together to enhance the coupling reaction. 
Collection and purification of 2c by the HPLC was straightforward 
because the solubility of the compound in the HPLC solvent (a mixture of water 
and acetonitrile) was acceptable. Centrifuging of the sample dissolved in the 
HPLC solvent at 19450 RCF for 5 minutes led to a very small amount of 
precipitate being visible in the bottom of the Eppendorf tube, in comparison to 
1c which resulted in extensive precipitate being visible.  
As can be seen from Figure 2.26, the HPLC chromatogram of the sample 
of the purified 15-mer cyclic peptide (2c), shows a single sharp peak without 
any overlap and less than 1 min width at the retention time 12.29 min that is 
considered to be the purified cyclic compound (2c).  
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Figure 2.26: HPLC chromatogram of 15-mer purified cyclic peptide (2c). 
 
LCMS analysis for the same sample of purified 15-mer cyclic peptide (2c) 
reinforced the HPLC results. As is demonstrated in Figure 2.27, showing the 
total ion chromatogram of a cyclic peptide (2c), here the peak of 923.9 m/z at 
the retention time 10.9 min was a significant result because it matched the 
theoretically calculated value of 923.5 m/z for 2c in the +2 charge state, as in 
Figure 2.28. 
 
Figure 2.27: Total ion chromatogram of 15-mer purified cyclic peptide (2c) 
([M+2H]2+ m/z = 923.5). 
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Figure 2.28: Structure of 15-mer cyclic peptide (2c) in the +2 
charge state (m/z = 923.5). 
 
 This result provides evidence of the success of the cyclisation reaction 
converting the protected linear compound (2b) to 2c (cyclic form) using the 
DEPBT reagent. 
It is important to note that the retention time of 2c (12.29 min) is less than 
that of 2b (12.67 min), as in Figure 2.17. This result was not expected because 
the polarity of the linear peptide (2b) was predicted to be higher than the cyclic 
compound (2c); the reason could be that the restricted conformation of the 
cyclic peptide (2c) results in a more polar shape than the linear peptide (2b). 
The other peaks 242.2, 354.3, 282.3 m/z at the retention times 10.1, 13.5, 19.0 
min respectively could be attributed to impurities from the column. 
 Synthesis of the 13-mer cyclic peptide (3c) 
Synthesis of compound 3c was conducted using the same reagent, method, 
and conditions as entry five in Table 2.1. One attempt was needed to convert 
resin-bound protected 3b to 3c successfully. This result is evidence that the 
insertion of the fragment KSSK in the Bax peptide sequence was also 
successful in rearranging the linear peptide (3b) to permit adoption of 
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conformations that bring the two termini close to each other, supporting the 
coupling reaction.  
As shown in Figure 2.29, the HPLC chromatogram of the sample of 13-
mer purified cyclic peptide (3c) has a single strong peak at the retention time 
14.69 min that represented the target compound (3c).  
 
Figure 2.29: HPLC chromatogram of 13-mer purified cyclic peptide (3c). 
 
The total ion chromatogram for the same sample shown in Figure 2.30 
reinforced the HPLC result. In the total ion chromatogram of the purified sample 
for compound 3c, here the peak of 754.7 m/z at the retention time 12.0 min 
matches the theoretically calculated value of 754.4 m/z for the cyclic peptide 
(3c) in the +2 charge state. The structure of this cyclic peptide (3c) is shown in 
Figure 2.31. This result provides further evidence for the success of DEPBT as 
a cyclisation reagent. 
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Figure 2.30: Total ion chromatogram of 13-mer purified cyclic peptide (3c) 
([M+2H]2+ m/z = 754.4). 
 
 
 
Figure 2.31: Structure of 13-mer cyclic peptide (3c) in the +2 
charge state (m/z = 754.4). 
 
There is a possibility that the length of the peptide (13-mer) may assist in 
allowing the termini of the peptide to approach close together. In addition, the 
presence of two Lys residues in the backbone of the peptide may have 
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contributed to drawing the termini of the peptide close together, forming more 
intramolecular hydrogen bonding with carbonyl groups of the peptide bonds. 
 It is should be noted that purification of compound 3c by HPLC was more 
straightforward than compound 2c because the solubility of 3c in the HPLC 
solvent (a mixture of water and acetonitrile) was greater than 2c. It appears that 
the insertion of the KSSK fragment in the sequence of the Bax peptide was a 
more decisive factor than the RELIRT fragment in increasing the yield (the yield 
of 2c was 0.4 × 10−3 mmole, 2%, while the yield of 3c was 1.8 × 10−3 mmole, 
9%) and the solubility of the cyclic peptide in the HPLC solvents (See Table 
2.2). The retention time of 3c is an indicator that the cyclic compound (3c) has 
formed from its linear counterpart (3b) because the retention time of 3c (14.69 
min) is higher than compound 3b (10.68 min), as in Figure 2.20. This result was 
expected as the polarity of the linear compound (3b) which has five free 
charged groups is greater than the cyclic compound (three ionisable groups). 
Table 2.2: Comparison between the three cyclic peptides (1c, 2c, 3c). 
Peptide 1c 2c 3c 
Inserted 
fragment 
- RELIRT KSSK 
Yield (mg) 
Crude* = 19.2 
Purifiedǂ = <0.5 
Crude = 31.5 
Purified = 0.76 
Crude = 43.6 
Purified = 2.7 
Yield mmole 
(purified) 
- 0.4 × 10−3 1.8 × 10−3 
Yield% - 2 9 
Coupling 
reagent 
DEPBT DEPBT DEPBT 
Solubility in 
H2O 
Insoluble 
Trace 
precipitate 
No precipitate 
Solubility in 
MeCN 
Clearly visible 
precipitate 
Trace 
precipitate 
No precipitate 
Solubility in 
(H2O+MeCN) 
Insoluble 
Trace 
precipitate 
No precipitate 
Solubility in 
methanol 
Insoluble 
Trace 
precipitate 
Trace precipitate 
Solubility in 
isopropanol 
Insoluble 
Clearly visible 
precipitate 
Trace precipitate 
* Mass of crude sample measured by analytical balance.  
ǂ Mass of the purified sample calculated from abs at 280 nm.  
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 Synthesis of the linear peptide (2b, 3b) 
In the following two experiments, dedicated syntheses of linear peptides (2b, 
3b) were performed. The peptides were cleaved from the resin and purified to 
obtain sufficient amounts of these peptides for studies of their enzymatic 
degradation and stability in serum as a comparison with their cyclic 
counterparts (2c, 3c). 
 Synthesis of the 15-mer linear peptide (2b) 
The HPLC chromatogram of the sample of the purified 15-mer linear peptide 
(2b) after deprotection from the resin and removal of the side protecting groups 
of the amino acids is shown in Figure 2.32. The single sharp peak at the 
retention time 12.62 min without any overlap was consistent with the peak of 
12.67 min in Figure 2.17 for the same intermediate compound (2b) during 
synthesis of the cyclic peptide (2c). Therefore, this peak was considered to be 
the target compound (2b). 
 
Figure 2.32: HPLC chromatogram of 15-mer purified linear peptide 
(2b). 
 
LCMS analysis (Figure 2.33) supported the HPLC result; the mass of 
622.3 m/z at the retention time 10.5 min was consistent with the theoretically 
calculated value of 622.0 m/z for the 15-mer linear peptide (2b) in the +3 charge 
state (Figure 2.19). It is important to observe that the synthesis of this linear 
peptide using DEPBT as a coupling reagent was successful after the first 
attempt. In addition, the purification of this compound was also straightforward 
because of its good solubility in the HPLC solvent (water + acetonitrile). 
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Figure 2.33: Total ion chromatogram of 15-mer purified linear peptide (2b) 
([M+3H]3+ m/z = 622.0). 
 
 Synthesis of the 13-mer linear peptide (3b) 
Figure 2.34 shows the HPLC chromatogram of the sample for the purified 13-
mer linear peptide (3b) after deprotection from the resin and removal of the side 
chain protecting groups of the amino acids. The peak at the retention time 10.70 
min was consistent with the peak of 10.68 min in Figure 2.20 for the same 
sample of the peptide (3b) after deprotection of the allyl group during synthesis 
of the cyclic peptide (3c). Therefore, this peak was considered to be the target 
compound (3b). 
 
Figure 2.34: HPLC chromatogram of 13-mer purified linear peptide 
(3b). 
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The mass spectral analysis reinforced the HPLC result; the total ion 
chromatogram in Figure 2.35 gave a peak of 509.6 m/z at the retention time 8.9 
min, which is the same peak observed in Figure 2.21 during synthesis of the 
cyclic peptide (3c). This peak matched the theoretically calculated value of 
509.3 m/z for the 13-mer linear peptide (3b) in the +3 charge state (Figure 
2.22). This result is an indicator that the process of synthesis for this linear 
peptide (3b) using DEPBT as a coupling reagent was successful. The 
purification of the peptide was also straightforward because its solubility was 
acceptable (no precipitate) in the HPLC solvents (water, acetonitrile).  
 
Figure 2.35: Total ion chromatogram of 13-mer purified linear peptide (3b) 
([M+3H]3+ m/z = 509.5). 
 
Both of the linear peptides (2b, 3b) exhibited acceptable solubility (no 
precipitate) in HPLC solvents, as indicated in Table 2.3. The cause for this 
solubility in a range of different solvents is that they have more than one polar 
side chain added to the free polar termini of the two compounds. 
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Table 2.3: Properties of the two synthesised linear peptides (2b, 3b). 
Linear peptide 2b 3b 
Mass (m/z) 622.3 509.5 
RT (min) 12.62 10.70 
Solubility in H2O No precipitate No precipitate 
Solubility in MeCN No precipitate No precipitate 
Solubility in MeCN+H2O No precipitate No precipitate 
Solubility in methanol 
Trace 
precipitate 
Trace precipitate 
Solubility in isopropanol 
Trace 
precipitate 
Trace precipitate 
 
 Results of calculation of the concentration of 
polypeptides 
 Introduction 
It has been found that significant amounts (10−70%) of salt and bound water 
or counterion remain in lyophilised peptides.180 Thus, calculation of the 
concentration based on the mass is inaccurate. The number and type of 
counterions are affected by the sequence of the peptide therefore the 
concentration of peptides is best calculated based upon spectroscopic means. 
The concentration of the peptides was calculated according to the 
following equation (Beer’s law); 
[Peptide concentration] = (A280 / ε) 
A280 is the absorbance of the peptide solution at 280 nm in a 1 cm cell. 
ε is the molar extinction coefficient of Tryptophan and/or Tyrosine at 280 nm. 
ε(Trp) = 5690 M−1cm−1 
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 The 9-mer cyclic polypeptide (1c) 
The concentration of the 9-mer cyclic peptide (1c) has not been calculated, for 
several reasons: the first was that a very small amount was collected, which 
was insufficient to prepare many samples to study the enzymatic degradation 
and to perform kinetic and stability studies in serum. The second reason was 
that some of this cyclic peptide was potentially exposed to hydrolysis during 
storage in the freezer at −20 °C after 15 days. Figure 2.36 presents the HPLC 
chromatogram of 1c after 15 days’ storage in the freezer at −20 °C. The 
appearance of three small peaks at the retention times 12.96, 13.51, 15.37 min 
around the peak of the cyclic compound (1c) at the retention time 14.41 min 
was an indicator of hydrolysis of 1c.  
 
Figure 2.36: HPLC chromatogram of 9-mer purified cyclic peptide 
(1c) after 15 days’ storage in the freezer at −20 °C. 
 
A total ion chromatogram for the same sample, as shown in Figure 2.37, 
supported the HPLC result. In addition to the peak of 1077.7 m/z at the retention 
time 13.1 min for the cyclic peptide (1c), there is more than one peak around 
the cyclic peptide peak such as 953.4 m/z at the retention time 11.8 min, and 
the peak of 892.1 m/z at the retention time 11.7 min. The stability of this 
compound (1c) was very low under these storage conditions. Possibly the 
reason was the short length of compound 1c. Therefore, repurification of the 
cyclic peptide would cause a problem by reducing the yield further. The third 
important reason for not calculating the 9-mer cyclic peptide (1c) concentration 
is that the solubility of this compound in water was very low. Therefore, it will 
precipitate in the buffer solution; for example, ammonium bicarbonate 
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(NH4)HCO3 (0.01 M) during the study of enzymatic hydrolysis by trypsin or 
chymotrypsin. 
 
Figure 2.37: Total ion chromatogram of 9-mer purified cyclic peptide (1c) 
after 15 days’ storage in the freezer at −20 °C, ([M+H]+ m/z = 1077.5). 
 
 The 9-mer linear peptide (1b) 
The project focused on the study of the synthesis of the cyclic peptides and the 
biological activity of these cyclic compounds, therefore, this linear peptide (1b) 
was excluded from this experiment and the biological study, due to there being 
an insufficient amount of compound 1c (as was mentioned in section 2.5.2), in 
addition to that, the solubility of 1c in water (which was used for preparation of 
the buffer solution) was very low. 
 The 15-mer cyclic peptide (2c) 
A = 0.052, MW = 1864.2 g/mol, ε(Trp) = 5690 M−1cm−1 
Utilizing Beer’s law; 
[9-mer cyclic peptide] = 0.052/5690  
= 9.1 × 10−6 M 
This concentration, C1, was in 103 µL (V1, volume of UV cuvette) which 
had been prepared by dilution of stock solution (V2, 4 µL) of concentration C2. 
The concentration of the stock solution is then given by: C1 × V1 = C2 × V2 
9.1 × 10−6 × 103 = C2 × 4 
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C2 (mol/L) = 2.2 × 10−3 (conc. of the stock solution) 
Weight (mg) = [2.2 × 10−3 × 1846.2 × 180 × 10−3 / 103] × 103 
 = 0.76 mg 
Number of mmoles = concentration of the stock solution × stock solution 
volume × 103 
= 2.2 × 10−3 × 180 × 10−3 
= 0.4 × 10−3 
Percentage of yield = number of mmoles of peptide × 100 / meq of resin (0.02) 
= 0.4 × 10−3 × 100 / 0.02 
= 2 
The above procedure was used to calculate the weight, concentration, 
number of moles, and the percentage of the yield for 2b, 3b, and 3c. All the 
results are presented in Table 2.4.  
Table 2.4: The value of concentration, weight, number of moles, and the 
percentage yield of the peptides (2b, 2c, 3b, 3c) in their stock solutions. 
Peptide 2b 2c 3b 3c 
Absorbance 0.032 0.052 0.206 0.131 
MW (g/mol) 1864.2 1846.2 1526.8 1508 
Con. (M) in 103 µL* 5.6 × 10−6 9.1 ×10−6 3.5 × 10−5 2.3 × 10−5 
Con. (M) in stock 
solution 
5.6 ×10−3 2.2 × 10−3 3.5 × 10−3 7.7 × 10−3 
Weight (mg) 1.1 0.76 0.74 2.7 
Number of mmoles 0.6 × 10−3 0.4 × 10−3 0.5 × 10−3 1.8 × 10−3 
Percentage yield 3 2 2.5 9 
* 103 µL = UV cuvette volume 
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 Results of peptide fragmentation 
 Introduction 
MS analysis is one of the most important techniques used to study and 
characterise the sequence of amino acids in peptides and proteins. 
Determination of the sequence of these compounds is undertaken after 
ionisation, converting them to charged compounds (mainly positive ions) in the 
gas phase. ESI (electrospray ionisation)181 or MALDI (matrix−assisted laser 
desorption/ionisation)182 are used as an ionisation technique to form these ions 
without fragmentation. The mass to charge ratio (m/z) of these ions can be 
measured accurately. 
The MS2 method is usually used for deriving sequence information of 
peptides and proteins.183 It is an attractive alternative method to NMR (nuclear 
magnetic resonance) for two main reasons: the first is that NMR technique 
requires large amounts of sample (milligrams), while in MS2, picograms are 
sufficient. The second is that a highly purified sample is used to verify structure 
by NMR, while in MS2, a non−purified sample can be employed.184 In addition, 
interpretation of NMR spectra is time consuming. In the MS2 method, the ions 
are exposed to excitation and dissociation after passing from the analyser to 
measure the value of m/z for the dissociation products. Low energy is used to 
excite the precursor ion by using an inert gas, such as argon, to create 
energetic collisions; this process is called collision induced dissociation 
(CID).185 Under this low energy collision, protonated peptides are often 
fragmented by peptide bond cleavage to produce b ions (N−terminal fragment) 
and y ions (C−terminal fragment)186 as shown in Scheme 2.2.  
  
   
 
77 
 
 
Scheme 2.2: Mechanism of peptide fragmentation using the CID method. 
 
It was observed that there is an alternative, more stable structure 
(non−oxazolone) for the fragments (acyl b1, b2) where certain amino acids such 
as Lys or Arg are present in the sequence of the fragment.184 A caprolactam 
derivative is formed with or without loss of ammonia from the side chain of 
Lys187 as in Schemes 2.3 and 2.4. 
 
Scheme 2.3: Loss of ammonia from lysine-containing peptide forming a 
stable caprolactam derivative. 
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Scheme 2.4: Caprolactam derivative formed from 
lysine without loss of ammonia. 
 
 Regarding Arg, an ammonia molecule is eliminated from the guanidino 
side chain of arginine,188 providing a stable structure as in Scheme 2.5. Without 
loss of ammonia, the cyclic structure is formed as in Scheme 2.6.  
 
Scheme 2.5: Loss of ammonia from arginine-containing 
peptide. 
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Scheme 2.6: Caprolactam derivative formed by Arg 
side chain without loss of ammonia. 
 
Loss of water molecules and formation of a cyclic structure in the gas 
phase was observed when Ser or Met residues were present in the 
sequence,189 as in Scheme 2.7 for Ser, while in the presence of aspartic acid 
at the C−terminus,190 the cyclic structure is formed as in Scheme 2.8. 
 
Scheme 2.7: Loss of water from Ser-containing 
peptide. 
 
 
Scheme 2.8: Formation of a stable cyclic anhydride from an Asp 
residue. 
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One of the significant advantages to the MS2 mass spectrometry is that 
this technique is used to provide evidence of the conversion of the linear form 
to the cyclic compound. The linear compound could eliminate a water molecule 
during measurement of the mass spectrum when it has a threonine or serine 
residue, giving the same mass of its cyclic counterpart. On the other hand, the 
process of cyclisation of the linear peptide by the head to tail method also 
involves loss of a water molecule. Therefore, the result of MS mass for the 
putative cyclic compound has the potential to be misleading. The MS2 
technique has the ability to resolve this issue. There is not a fragment that 
contains the two termini (C−terminal residue and N−terminal residue) bonded 
together in the MS2 mass spectrum of the linear compound, while the presence 
of this fragment is possible in the MS2 mass spectrum of the cyclic compound. 
 Comparison between fragmentation of the 9-mer cyclic 
peptide (1c) and its linear counterpart (1b) 
The MS2 mass spectrum of the 9-mer purified cyclic peptide (1c) is shown 
in Figure 2.38. The observed masses of the fragments were consistent with the 
theoretically calculated values. The possible sequences of these fragments are 
suggested in Table 2.5. The structures of these fragments are given in Table 
A.1 in Appendix A. 
 
Figure 2.38: MS2 mass spectrum of 9-mer cyclic peptide (1c) precursor 
(m/z = 1077). 
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Table 2.5: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 9-mer cyclic peptide (1c). (See Figure 2.38) 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 1059.7 1059.5 MH-2H2O 
2 962.0 962.5 b8 
3 946.6 
946.5 
946.4 
b8 
b8-H2O 
4 831.5 831.4 b7-H2O 
5 748.5 748.4 b6 
6 704.0 704.3 b6 
7 555.4 555.3 b5-H2O 
 
Notably, the observed mass of 946.6 m/z was consistent with the 
theoretically calculated values of 946.5 and 946.4 m/z for the fragments which 
have the possible sequences of b8 and b8−H2O respectively. There are three 
proposed structures for the fragment of b8−H2O, as in entry 3 in Table A.1 in 
Appendix A. These four fragments were expected to exist among the other 
fragments because there were several possibilities for the site of the initially 
cleaved amide bond in the cyclic peptide (1c). All four fragments have the two 
residues Phe and Asp bonded together (Scheme 2.9).  
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Scheme 2.9: Possible sites of cleaved peptide bonds during 
fragmentation of 9-mer cyclic peptide (1c) by MS2 to result in the 
fragment of 946.6 m/z (b8, b8-H2O) which has a bond between F and D.  
  
As a comparison with the 9-mer linear peptide (1b), a fragment with 946.6 
m/z did not appear in the MS2 mass spectrum of 1b (See Figure 2.39, Table 
2.6 and Table A.2 in Appendix A) because it is impossible to find a fragment 
that has Asp and Phe residues bonded together. These two residues are each 
found at opposing termini of the linear peptide. 
 
Figure 2.39: MS2 mass spectrum of 9-mer linear peptide (1b) precursor 
(m/z = 1095.7). 
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Table 2.6: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 9-mer linear peptide (1b). (See Figure 2.39). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 1077.7 1077.5 MH-H2O 
2 962.0 962.5 b8 
3 944.6 944.5 b8-H2O 
4 849.0 849.4 b7 
5 831.5 831.4 b7-H2O 
6 748.5 748.4 b6 
7 722.0 722.3 y6 
 
The observed mass of 1077.7 m/z was consistent with the theoretically 
calculated value of 1077.5 m/z for the linear peptide (1b); the mass of this 
peptide was reduced by the mass of a water molecule (See fragment 1 in Table 
2.6). The structure of this fragment is entry number 1 in Table A.2 in Appendix 
A.  
It should be noted that some of the observed fragments in the MS2 mass 
spectrum of 1c were observed in the MS2 mass spectrum of 1b; for example, 
b6 and b7−H2O. On the other hand, some of the observed fragments in the MS2 
mass spectrum of 1c did not appear in the MS2 mass spectrum of 1b; for 
example, y6−H2O and b5−2H2O. This result was expected because the first 
fragmentation of the cyclic peptide (1c) to the linear compound (1b) gives a 
different sequence in comparison with its linear counterpart (1b). Therefore, 
this fragment produces different sub-fragments compared to the fragments of 
its linear counterpart (1b). 
 Comparison between fragmentation of the 15-mer 
cyclic peptide (2c) and its linear counterpart (2b) 
Figure 2.40 reveals the MS2 mass spectrum of the 15-mer cyclic peptide (2c). 
The observed masses of the fragments were matched to theoretically 
calculated values (See Table 2.7).  
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Figure 2.40: MS2 mass spectrum of 15-mer cyclic peptide (2c) precursor (m/z 
= 924.0). 
 
The possible sequences of these fragments are suggested in Table 2.7. 
The structures of these possible sequences are given in Table A.3 in Appendix 
A. 
Table 2.7: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 15-mer cyclic peptide (2c). (See Figure 2.40). 
No 
Observed 
 m/z 
Calculated  
m/z 
Suggested  
sequence 
1 1300.9 1300.7 b11 
 
 
2 
 
 
915.0 
915.0 
915.5 
914.5 
914.5 
914.5 
1-MH2-NH3 
2-y8−NH3, 
3-a8−NH3 
4-a8−NH3* 
5-b8 
3 659.4 659.4 b5 
4 546.4 546.3 b4 
5 417.3 417.3 b3ǂ 
6 330.2 330.2 b3 
a8−NH3* and b3ǂ are sequences were formed from fragmentation of a different ring-
opened sequences in comparison to the a8−NH3 and b3 sequences respectively.  
Notably, the observed mass of 915.0 m/z was consistent with the 
theoretically calculated values of 915.0, 915.5, 914.5, 914.5, 914.5 m/z for the 
fragments that have the possible sequences MH2−NH3, y8−NH3, a8−NH3, 
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a8−NH3*, b8 respectively as in above Table 2.7. The structures of these 
fragments are in entry 2 in Table A.3 in Appendix A. Scheme 2.10 includes the 
possible sites for the cleaved peptide bonds in compound 2c to give the 
fragment that has an observed mass of 915.0 m/z in Figure 2.40. None of the 
observed fragments except doubly charged MH2−NH3 contain both the Asp and 
Phe residues that were at the termini of the linear peptide precursor.  
 
Scheme 2.10: Possible sites of cleaved peptide bonds in the 15-mer 
cyclic peptide (2c) during fragmentation by MS2 to produce the fragment 
of MH2-NH3 (915.0 m/z) which has a bond between F and D. 
 
The presence of this fragment (MH2−NH3) was evidence for successful 
coupling reaction between two termini of 15-mer linear peptide (2b) forming the 
cyclic compound (2c). As a comparison with compound 2b, the corresponding 
fragment is not observed (See Figure 2.41, Table 2.8, Table A.4 in Appendix 
A). Phe represents the last residue at the N−terminus while Asp represents the 
last residue at C−terminus of 2b. 
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Figure 2.41: MS2 mass spectrum of 15-mer linear peptide (2b) precursor 
(m/z = 933.0). 
 
Table 2.8: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 15-mer linear peptide (2b). (See Figure 2.41). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 1447.8 1447.8 y12 
2 1256.8 1256.7 b10-NH3 
3 1125.8 1125.7 b9-NH3 
4 924.0 923.5 MH2-H2O 
5 835.0 835.4 y7 
6 637.4 637.4 b10 
7 546.3 546.3 b4 
8 417.3 417.3 b3 
 
The presence of Arg at the C−terminal of a b2 ion led to formation of an 
alternative cyclic structure to the oxazolone involving a side chain of arginine 
acting as a nucleophile to attack an acylium ion (Entry 5 in Table A.3 in 
Appendix A). Also, a b2 ion which has Asp at the C−terminal has an alternative 
cyclic structure to the oxazolone (entry 6 in Table A.3 in Appendix A), where 
the side chain of the aspartic acid has made a nucleophilic attack on an acylium 
ion. 
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 Comparison between fragmentation of the 13-mer 
cyclic (3c) peptide and its linear counterpart (3b) 
The MS2 mass spectrum of the 13-mer cyclic peptide (3c) can be seen in Figure 
2.42. The observed masses of the fragments were consistent with the 
theoretically calculated values. The sequences of these fragments are 
suggested in Table 2.9. The proposed structures of these fragments are given 
in Table A.5 in Appendix A. 
 
Figure 2.42: MS2 mass spectrum of purified 13-mer cyclic peptide (3c) 
precursor (m/z = 754.9). 
 
Table 2.9: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 13-mer cyclic peptide (3c). (See Figure 2.42). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 1507.9 1507.8 MH 
2 1378.7 1378.7 y12+H2O 
3 1178.5 1178.6 b10 
4 963.3 963.5 y8 
5 717.0 717.4 b6 
6 617.0 617.4 
y5 
b5 
7 545.4 545.3 b5-H2O 
8 330.2 330.2 y3 
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Of all the fragments appearing, the fragment of 617.0 m/z was consistent 
with the theoretically calculated value of 617.4 m/z with the suggested 
sequences of b5 and y5 in Table 2.9. The structure of this fragment is entry 6 in 
Table A.5 of Appendix A. Appearance of the b5 and y5 fragments provide 
evidence for the presence of the cyclic peptide (3c) because the sequence of 
these fragments included Asp and Phe bonded together by a peptide bond, 
indicating there was a successful cyclisation reaction between the two termini 
of the linear peptide (3b). The presence of these fragments (b5, y5) was 
expected, as more than one site of peptide bond cleavage was expected during 
fragmentation. It appears that the cleavage was at the peptide bond between 
K3 and S4 then loss of the fragment SSKIMGWT producing the y5 fragment. 
Initial cleavage between L12 and T11, then loss of the same fragment 
(SSKIMGWT) produced the b5 fragment as in Scheme 2.11. 
 
Scheme 2.11: Possible sites of cleaved peptide bonds during 
fragmentation of 13-mer cyclic peptide (3c) by MS2 to result in the 
fragment of 617.0 m/z (b5, y5) which has a bond between F and D. 
 
 In comparison with 3c, this fragment (617.0 m/z) did not appear in the 
MS2 mass spectrum of 3b (Figure 2.43, Table 2.10 and Table A.6 in Appendix 
A), as was expected because there was no bond between Asp and Phe in 
compound 3b. 
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Figure 2.43: MS2 mass spectrum of purified 13-mer linear peptide (3b) 
precursor (m/z = 509.6). 
 
Table 2.10: The comparison between theoretically calculated peaks and the 
observed CID fragments of purified 13-mer linear peptide (3b). (See Figure 2.43). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 696.9 696.9 b12 
2 640.4 640.3 b11 
3 589.8 589.8 b10 
4 458.9 459.3 b4-NH3 
5 348.1 348.2 y3 
6 247.1 247.1 y2 
 
Alternative cyclic structures to the oxazolone can be proposed in some b2 
ion fragments (linear and cyclic) resulting from the presence of Asp, Lys, or 
serine at the C−terminal of the b2 ion, as mentioned for compounds 1c or 2c. 
As was referred to in the study of fragmentation of compound 1c and its 
linear counterpart (1b), here some of the fragments were also observed in both 
MS2 mass spectra of 3b and 3c. In addition, some of the fragments were not 
seen in the MS2 mass spectrum of 3b that had been seen in the MS2 mass 
spectrum of 3c, for example, y8. 
The three cyclic peptides (1c, 2c, 3c) with their linear counterparts (1b, 
2b, 3b) have been synthesised and identified. The first, Bax peptide (1c) was 
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excluded from the next experiments (enzymatic degradation and stability of the 
peptides in FCS) because of its yield being very low and its low solubility in 
water. In addition, it was hydrolysed during storage in the freezer. Therefore, 
its linear counterpart (1b) was also excluded from these experiments. MS2 
mass spectra for each cyclic peptide (1c, 2c, 3c) demonstrated different peaks 
from its linear counterpart (1b, 2b, 3b) in addition to the possibility of a fragment 
that has a bond between Phe and Asp. Insertion of a new fragment (RELIRT 
or KSSK) between the Ile and Leu residues of the Bax peptide sequence to 
form new derivatives (2c or 3c) respectively increased the solubility of the 
peptides (2c, 3c) in HPLC solvents and enhanced the synthesis yield following 
purification. 
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Chapter 3 
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 Biological studies of the peptides 
 Introduction 
The degradation experiments and kinetic study of the peptides (2b, 2c, 3b and 
3c) used two members of the serine protease family of enzymes, chymotrypsin 
and trypsin. This type of enzyme is one of the six families that are classified 
according to the nature of their catalytic residues191 (serine acts as a 
nucleophilic residue at the active site of the enzyme) which can be found in the 
digestive tract and serum of humans, in addition to the bovine pancreas. They 
are endopeptidases that can cleave the internal peptide bonds with high 
specificity; for example, trypsin cleaves the peptide bond at the carboxyl side 
of the Arg or Lys amino acids by the addition of a water molecule.192 The 
commercial availability of this type of enzyme was an advantage to their use in 
these experiments. Additionally, there is precedent for their use in many 
well−documented studies.193 The source of the two enzymes was the bovine 
pancreas. 
The reaction rate for the disappearance of the starting material during the 
enzyme catalysed peptide hydrolysis was modelled using first order kinetics. 
Therefore, the t½ of the peptides (2b, 3b, 2c, 3c) was calculated using the 
following equation: 
t½ = ln 2 / k 
where k = rate constant 
 Results and discussion of the study of enzymatic 
degradation of peptides 
 Results of calculation of the concentration of trypsin 
and chymotrypsin 
The concentration of the trypsin and chymotrypsin was determined using the 
Bradford assay using BSA as a standard protein. The absorbance of the 
Bradford reagent after addition of BSA at known concentration is given in Table 
3.1. 
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Table 3.1: Absorbance at 595 nm for the different concentrations of standard 
protein (BSA) with Bradford reagent. 
BSA µL 
[BSA] µg/mL 
in 200 µL 
Absorbance 
595 nm 
2 10 0.429 
4 20 0.490 
6 30 0.546 
8 40 0.570 
10 50 0.628 
12 60 0.663 
14 70 0.698 
16 80 0.761 
18 90 0.781 
20 100 0.844 
 
The calibration curve of the concentration of BSA (µg/mL) against the 
absorbance at 595 nm was plotted in Figure 3.1. The x parameter in the 
equation (y = 0.0044 x + 0.3996) represents the concentration of the protein 
(C1) in 200 µL of solution prior to addition of the Bradford reagent. 
 
Figure 3.1: Calibration graph of the protein standard (BSA). 
 
After measuring the absorbance of the enzyme (trypsin, chymotrypsin) at 
the wavelength 595 nm, which is represented by the letter y in the equation, 
the concentration of the enzyme (C1) was calculated and the results are shown 
in Table 3.2. 
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Table 3.2: Concentration of trypsin and chymotrypsin in 200 µL (C1) and the 
stock solution (C2) with the mean of C2. 
Enzyme MW µL Abs (595 
nm) 
C1 
(µg/mL) 
C2 
(µM) 
Mean of 
C2(µM) 
Chymotrypsin 25000 4 0.6123 48.032 96.064 
106 
Chymotrypsin 25000 6 0.7844 87.157 116.21  
       
Trypsin 23800 2 0.4261 5.704 23.969 
41 
Trypsin 23800 4 0.5208 27.225 57.195  
 
Subsequently, the concentration of the enzymes (µM) in the stock solution 
(C2) and the mean of the two measurements were calculated for the two 
enzymes (See above Table 3.2), according to the following equation: 
C1 × V1 = C2 × V2 
C1 = concentration of the enzyme in 200 µL  
V1 = 200 µL 
C2 = concentration of the enzyme in the stock solution (µg/mL) 
V2 = the withdrawn volume of the stock solution  
Then C2 (µg/mL) was converted to C2 (g/L), according to:  
 C2 (g/L) = C2 × 10−6/10−3 
Then C2 (g/L) was converted to C2 (µM), by the following relationship: 
C2 (µM) = (C2 (g/L) /MW) × 106  
MW = molecular weight of the enzyme (trypsin, chymotrypsin) 
 Results of the study of the activity of trypsin and 
chymotrypsin 
 Mass spectrum of standard BSA 
Figure B.1 and B.2 in Appendix B show the total ion chromatogram and mass 
spectrum of the bovine serum albumin (BSA) analysed as a positive control to 
check the proteolytic activity of the enzymes. The peak at the retention time 
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8.29 min in Figure B.1 is for the BSA. The observed mass in Figure B.2 (66.418 
kDa) was consistent with the theoretically calculated value (66.46 kDa).  
 Result of BSA degradation with chymotrypsin 
Figure B.3 in Appendix B is a total ion chromatogram of the hydrolysis products 
of the BSA by chymotrypsin at 37 °C and pH 7.4 for 15 min. The chromatogram 
has many peaks due to hydrolysis of the bovine serum albumin by the enzyme 
at a peptide bond on the C−terminal side of an aromatic amino acid residue. 
The chromatogram should be compared to the control chromatogram of BSA 
before digestion (Figure B.1 in Appendix B). This result provides evidence that 
the chymotrypsin was active and ready for use in the enzymatic degradation 
experiments.  
 Result of BSA degradation with trypsin 
The total ion chromatogram of the trypsin digest of BSA that is shown in Figure 
B.4 of Appendix B was evidence for the presence of active trypsin. The peak of 
the protein (BSA), as in Figure B.1 in Appendix B, was converted to many peaks 
when the BSA was incubated in the presence of trypsin under the same 
conditions for the chymotrypsin digest.  
 Enzymatic degradation and kinetic study of the 15-mer 
linear peptide (2b) in the presence of chymotrypsin 
Figure B.5 in Appendix B depicts HPLC chromatograms of the reaction 
between chymotrypsin and 15-mer linear peptide (2b) at 10 °C, and pH 8.6 over 
0−30 min. The purpose of these conditions was to obtain a lower rate of 
enzymatic hydrolysis for the peptides, consequently allowing the degradation 
of the peptides to be followed more precisely, as the reaction was very rapid 
under the standard conditions of 37 °C and pH 7.4. The peak at the retention 
time 12.39 min is for 2b. The hydrolysis products were observable as new 
peaks even at the initial time point, shown in Figure 3.2. By the time the peak 
of 2b began to decrease, several overlapping peaks with lower retention time 
had appeared; for example, a peak at the retention time of 7.51 min and a peak 
at the retention time of 10.39 min. The intensity of 2b decreased to less than 
half at 30 min (See Figure 3.2). 
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Chymotrypsin + 2b at 0 min. 
 
Chymotrypsin + 2b at 30 min. 
Figure 3.2: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 
8.6 for 0 and 30 min. 
 
 The total ion chromatogram of the sample at 20 min of enzymatic reaction 
(Figure 3.3) demonstrated many peaks, 348.1, 364.2, 1540.9, 304.3 m/z at the 
retention time 1.9, 6.4, 11.3, 18.4 min respectively. Also, a contamination peak 
was visible (338.3 at the retention time 28.8 min). None of the peaks matched 
the mass of any of the expected products (Table B.1 in Appendix B), except the 
peak of 348.1 m/z. This was consistent with the theoretically calculated value 
of 348.2 m/z for the protonated peptide (+1) which is peptide 2b1 in Scheme 
3.1. As was expected, chymotrypsin cleaved the peptide bond between Trp and 
Thr. The structure of peptide 2b1 is shown in Figure 3.4. Hydrolysis of the N-
terminal peptide bond between Phe and Leu may be slower than the hydrolysis 
of the bond between Trp and Thr.  
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Figure 3.3: Total ion chromatogram of 15-mer linear peptide (2b) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
 
Scheme 3.1: Site of the peptide bond in 15-mer linear 
peptide (2b) that is cleaved by chymotrypsin at 10 °C and 
pH 8.6 for 20 min. 
 
 
 
Figure 3.4: Suggested structure of peptide 2b1 (348.2 m/z) in 
the +1 charge state produced by enzymatic hydrolysis of 15-
mer linear peptide (2b) in the presence of chymotrypsin at 10 
°C and pH 8.6 for 20 min. 
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The MS2 mass analysis (Figure B.6 in Appendix B) for the peak of 348.1 
m/z was evidence of the validity of the proposed structure for peptide 2b1 due 
to the observed peaks for the precursor ion (348.1 m/z) having masses 
consistent with the theoretically calculated values of peptide 2b1 (Table 3.3). 
The structures of the suggested fragments are in Table B.2 in Appendix B.  
Table 3.3: The comparison between theoretically calculated peaks and the 
observed CID fragments of precursor ion 348.1 m/z, (peptide 2b1) produced by 
hydrolysis of 15-mer linear peptide (2b) in the presence of chymotrypsin (See 
Figure B.6 in Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 215.0 215.1 b2 
2 247.0 247.1 y2 
3 348.5 348.2 MH 
 
The area of 2b peaks in the HPLC chromatograms during its incubation 
with chymotrypsin at 10 °C and pH 8.6 for 0−30 min are reported in Table 3.4. 
Table 3.4: Areas of 15-mer linear peptide (2b) peaks in the HPLC 
chromatograms during its digestion with chymotrypsin at 10 °C and pH 8.6. 
Time (min) Area ln(area) 
0 773347 13.558 
2 601518 13.307 
4 459869 13.038 
6 418205 12.943 
8 388694 12.87 
10 374717 12.833 
15 259918 12.468 
20 186154 12.134 
30 176984 12.083 
 
 The t½ of 2b was calculated by plotting the logarithm of the area of 2b 
peaks against time, employing the Excel program. The value of k (0.0491 min−1) 
is the slope of the linear equation in Figure 3.5. The standard error (SE) was 
calculated from the linear regression using the LINEST function in the Excel 
program. Table 3.5 reveals the value of t½ (14.11 ± 1.7 min). 
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Figure 3.5: Enzymatic hydrolysis of 15-mer linear peptide (2b) 
by chymotrypsin at 10 °C and pH 8.6. 
 
Table 3.5: t½ of 15-mer linear peptide (2b) during incubation with chymotrypsin at 
10 °C and pH 8.6, including the rate constant (k min−1) and the standard error 
(SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.0491 0.006 12 14.11 1.7 
%error of k = 100 × SE / k  
error of t½ = %error k × t½ / 100 
 Enzymatic degradation and kinetic study of the 15-mer 
cyclic peptide (2c) in the presence of chymotrypsin and the 
comparison with its linear counterpart (2b) 
Figure B.7 in Appendix B indicates the HPLC chromatograms of enzymatic 
hydrolysis of 2c by chymotrypsin under the same conditions for hydrolysis of 
its linear counterpart (2b). The single sharp peak at the retention time 11.77 
min is for 2c. By the time the peak of 2c began to decrease, a new peak had 
appeared with retention time of 13.99 min. The intensity of the new peak 
reached approximately the same intensity of 2c at 10 min; then it became more 
intense at 20 min (See Figure 3.6).  
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Chymotrypsin + 2c at 0 min. 
 
Chymotrypsin + 2c at 20 min. 
Figure 3.6: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 2c (100 µM) at 10 °C and pH 
8.6 at 0 and 20 min. 
 
 
Figure 3.7: Total ion chromatogram of 15-mer cyclic peptide (2c) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
Figure 3.7 shows the total ion chromatogram of the 15-mer cyclic peptide 
(2c) at 20 min of the enzymatic reaction with chymotrypsin. The peak of 924.0 
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m/z at the retention time 20.8 min could represent compound 2c, as it was very 
close to the theoretically calculated value of 923.5 m/z for 2c in the +2 charge 
state as in Figure 2.28. However, this suggestion is inconsistent with the 
retention time of the genuine compound 2c (See Figure 2.27) using the same 
method. Furthermore, this peak could represent the peptide in Figure 3.8 
produced by the enzymatic cleavage of the peptide bond between Phe and Leu 
providing a 15-mer linear compound with elimination under the LC-MS 
conditions of one water molecule from a threonine residue. The mass of this 
peptide (923.5 m/z) was very close to the observed mass (924.0 m/z) in Figure 
3.7. This suggestion is also unlikely because the HPLC retention time of this 
peptide (13.68 min) is different to the retention time of the very similar 15-mer 
linear peptide (2b) with the same enzyme (12.39 min) as shown in Figure 3.2. 
Moreover, the retention time of this peptide is different to the retention time of 
the genuine compound 2b (12.67 min) as shown in Figure 2.17.  
 
 
Figure 3.8: Suggested structure of peptide (m/z = 923.5) in the +2 charge state 
produced from 15-mer cyclic peptide (2c) by trypsin catalysed hydrolysis of the 
peptide bond between Asp and Phe with elimination of one water molecule 
from one of the threonine residues. 
 
The peak of 924.0 m/z could also represent the peptide in Figure 3.9 
produced by cleavage of the peptide bond between Thr and Trp by 
chymotrypsin, in addition to elimination of a water molecule from one of the 
threonine residues as shown in Scheme 3.2 (peptide 2c1). 
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Figure 3.9: Suggested structure of peptide 2c1 (m/z = 923.5,) in the +2 charge 
state produced from cyclic peptide (2c) by chymotrypsin catalysed hydrolysis of 
the peptide bond between Thr and Trp with elimination of a water molecule 
from one of the threonine residues. 
 
 
Scheme 3.2: Site of the cleaved peptide bond in 15-mer cyclic peptide (2c) 
by chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
 The MS2 mass analysis for the precursor of 924.0 m/z (Figure B.8 in 
Appendix B) supported the third−choice (peptide 2c1) due to the fragmentation 
of this precursor ion to fragments that have peaks consistent with the 
theoretically calculated values for peptide 2c1 (Table 3.6). The structures of the 
suggested fragments are given in Table B.3 in Appendix B. 
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Table 3.6: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 924.0 m/z (peptide 2c1) produced 
by hydrolysis of 15-mer cyclic peptide (2c) by chymotrypsin (See Figure B.8 in 
Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 877.1 876.5 y7 
2 590.0 590.3 b5 
3 572.2 572.3 b5-H2O 
4 562.0 562.3 a5 
5 477.0 477.2 b4 
6 330.0 330.2 b3 
7 196.9 197.1 b2-H2O 
 
It should be noted that the retention time of peptide 2c1 (924.0 m/z) was 
higher than the retention time of 2c, although the total charge of 2c is +2 while 
the full charge of peptide 2c1 is +3 in the acidic medium of the HPLC solvents. 
The restricted conformation of the 15-mer cyclic peptide (2c) was potentially 
enhancing the polarity of the compound that resulted in a lower retention time. 
In addition, peptide 2c1 (Figure 3.9) has greater HPLC retention time than that 
of 2b (12.67 min) as in Figure 2.17, which has the same sequence but a 
different order of the amino acids. It appears that the different order of the 
amino acids for the same sequence of 2b has a significant effect on the 
retention time of 2b. 
 The other peaks of 386.9, 607.3, 773.5, 663.5 at 1.5, 10.1, 16.3, 31.5 min 
respectively in Figure 3.7 did not match the mass of any of the expected 
peptides produced by enzymatic hydrolysis of 2c by chymotrypsin (See Table 
B.4 in Appendix B). 
The t½ of 2c was calculated using the data in Table 3.7 by the same 
method that was used to calculate the t½ of the 15-mer linear peptide (2b). 
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Table 3.7: Areas of 15-mer cyclic peptide (2c) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. 
 
 
 
The linear regression shown in Figure 3.10 gave the value of k min−1 
(slope). Table 3.8 shows the value of t½ (11.07 ± 0.9 min). 
 
Figure 3.10: Enzymatic hydrolysis of 15-mer cyclic peptide (2c) 
by chymotrypsin at 10 °C and pH 8.6. 
 
Table 3.8: t½ of 15-mer cyclic peptide (2c) during incubation with chymotrypsin at 
10 °C and pH 8.6 including rate constant (k min−1) and the standard error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.0626 0.005 8 11.07 0.9 
 
It appears that the peptide bond between Phe and Asp in the two peptides 
(2b, 2c) was not cleaved as rapidly by chymotrypsin as the peptide bond 
Time(min) Area ln(area) 
0 549136 13.216 
2 512582 13.147 
4 497582 13.117 
6 434692 12.982 
8 343782 12.747 
10 223228 12.315 
15 211670 12.262 
20 146052 11.891 
30 96890 11.481 
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between Trp and Thr. This result provides evidence that the conformation of 
the first peptide bond (Phe−Asp) has remained the same after cyclisation of the 
15-mer linear peptide (2b) to form 2c or the new orientation remains unsuitable 
as a substrate for the enzyme; consequently, it was not broken down by the 
enzyme. According to the HPLC chromatograms, the retention times for the 
peptides produced by hydrolysis of 2b were less than the retention time of 2b, 
while the retention time of the peptide that was generated by hydrolysis of 2c 
was greater than the retention time of 2c. 
It should be noted that the t½ of 2c (11.07 ± 0.9 min) was less than the t½ 
of 2b (14.11 ± 1.7 min). It was concluded that the 15-mer cyclic peptide (2c) is 
less stable than its linear counterpart (2b) towards chymotrypsin-catalysed 
hydrolysis. This implies that cyclisation of 2b did not boost the stability of the 
compound against the enzymatic hydrolysis by chymotrypsin. Potentially, the 
constricted conformation of the cyclic peptide (2c) was a more favourable 
substrate for chymotrypsin than its linear counterpart (2b). Consequently, in 
human serum the compound 2c may stand less chance of reaching its target. 
 Enzymatic degradation and kinetic study of the 15-mer 
linear peptide (2b) in the presence of trypsin 
Figure B.9 in Appendix B shows the HPLC chromatograms of the reaction 
between trypsin and 15-mer linear peptide (2b) over 0−20 min at 10 °C and pH 
6.2. The purpose of these conditions was, as previously in the hydrolysis of 2b 
by chymotrypsin, to retard degradation to more easily observables rates. The 
single sharp peak at the retention time 11.66 min is for the linear peptide (2b). 
As 2b began to decrease, a new peak started to appear at the retention time 
9.93 min. The intensity of the new peak reached approximately the same 
intensity as the linear peptide (2b) at 8 min, then it became greater at 10 min. 
The peak of 2b disappeared completely at 15 min (See Figure 3.11).  
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Trypsin + 2b at 0 min. 
 
Trypsin + 2b at 8 min. 
 
Trypsin + 2b at 15 min. 
Figure 3.11: HPLC chromatograms of the reaction between 25 µL of 
trypsin (0.41 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 6.2 for 
0, 8, 15 min. 
 
Figure 3.12 shows the total ion chromatogram of 2b at a reaction time of 
20 min in the presence of trypsin. The peak of 936.6 m/z at the retention time 
23.0 min was consistent with the theoretically calculated value of 936.4 m/z for 
the protonated peptide (+1) which is peptide 2b4 in Scheme 3.3. As expected, 
trypsin cleaved the peptide bond between Arg and Thr; the suggested structure 
of peptide 2b4 is shown in Figure 3.13. 
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Figure 3.12: Total ion chromatogram of 15-mer linear peptide (2b) in the 
presence of trypsin at 10 °C and pH 6.2 for 20 min. 
 
 
Scheme 3.3: Site of the peptide bond in the 15-mer linear 
peptide (2b) that is cleaved by trypsin at 10 °C and pH 6.2 for 
20 min. 
 
 
 
Figure 3.13: Suggested structure of peptide 2b4 (936.4 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 15-mer linear peptide (2b) by 
trypsin at 10 °C and pH 6.2 for 20 min. 
 
The MS2 mass analysis for the precursor of 936.6 m/z (Figure B.10 in 
Appendix B) was evidence for the validity of the proposed structure of peptide 
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2b4, with the fragment peaks observed having masses consistent with the 
theoretical values (Table 3.9). All the structures of the proposed fragments for 
these peaks are shown in Table B.5 in Appendix B.  
Table 3.9: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 936.6 m/z (peptide 2b4) produced 
by trypsin digestion of 2b (Figure B.10 in Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 918.4 918.4 MH-H2O 
2 803.3 803.4 b7 
3 785.3 785.4 b7-H2O 
4 767.2 767.4 b7-2H2O 
5 722.2 722.3 y6 
6 690.1 690.3 b6 
7 672.1 672.3 b6-H2O 
8 573.0 573.3 y5-H2O 
 
Peptide 2b3 (946.17 m/z), shown in Scheme 3.3, did not appear in the 
HPLC chromatograms or the total ion chromatogram. Potentially this 
compound eluted with the DMSO solvent front due to its polarity. The other 
peaks (318.4, 441.6, 296.7, 418.8 m/z at 2.2, 3.2, 3.5, 17.6 min respectively) in 
Figure 3.12 did not match any expected m/z ratio. Table B.6 in Appendix B 
indicates all the expected masses produced by enzymatic hydrolysis of 2b by 
trypsin.  
The peptide bond between Arg and Glu did not hydrolyse. An adverse 
effect on enzymatic cleavage due to negatively charged amino acids such as 
Glu surrounding the cleavage site was previously observed during a study of 
protein identification in proteomics.194 Furthermore, the intramolecular 
hydrogen bonds between the side groups of the two amino acids (Arg, Glu) 
may also shield the peptide bond from being cleaved by the trypsin.  
A kinetic study of digestion of 2b by trypsin was undertaken; the data are 
shown in Table 3.10. Areas of HPLC peaks of 2b were determined during its 
enzymatic hydrolysis by trypsin at 10 °C and pH 6.2 for 0−10 min. 
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Table 3.10: Areas of 15-mer linear peptide (2b) peaks in the HPLC 
chromatograms during trypsin digestion at 10 °C and pH 6.2. 
Time (min) Area ln(area) 
0 572744 13.258 
2 439664 12.993 
4 346068 12.754 
6 344968 12.751 
8 259532 12.466 
10 241908 12.396 
 
 The t½ of 2b was computed in the same way that was used to calculate 
the t½ of the same compound in the presence of chymotrypsin. k min−1 (slope) 
was obtained from Figure 3.14 (a plot of ln area versus time). Table 3.11 
includes the value of t½ (8.23 ± 0.8 min). 
 
Figure 3.14: Enzymatic hydrolysis of 15-mer linear peptide (2b) by 
trypsin at 10 °C and pH 6.2. 
 
Table 3.11: t½ of 15-mer linear peptide (2b) in the presence of trypsin at 10 °C 
and pH 6.2, including the rate constant (k min−1) and the standard error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.0842 0.009 10 8.23 0.8 
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 Enzymatic degradation and kinetic study of the 15-mer 
cyclic peptide (2c) in the presence of trypsin and the 
comparison with its linear counterpart (2b) 
Figure B.11 in Appendix B shows the HPLC chromatograms of the reaction 
between trypsin and 2c at 10 °C and pH 6.2 over 0−30 min. The single peak at 
the retention time 11.75 min corresponds to 2c. The effect of the trypsin on 2c 
first became apparent at 2 min, where a new peak was visible at the retention 
time 12.48 min. By the time the intensity of 2c peak began to drop, the intensity 
of the new peak had increased up until 10 min, when a second new peak 
appeared at the retention time 10.95 min. The intensity of the two new peaks 
continued to increase until after 30 min the first new peak (12.56 min) became 
more intense than the peak of 2c (See Figure 3.15). 
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Trypsin + 2c at 0 min 
 
Trypsin + 2c at 2 min 
 
Trypsin + 2c at 30 min 
Figure 3.15: HPLC chromatograms of the reaction between 25 µL of 
trypsin (0.41 µM) and 250 µL of 2c (100 µM) at 10 °C and the pH 6.2 
for 0, 2, 30 min. 
 
Figure 3.16 is the total ion chromatogram of 2c after 20 min in the 
presence of trypsin. More than one peak appeared in this chromatogram; the 
peak of 676.6 m/z at the retention time 1.8 min, which potentially represented 
the first new peak at 12.48 min in the HPLC chromatogram.  
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Figure 3.16: Total ion chromatogram of 15-mer cyclic peptide (2c) 
after its digestion by trypsin at 10 °C and pH 6.2 for 20 min. 
 
As was expected, the sites of the peptide bonds cleaved by trypsin in 
compound 2c are between Arg and Thr, Arg and Glu. The sequence of the 
peptide which has a peak of 676.6 m/z is shown in Scheme 3.4 (peptide 2c2). 
The suggested structure of peptide 2c2 is given in Figure 3.17.  
 
Scheme 3.4: Sites of the peptide bonds in the 15-mer cyclic 
peptide (2c) that are cleaved by trypsin at 10 °C and pH 6.2 for 20 
min. 
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Figure 3.17: Suggested structure of peptide 2c2 (676.9 m/z) in the +2 charge 
state produced by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the 
presence of trypsin where the peptide bonds between Arg and Thr, Arg and 
Glu were cleaved.  
 
The MS2 mass analysis for the precursor ion (peptide 2c2) which has the 
peak of 676.6 m/z is illustrated in Figure B.12 in Appendix B and provided 
evidence for the validity of the proposed structure of peptide 2c2, with peaks 
observed that have masses consistent with the theoretically calculated values 
(Table 3.12). All the structures of the proposed fragments for these peaks are 
in Table B.7 in Appendix B. 
Table 3.12: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 676.6 m/z (peptide 2c2) produced 
by enzymatic hydrolysis of 2c in the presence of trypsin (See Figure B.12 in 
Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 1178.6 1178.6 b10 
2 1160.7 1160.6 b10-H2O 
3 1138.7 1138.6 y9 
4 1121.7 1121.5 y9-NH3 
5 1007.6 1007.5 y8 
6 950.5 950.5 y7 
7 803.2 803.4 b7 
8 785.4 785.4 b7-H2O 
9 764.3 764.4 y6 
 
The peak of 247.6 m/z at the retention time 1.1 min (Figure 3.16) has a 
mass that did not match the mass of the second expected peptide (530.3 m/z) 
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produced by trypsin which has the sequence given in Scheme 3.4 (peptide 
2c3). The suggested structure for this second peptide is in Figure 3.18. The 
MS2 mass for the precursor ion 247.6 m/z is illustrated in Figure B.13 in 
Appendix B. 
 
Figure 3.18: Suggested structure of peptide 2c3 (m/z = 530.3) in the +1 
charge state produced by enzymatic hydrolysis of 15-mer cyclic peptide 
(2c) in the presence of trypsin where the peptide bonds between Arg and 
Thr, Arg and Glu were cleaved. 
 
The third observed peak in the mass spectrum (Figure 3.16) is 622.3 m/z 
at the retention time 35.2 min. Although the mass of this peak is consistent with 
the mass of 2b in the +3 charge state (Figure 3.19), the MS2 mass spectrum 
(Figure B.14 in Appendix B) did not support this assignment. The observed 
peaks for the fragmentation of the precursor ion which has the peak of 622.0 
m/z differ from theoretically calculated values for 2b (See Table 2.8). Therefore, 
this peak was potentially due to contamination of the column.  
 
Figure 3.19: Structure of 15-mer linear peptide (2b) in the +3 charge state (m/z 
= 622.0). 
 
The peak of 11.89 min in the HPLC chromatogram of 20 min for 2c (Figure 
B.11 in Appendix B) did not appear in the mass spectrum. Possibly some of the 
trypsin remained active after conclusion of the reaction and storage for 24 h in 
the freezer, leading to the conversion of all the cyclic compound (2c) to the two 
new compounds.  
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A kinetic study for the 15-mer cyclic peptide (2c) during digestion with 
trypsin was performed and the data given in Table 3.13.  
Table 3.13: Areas of 15-mer cyclic peptide (2c) peaks in the HPLC 
chromatograms during digestion with trypsin at 10 °C and pH 6.2. 
Time(min) Area ln(area) 
0 594329 13.295 
2 509911 13.141 
4 417448 12.941 
6 414081 12.933 
8 396831 12.891 
10 387189 12.866 
15 315297 12.661 
20 177260 12.085 
30 160943 11.988 
 
The t½ of 2c was computed in the same way that was used to calculate 
the t½ of the same compound in the presence of chymotrypsin. k min−1(slope) 
was obtained from Figure 3.20 (a plot of ln area versus time). Table 3.14 
includes the value of t½. (15.53 ± 1.4 min−1). 
 
Figure 3.20: Enzymatic hydrolysis of 15-mer cyclic peptide (2c) by 
trypsin at 10 °C and pH 6.2. 
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Table 3.14: t½ of 15-mer cyclic peptide (2c) during digestion with trypsin at 10 °C 
and pH 6.2, including the value of rate the constant (k min−1) and the standard 
error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.0446 0.004 9 15.53 1.4 
 
According to the results in the HPLC chromatograms for the two 
compounds (2b, 2c), hydrolysis of the linear peptide (2b) by trypsin occurred 
at the peptide bond between Arg and Thr. The peptide identified in this reaction, 
2b4 in Scheme 3.3, provided evidence for this cleaved peptide bond site, while 
the cyclic peptide (2c) was cleaved at the peptide bond between Arg and Thr 
in addition to Arg and Glu. The identified peptide 2c2 in Scheme 3.4 was 
evidence for these two cleaved peptide bond sites. It should be noted that the 
linear peptide (2b) disappeared completely after 20 min, while the cyclic peptide 
(2c) was still present at 30 min. This result indicated that the stability of the 
cyclic peptide (2c) against trypsin was greater than the stability of its linear 
counterpart (2b) at 10 °C and pH 6.2. The t½ of the two compounds (2b, 2c) 
supported this result, with the t½ of 2c (15.53 ± 1.4 min) greater than the t½ of 
2b (8.23 ± 0.8 min). Possibly the restricted conformation of 2c rendered this 
compound less suitable as a substrate for the enzyme. Therefore, compound 
2c should have a greater chance of reaching the target than its linear 
counterpart (2b).  
 Enzymatic degradation and kinetic study of the 13-mer 
linear peptide (3b) in the presence of chymotrypsin 
Figure B.15 in Appendix B shows the HPLC chromatograms of the reaction 
between chymotrypsin and 13-mer linear peptide (3b) at 10 °C and pH 8.6 over 
0−30 min. The peak at the retention time 10.76 min is for 3b. The effect of 
hydrolysis of 3b became apparent at 4 min, where the first new peak was visible 
at the retention time 10.17 min. The intensity of the new peak increased and 
became more intense than the peak of 3b after 30 min (See Figure 3.21). 
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Chymotrypsin + 3b at 0 min 
 
Chymotrypsin + 3b at 4 min 
 
Chymotrypsin + 3b at 30 min 
Figure 3.21: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 13-mer linear peptide (3b) (200 
µM) at 10 °C and the pH 8.6 for 0, 4, 30 min. 
 
As expected, chymotrypsin cleaved the peptide bond between Trp and 
Thr as shown in Scheme 3.5. 
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Scheme 3.5: Site of the peptide bond (Trp−Thr) cleaved by 
chymotrypsin in the 13-mer linear peptide (3b) at 10 °C and pH 8.6 for 
20 min. 
 
Figure 3.22 shows the total ion chromatogram of 3b after 20 min of 
enzymatic reaction in the presence of chymotrypsin. The peak of 399.6 m/z at 
the retention time 7.8 min was consistent with the theoretically calculated value 
of 399.6 m/z for the compound in the +3 charge state (peptide 3b1 in Scheme 
3.5). The suggested structure of this peptide is shown in Figure 3.23. 
 
Figure 3.22: Total ion chromatogram of 13-mer linear peptide (3b) after 
digestion by chymotrypsin at 10 °C and pH 8.6 for 20 min. 
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Figure 3.23: Suggested structure of peptide 3b1 (399.6 m/z) in the +3 
charge state produced by enzymatic hydrolysis of 13-mer linear peptide (3b) 
in the presence of chymotrypsin where the peptide bond between Trp and 
Thr was cleaved. 
 
The MS2 mass spectrum for the precursor of 399.6 m/z (See Figure B.16 
in Appendix B) provided evidence for the validity of the proposed structure for 
peptide 3b1, due to the observed peaks that were consistent with the 
theoretically calculated values for the compound (Table 3.15). All the structures 
of these proposed fragments are in Table B.8 in Appendix B. 
Table 3.15: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 399.6 m/z (peptide 3b1) produced 
by enzymatic hydrolysis of 13-mer linear peptide (3b) in the presence of 
chymotrypsin (See Figure B.16 in Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 344.2 344.2 a3-NH3 
2 361.3 361.3 a3 
3 389.3 389.3 b3 
4 476.3 476.3 b4 
5 546.3 546.3 b5-NH3 
6 646.4 646.4 a6-NH3 
7 663.3 663.3 a6 
8 759.5 759.5 a7-NH3 
9 776.5 776.5 a7 
10 1179.6 1179.6 MH-NH3 
 
A peak from remaining 3b (Figure 3.21, peak 10.70 min) did not appear 
in the mass spectrum for the sample at 30 min (Figure 3.22). It is possible that 
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the enzyme was still active after completion of the reaction step for the 
chymotrypsin and 24 h storage in the freezer, leading to essentially complete 
conversion of 3b to the product. 
Peptide 3b2 (348.2 m/z), shown in Scheme 3.5, did not appear in the 
HPLC chromatograms and the total ion chromatogram; potentially this 
compound eluted with the DMSO solvent front due to its polarity. 
The peptide bond between Phe and Leu in 3b (Scheme 3.5) that was 
expected to be cleaved by chymotrypsin was left intact. During the entire time 
series, HPLC chromatograms did not show any second peak in addition to the 
new peak at the retention time 10.11 min (Figure 3.21). The conformation of 
the 13-mer linear peptide (3b) possibly prevented the peptide from occupying 
the active site. In addition, the presence of the charged amino group on the Phe 
residue at the N−terminus may have been negatively affecting the enzymatic 
interactions with neighbouring amino acids thus inhibiting the hydrolysis. 
The t½ of 3b was computed using the data in Table 3.16 in the same way 
that was used to calculate the t½ of the 15-mer linear peptide (2b) with the same 
enzyme. 
Table 3.16: Areas of 13-mer linear peptide (3b) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. 
Time (min) Area ln(area) 
0 379560 12.846 
2 353080 12.774 
4 305907 12.631 
6 247309 12.418 
8 231773 12.353 
10 203199 12.221 
15 195252 12.182 
20 118676 11.684 
30 92130 11.430 
 
Figure 3.24 (a plot of ln area versus time) gave the value of k (min−1). 
Table 3.17 includes the value of t½. (14.35 ± 0.9 min). 
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Figure 3.24: Enzymatic hydrolysis of 13-mer linear peptide (3b) by 
chymotrypsin at 10 °C and pH 8.6. 
 
Table 3.17: t½ of 13-mer linear peptide (3b) during digestion with chymotrypsin at 
10 °C and pH 8.6, including the value of the rate constant (k min−1) and the 
standard error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.0483 0.003 6 14.35 0.9 
 
 Enzymatic degradation and kinetic study of the 13-mer 
cyclic peptide (3c) in the presence of chymotrypsin and the 
comparison with its linear counterpart (3b) 
Figure B.17 in Appendix B shows the HPLC chromatograms of the reaction 
between the chymotrypsin and 13-mer cyclic peptide (3c) at 10 °C and pH 8.6 
over 0−20 min. The peak at the retention time 14.71 min corresponds to the 
cyclic peptide (3c). The effect of hydrolysis by the chymotrypsin on 3c is 
apparent after 4 min, where a new peak is visible at a retention time of 11.41 
min. By the time that the intensity of 3c began to decrease, the intensity of the 
new peak increases. The intensity of 3c decreased to almost half of its value at 
15 min, then less than half at 20 min (See Figure 3.25).  
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Chymotrypsin + 3c at 0 min. 
 
Chymotrypsin + 3c at 4 min. 
 
Chymotrypsin + 3c at 20 min. 
Figure 3.25: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 3c (200 µM) at 10 °C and pH 
8.6 for 0, 4, 20 min. 
 
Figure 3.26 is a total ion chromatogram of the 13-mer cyclic peptide (3c) 
at 20 min of the enzymatic hydrolysis by chymotrypsin. As expected, 
chymotrypsin cleaved the peptide bond between Thr and Trp, as shown in 
Scheme 3.6. The peak of 763.5 m/z at the retention time 5.2 min in Figure 3.26 
was consistent with the theoretically calculated value of 763.4 m/z for peptide 
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3c1 (+2 charge state). Figure 3.27 illustrates the suggested structure of this 
peptide. 
 
Figure 3.26: Total ion chromatogram of 13-mer cyclic peptide (3c) after its 
digestion with chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
 
Scheme 3.6: Site of the peptide bond (Trp−Thr) cleaved by chymotrypsin 
in the 13-mer cyclic peptide (3c) at 10 °C and pH 8.6 for 20 min. 
 
 
 
Figure 3.27: Suggested structure of peptide 3c1 (763.4 m/z) in the +2 charge 
state produced by enzymatic hydrolysis of 3c in the presence of chymotrypsin 
where the peptide bond between Trp and Thr was cleaved. 
 
The MS2 mass spectrum in Figure B.18 in Appendix B for the peak of 
763.5 m/z provided evidence for the validity of the proposed structure for 
peptide 3c1 with peaks observed having masses consistent with the 
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theoretically calculated values for the peptide (Table 3.18). The structures of all 
the suggested fragments from the precursor ion (peptide 3c1) with 763.5 m/z 
are shown in Table B.9 in Appendix B.  
Table 3.18: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 763.5 m/z (peptide 3c1) produced 
by enzymatic hydrolysis of 3c in the presence of chymotrypsin (See Figure B.18 
in Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 262.0 262,1 y2 
2 330.2 330,2 b3 
3 477.3 477.2 b4 
4 572.3 572.3 b5-H2O 
5 808.4 808.4 y7 
6 875.6 875.5 b8-NH3 
7 936.6 936.5 y8 
8 1020.8 1020.6 b9 
9 1133.8 1133.7 b10 
10 1264.9 1264.7 b11 
 
The peptide bond in 3c between Phe and Leu that was expected to be 
cleaved by chymotrypsin to result in the peptide TLDF remained intact. The 
HPLC chromatograms for the entire time series (Figure B.17 in Appendix B) 
showed no additional peaks that could correspond to this peptide. It is possible 
that the conformation of the 13-mer cyclic peptide (3c) prevented it from 
occupying the active site of the enzyme, or potentially the enzymatic hydrolysis 
at this site was slow due to the same cause (local conformation of the peptide); 
thus, the HPLC detector was not sufficiently sensitive to detect this product. 
Moreover, the masses (495.2)1+, (477.2)1+ m/z corresponding to the protonated 
peptide (TLDF) and protonated peptide with the elimination of a water molecule 
from the threonine residue respectively did not match with any one of the peaks 
387.0, 896.3, 718.1, 415.3, 927.4 m/z at 2.0, 5.5, 5.7, 6.4, 11.2 min respectively 
in Figure 3.26. These peaks were possibly due to contamination on the column.  
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The t½ of 3c was computed in the same way used to calculate the t½ of 
the 15-mer linear peptide (2b) with the same enzyme using the data in Table 
3.19.  
Table 3.19: Areas of 13-mer cyclic peptide (3c) peaks in the HPLC 
chromatograms during digestion with chymotrypsin at 10 °C and pH 8.6. 
Time Area ln(area) 
0 207015 12.240 
2 186115 12.134 
4 122830 11.718 
6 148703 11.909 
8 120222 11.697 
10 109000 11.599 
15 107023 11.580 
20 81239 11.305 
 
The rate constant, k (min−1), was obtained from Figure 3.28 (a plot of ln 
area versus time). Table 3.20 includes the value of t½. (16.9 ± 2.8 min). 
 
Figure 3.28: Enzymatic hydrolysis of 13-mer cyclic peptide (3c) in 
the presence of chymotrypsin at 10 °C and pH 8.6. 
 
Table 3.20: t½ of 13-mer cyclic peptide (3c) during digestion with chymotrypsin at 
10 °C and pH 8.6, including value of rate constant (k min−1) and the standard 
error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.041 0.007 17 16.9 2.8 
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The effect of the chymotrypsin on the two peptides (3c, 3b) was the same. 
The peptide bond between Trp and Thr was hydrolysed by the enzyme in the 
two compounds (3c, 3b), while the peptide bond between Phe and Leu 
remained intact. It was possible that the conformation of the first site (Trp−Thr) 
was in a more susceptible orientation to hydrolysis by chymotrypsin than the 
second site (Phe−Leu). Therefore, the minor reaction products were not 
detected by the HPLC. The rate of enzymatic hydrolysis for 3b (t½ = 14.35 ± 
0.9 min) was close to 3c (t½ = 16.90 ± 2.8 min). It was deduced that the 
conversion of the 13-mer linear peptide (3b) to the cyclic peptide (3c) did not 
significantly affect the stability of the peptide against chymotrypsin, considering 
the magnitude of error in the determination of t½. 
It is important to note that hydrolysis of 3c by chymotrypsin produced 
linear peptide that has the same length but different sequence (Scheme 3.6, 
Figure 3.27) and greater retention time (11.47 min, Figure 3.25) than its linear 
peptide 3b (10.76 min, Figure 3.21). There is a possibility that the sequence of 
the linear peptide (3b) with the new order and different polarity would give 
greater chance of reaching the target than the original linear peptide (3b).  
 Enzymatic degradation and kinetic study of the 13-mer 
linear peptide (3b) in the presence of trypsin 
Figure B.19 in Appendix B shows the HPLC chromatograms of the reaction 
between trypsin and 13-mer linear peptide (3b) at 10 °C and pH 6.2 over 0−20 
min. The peak at the retention time 8.61 min is 3b. Enzymatic hydrolysis was 
detectable almost immediately, with a new peak beginning to appear at the 
retention time 9.55 min. The intensity of 3b peak dropped to less than half at 8 
min, then it almost disappeared, and the intensity of the new peak increased 
significantly at 20 min (Figure 3.29). 
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Trypsin + 3b at 0 min. 
 
Trypsin + 3b at 8 min. 
 
Trypsin + 3b at 20 min. 
Figure 3.29: HPLC chromatograms of the reaction between 25 µL of 
trypsin (0.41 µM) and 250 µL of 3b (200 µM) at 10 °C and the pH 6.2 
over 0, 8 and 20 min. 
 
Figure 3.30 is the total ion chromatogram of 3b at 20 min of the enzymatic 
hydrolysis in the presence of trypsin. The peak of 835.3 m/z at the retention 
time 22.3 min was consistent with the theoretically calculated value of 835.4 
m/z for the protonated peptide in the +1 charge state. The sequence of this 
peptide is shown in Scheme 3.7 (peptide 3b4). As was expected, trypsin 
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cleaved the peptide bond between Lys and Ile. The suggested structure of this 
peptide is shown in Figure 3.31.  
 
Figure 3.30: Total ion chromatogram of 13-mer linear peptide (3b) during 
digestion by trypsin at 10 °C and pH 6.2 for 20 min. 
 
 
Scheme 3.7: Site of the peptide bond (Lys−Ile) cleaved by trypsin 
in the 13-mer linear peptide (3b) at 10 °C and pH 6.2 for 20 min. 
 
 
Figure 3.31: Suggested structure of peptide 3b4 (835.4 m/z) in the +1 
charge state produced by enzymatic hydrolysis of 3b in the presence 
of trypsin where the peptide bond between Lys and Ile was cleaved. 
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The MS2 mass spectrum for the precursor of 835.3 m/z (Figure B.20 in 
Appendix B) supported the suggested structure of peptide 3b4. The observed 
peaks were consistent with the theoretically calculated values (Table 3.21). All 
the structures of these proposed fragments are in Table B.10 in Appendix B. 
Table 3.21: The comparison between theoretically calculated peaks and the 
observed CID fragments of the precursor ion 835.6 m/z (peptide 3b4) produced 
by enzymatic hydrolysis of 3b by trypsin (See Figure B.20 in Appendix B). 
No 
Observed 
m/z 
Calculated 
m/z 
Suggested 
sequence 
1 330.0 330.2 y3-H2O 
2 488.0 488.2 b4 
3 573.0 573.3 y5-H2O 
4 589.0 589.3 b5 
5 684.1 684.4 b6-H2O 
6 704.0 704.3 y6-H2O 
7 817.2 817.4 MH-H2O 
 
Peptide 3b3 (709.4 m/z) in Scheme 3.7 which has suggested structure 
shown in Figure 3.32 did not appear in the HPLC chromatograms (Figure B.19 
in Appendix B) and the total ion chromatogram (Figure 3.30). There was the 
possibility that peptide 3b3 was eluted with the DMSO solvent due to the triply 
charged nature of the compound under acidic conditions. The other peaks 
253.2, 364.7, 414.5, 571.1 at 1.5, 2.2, 3.3, 20.5 min respectively (Figure 3.30) 
did not match with a mass of any one of the expected peptides produced by 
trypsin hydrolysis of peptide 3b3 (Table B.11 in Appendix B). Thus, there could 
be contamination on the column. 
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Figure 3.32: Suggested structure of peptide 3b3 (709.4 m/z) in the +1 charge 
state produced by enzymatic hydrolysis of 13-mer linear peptide (3b) in the 
presence of trypsin where the peptide bond between Lys and Ile was cleaved. 
 
The t½ of 3b towards trypsin digestion at 10 °C and pH 6.2 was computed 
using the areas of the 3b peak in the HPLC chromatograms (Table 3.22). The 
t½ was computed in the same way that had been used to calculate the t½ of the 
15-mer linear peptide (2b) with chymotrypsin.  
Table 3.22: Areas of 13-mer linear peptide (3b) peaks in the HPLC 
chromatograms during digestion with trypsin at 10 °C and pH 6.2. 
Time(min) Area ln(area) 
0 328008 12.700 
2 270232 12.507 
4 258916 12.464 
6 183361 12.119 
8 148347 11.907 
10 72609 11.297 
15 21304 9.966 
20 19024 9.853 
 
The rate constant k (min−1) was obtained from Figure 3.33 (a plot of ln 
area versus time). Table 3.23 includes the value of t½. (4.22 ± 0.6 min). 
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Figure 3.33: Enzymatic hydrolysis of 13-mer linear peptide (3b) by 
trypsin at 10 °C and pH 6.2. 
  
Table 3.23: t½ of 13-mer linear peptide (3b) during digestion with trypsin at 10 °C 
and pH 6.2, including the value of the rate constant (k min−1) and the standard 
error (SE). 
k (min−1) SE %Error of k t½ (min) Error of t½ (min) 
0.163 0.023 14 4.22 0.6 
 
 Enzymatic degradation and kinetic study of the 13-
mer cyclic peptide in the presence of trypsin and the 
comparison with its linear counterpart (3b) 
Figure B.21 in Appendix B indicates the HPLC chromatograms of the reaction 
between trypsin and 13-mer cyclic peptide (3c) at 10 °C, and pH 6.2 over 0−30 
min. 2.7 × 10−2 M of Fmoc−tryptophan(Boc) compound was used as an internal 
standard (IS). The peak at the retention time 11.79 min is for 3c and the second 
peak at the retention time 20.05 min is for the internal standard. Clearly, 
compound 3c has significant stability against trypsin, due to the ratio of the 
intensity of 3c peak to the intensity of the internal standard peak (3c/IS) which 
did not decrease (1.172 ± 0.005) until 30 min, as in Table 3.24 (See Figure 
3.34). There was no new peak in the HPLC chromatograms during the entire 
time series (0−30 min) of the enzymatic hydrolysis. 
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Table 3.24: The ratio of areas of 13-mer cyclic peptide (3c) peaks to areas of the 
internal standard peaks in the HPLC chromatograms during digestion with trypsin 
at 10 °C and pH 6.2. 
Time (min) Area of 3c Area of IS 3c/IS 
0 578696 266196 2.173 
2 525208 241173 2.177 
4 547966 252684 2.168 
6 575126 265486 2.166 
8 542063 250446 2.164 
10 561642 257867 2.178 
15 591169 271162 2.180 
20 611451 281008 2.175 
30 559752 257509 2.173 
 
 
Trypsin + 3c + IS at 0 min. 
 
Trypsin + 3c + IS at 30 min. 
Figure 3.34: HPLC chromatograms of the reaction between 25 µL of 
trypsin (0.41 µM) and 250 µL of 3c (200 µM) with an internal standard 
(IS) at 10 °C and the pH 6.2 for 0, 30 min.  
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There is the potential that the constricted conformation of this cyclic 
peptide (3c) in the solution negatively affected its ability to act as a substrate 
for trypsin. The sequence and the order of the residues in this cyclic peptide 
(3c) may also contribute to the stability of the compound (Figure 3.35). The 
presence of polar side groups, such as the Lys residues, possibly strengthened 
intramolecular hydrogen bonds as well as the intermolecular hydrogen bonds 
(with water) enhancing the folding of 3c therefore making it less able to occupy 
the active site of the enzyme. 
 
 
Figure 3.35: Structure of 13-mer cyclic peptide (3c) in the 
+2 charge state (m/z = 754.4). 
 
There is a significant contrast between 13-mer cyclic peptide (3c) and its linear 
counterpart (3b) in their stability towards the trypsin at 10 °C and pH 6.2 over 
0−30 min. It was concluded that the stability of peptide bond between Lys and 
Ile in the two compounds (3b, 3c) against trypsin was different. It was stable in 
the cyclic peptide (3c) until 30 min, while it was hydrolysed in the linear peptide 
(3b). The HPLC peak of 3b disappeared within 20 min, while the HPLC peak 
of 3c still remained at 30 min (See Figure 3.36). 
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Converting the 13-mer linear peptide (3b) to cyclic peptide (3c), with the 
KSSK fragment in the sequence, significantly increased the stability of the 
peptide against hydrolysis by trypsin. Thus, the cyclic compound (3c) may 
stand a greater chance than its linear counterpart (3b) to survive proteolysis in 
the body to reach an antigen presenting cell (B cell) that activates T−cells to 
destroy a tumour. 
 
Trypsin + 3b at 0 min.                         Trypsin + 3b at 20 min. 
 
 
Trypsin + 3c + IS at 0 min.               Trypsin + 3c + IS at 30 min. 
Figure 3.36: HPLC chromatograms of 13-mer cyclic peptide (3c) and its 
linear counterpart (3b) during their digestion with trypsin at 0, 20 min for 3b 
and 0, 30 min for 3c. 
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Chapter 4 
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 Stability of the peptides in fetal calf serum 
 Introduction 
The stability of the peptides (2b, 2c, 3b, 3c) in fetal calf serum (FCS) was 
examined because this is the medium that is commonly used in immunological 
experiments to investigate T-cell activation by peptides. FCS contains growth 
factors, a low content of immunoglobulin and a lower level of complement in 
comparison to an adult. Complement proteins have an undesirable effect of 
inducing immunoglobulin aggregation which may produce false−positive tests 
in immunological assays and could negatively affect a variety of cell 
reactions.195 Therefore, FCS was heated at 56 °C for 30 minutes to inactivate 
the complement proteins. 
The measurement of the rates of peptide degradation is a relatively 
straightforward experiment, but some factors may lead to inconsistent results; 
for example, different results are obtained for in vitro peptide stabilities in 
non−human plasma which has varying levels of peptidases. Also, the results 
from plasma collected in different types of blood collection tube are complicated 
by the fact that peptidase inhibitors such as EDTA may be included in the 
tube.196 
Benzoic acid was used as an internal standard in all the experiments 
because it has good solubility in water and acetonitrile (HPLC solvents). In 
addition to that, its HPLC peak has no overlap with the peaks of the peptides 
(2b, 2c, 3b, 3c).  
 Stability of the 15-mer linear peptide (2b) in 20% FCS 
Table 4.1 shows the values for the HPLC peak areas of 0.7 mM 15-mer linear 
peptide (2b) relative to the internal standard peak areas (benzoic acid) in 20% 
FCS at 37 °C, and pH 7.4 for 2, 6, 12, 24, 48 h. The experiment was performed 
in triplicate; for example, Figure C.1 in appendix C represents the first replicate. 
The highest peak at the retention time 9.85 min is for the 15-mer linear peptide 
(2b). The peak at the retention time 9.10 min is for the internal standard. The 
peak at the retention time 8.89 min is for the FCS (See chromatogram at 0 h in 
the same Figure in appendix C). 
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Table 4.1: HPLC peak areas for 15-mer linear peptide (2b) relative to the internal 
standard (IS) peak areas during incubation in 20% FCS at 37 °C and pH 7.4 for 0 
– 48 h. Three replicates. 
Time (h) 0 2 6 12 24 48 
1-2b/IS 3.1428 2.9440 2.8504 2.6170 2.4862 2.4752 
2-2b/IS 2.6216 2.6121 2.5786 2.3963 2.3635 2.1856 
3-2b/IS 2.8181 2.8464 2.6764 2.3089 2.5766 2.2336 
       
1-ln2b/IS) 1.1451 1.0797 1.0474 0.9620 0.9107 0.9063 
2-ln(2b/IS) 0.9637 0.9601 0.9472 0.8739 0.8601 0.7818 
3-ln(2b/IS) 1.0360 1.0460 0.984 0.8367 0.9464 0.8036 
 
Over the whole period, there was a decrease in the peak area of the 15-
mer linear peptide (2b). It appears that up to 12 h there was a slight drop in the 
peak area of 2b relative to the internal standard (2b/IS). At 48 h the peak area 
of 3b in the FCS reached the lowest value compared to its starting point. There 
were some small fluctuations in replicate 3 in Figure 4.1. The reasons for 
irregular fluctuations could be down to the measurement errors; for instance, 
small difference in volumes withdrawn from the reaction vial and transferred to 
the mass spectrum vial by micropipette at each particular time may lead to this 
variance. Also, an inconsistent amount of internal standard being added 
(pipetting errors) could have contributed to this variation. 
The rate constant k was calculated from the slope of a straight line fitted 
to a plot of the logarithm of the peak area ratio 3b/IS versus time using the 
Excel software as in Figure 4.1. The t½ (Table 4.2) of the 15-mer linear peptide 
(2b) was calculated for the triplicate using the following formula,  
t½ = ln 2 / k 
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Replicate 1 
 
Replicate 2 
 
Replicate 3 
Figure 4.1: Stability of 15-mer linear peptide (2b) in 20% FCS at 
37 °C and pH 7.4 (Replicate 1, 2, 3). 
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Table 4.2: t½ of 15-mer linear peptide (2b) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. 
No k (h−1) t½ (h) Mean of t½ (h) σ 
1 0.0045 154   
2 0.0038 182 165 15 
3 0.0044 157   
 
 Stability of the 15-mer cyclic peptide (2c) in 20% FCS 
Table 4.3 shows the HPLC peak areas of 0.7 mM 15-mer cyclic peptide (2c) 
relative to the internal standard peak areas (2c/IS) in 20% FCS, at 37 °C, and 
pH 7.4 for 2, 6, 12, 24, 48 h. The experiment was repeated three times; for 
instance, Figure C.4 in appendix C represents the first replicate. The highest 
peak at the retention time 9.66 min is for the 15-mer cyclic peptide (2c). The 
peak at the retention time 8.92 min is for the internal standard. The peak at the 
retention time 8.69 min is for the FCS (See chromatogram at 0 h in the same 
Figure in appendix C). 
Table 4.3: HPLC peak areas for 15-mer cyclic peptide (2c) relative to the internal 
standard (IS) during incubation in 20% FCS at 37 °C and pH 7.4 for 0 – 48 h. 
Three replicates. 
Time (h) 0 2 6 12 24 48 
1-2c/IS 2.2528 2.0274 2.1849 1.7707 1.7692 1.78683 
2-2c/IS 2.2202 1.9971 1.8952 1.9537 1.6680 1.5886 
3-2c/IS 2.0906 2.1116 1.9596 1.8093 1.6913 1.4293 
       
1-ln(2c/IS) 0.8122 0.7067 0.7815 0.5714 0.5705 0.5804 
2-ln(2c/IS) 0.7976 0.6916 0.6393 0.6697 0.5116 0.4628 
3-ln(2c/IS) 0.7374 0.7474 0.6727 0.5929 0.5255 0.3572 
 
Over the entire period, there was a drop in the intensity of the peak of the 
15-mer cyclic peptide (2c) relative to the peak area of the internal standard 
(2c/IS). There was a slight decrease, between 0 and 12 h. During the time 
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between 12 to 48 h, the rate of decline was accompanied by minimal fluctuation 
only in replicate 1, as in Figure 4.2. The peak area for 2c reached the lowest 
value at 48 h compared to its initial value. 
The small variation in the rate of decrease of the peak area of 2c was 
possibly for the same reasons mentioned in the study of the stability of 2b in 
the same medium. In addition, one of the potential causes leading to this 
variation was the peptide adhering to tips/vials. 
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Replicate 1 
 
Replicate 2 
 
Replicate 3 
Figure 4.2: Stability of 15-mer cyclic peptide (2c) in 20% FCS at 37 °C 
and pH 7.4 (Replicate 1, 2, 3). 
 
After computing the values of k (gradient) of the 15-mer cyclic peptide 
(2c) using the Excel program as in Figure 4.2, the values of t½ and their mean 
and standard deviation (σ) were calculated and are reported in Table 4.4. 
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Table 4.4: t½ of 15-mer cyclic peptide (2c) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. 
No k (h−1) t½ (h) Mean of t½ (h) σ 
1 0.0043 161   
2 0.0061 114 120 38 
3 0.008 87   
 
In a comparison between the t½ of the 15-mer cyclic peptide (2c) and the 
t½ of its linear counterpart (2b), it appears that the results of this experiment did 
not support the hypothesis that the cyclic peptide has the larger t½. It was 
expected that the cyclic peptide would be an unsuitable substrate for 
exoprotease enzymes because it has no free terminus (N and C−terminus), 
while the linear peptide is more suitable as a substrate for the exoprotease 
enzymes because it has two free termini. Therefore, the expectation was that 
the t½ of 2c would be larger than the t½ of 2b, but the data of this experiment did 
not support the hypothesis. The results were that the t½ of 2c is 120 ± 38 h 
which was less than the t½ of 2b (165 ± 15 h). Although there was a difference 
in the mean values of the t½ between 2c and 2b, the standard deviations are 
sufficiently high that it cannot be concluded that there is a significant difference 
between them. Within experimental error, the two peptides (2c, 2b) have the 
same resistance against the protease enzymes in fetal calf serum. On the other 
hand, if this simple difference between them was real, it still does not support 
the hypothesis.  
 The constricted conformation of the cyclic peptide potentially influenced 
the t½ of the 15-mer cyclic peptide (2c) in the fetal calf serum. There are many 
possible conformations for the linear compound in solution and the number of 
conformations is reduced after cyclisation.4 The constricted conformation of the 
cyclic structure was expected to make the compound an unsuitable substrate 
for protease (providing a high t½), but the converse may have occurred for 
peptide (2c) and the compound may instead have been held in a suitable 
conformation for cleavage resulting in a low t½ value.  
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 Stability of the 13-mer linear peptide (3b) in 20% FCS 
Table 4.5 shows the values for the HPLC peak areas of 0.7 mM 13-mer linear 
peptide (3b) relative to the internal standard peak areas (3b/IS) in 20% FCS, at 
37 °C, and pH 7.4 for 2, 6, 12, 24, 48 h. The experiment was performed in 
triplicate; for example, Figure C.7 in appendix C represents the first replicate. 
The highest peak at the retention time 9.84 min is for the 13-mer linear peptide 
(3b). The peak at the retention time 10.61 min is for the internal standard. The 
broad peak at the retention time 11.35 min is for the fetal calf serum (See the 
chromatogram for 0 h in the same figure in appendix C). 
Table 4.5: HPLC peak areas for the 13-mer linear peptide (3b) relative to the 
internal standard (IS) during incubation in 20% FCS at 37 °C and pH 7.4 for 0 – 
48 h. Three replicates. 
Time(h) 0 2 6 12 24 48 
1-3b/IS 2.1533 2.0805 1.9752 1.8430 2.0048 1.5605 
2-3b/IS 2.0359 1.9628 1.8608 1.9726 1.8767 1.4871 
3-3b/IS 2.2962 2.1039 2.0515 2.1622 1.8292 1.5265 
       
1-ln(3b/IS) 0.7670 0.7326 0.6806 0.6114 0.6955 0.4450 
2-ln(3b/IS) 0.7109 0.6743 0.6210 0.6793 0.6295 0.3968 
3-ln(3b/IS) 0.8312 0.7438 0.7185 0.7711 0.6039 0.4230 
 
 As shown in Figure 3.4, the plot is approximately linear but with some 
fluctuation that appeared over the period between 12 and 24 h (entry replicate 
2, 3 in the same figure) but the peak area of 3b remained less than the peak 
area of 3b at 0 h. The peak area for 3b reached its lowest value at 48 h in all 
three experiments. The fluctuation in the decrease of 3b intensity was 
potentially for the same reasons that were mentioned in the study of the stability 
of 2b and 2c in the same reaction medium. 
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Replicate 1 
 
Replicate 2 
 
Replicate 3 
Figure 4.3: Stability of 13-mer linear peptide (3b) in 20% 
FCS at 37 °C and pH 7.4 (Replicates 1, 2, 3). 
 
The t½ of the 13-mer linear peptide (3b) was calculated using the same 
equation that was used to calculate the t½ of 2b. The results and the mean and 
standard deviation (σ) for the three replicates are given in Table 4.6. 
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Table 4.6: t½ of 13-mer linear peptide (3b) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. 
No k (h−1) t½ (h) Mean of t½ (h) σ 
1 0.0057 122   
2 0.0058 119 110 18 
3 0.0078 89   
 
 Stability of the 13-mer cyclic peptide (3c) in 20% FCS 
Table 4.7 indicates the areas of HPLC peaks of 0.7 mM 13-mer cyclic peptide 
(3c) in 20% FCS at 37 °C and pH 7.4 for 0, 2, 6, 12, 24, 48 h. The experiment 
was undertaken three times; for example, Figure C.10 in appendix C represents 
the first replicate. The highest peak at the retention time 12.26 min is for the 
13-mer cyclic peptide (3c). The peak at the retention time 10.57 min is for the 
internal standard. The smallest peak at the retention time 11.29 min is for the 
fetal calf serum (See chromatogram for 0 h in the same Figure in appendix C).  
Table 4.7: HPLC peak areas for 13-mer cyclic peptide (3c) relative to the internal 
standard (IS) during incubation in 20% FCS at 37 °C, and pH 7.4 for 0 – 48 h. 
Three replicates. 
Time (h) 0 2 6 12 24 48 
1-3c/IS 2.1427 1.9263 1.8343 2.0262 1.9255 1.7718 
2-3c/IS 2.0890 1.8604 2.1732 2.1910 2.0751 2.0000 
3-3c/IS 2.1152 2.2026 2.2327 2.6377 2.4098 1.8212 
       
1-ln(3c/IS) 0.7620 0.6556 0.6066 0.7061 0.6552 0.5720 
2-ln(3c/IS) 0.7367 0.6208 0.7762 0.7844 0.7300 0.6931 
3-ln(3c/IS) 0.7491 0.7896 0.8032 0.9699 0.8795 0.5995 
 
As shown in Figure 4.4, the peak area of the 13-mer cyclic peptide (3c) 
decreased to the lowest level in all three experiments at 48 h in comparison to 
its peak area at 0 h. The rate of decrease of the peak area for 3c relative to the 
internal standard (3c/IS) was accompanied by some fluctuation in replicates 2 
and 3 in Figure 4.4. The reasons for this variation in the peak areas could be 
the same reasons that were mentioned in the study of the stability of 2b and 2c 
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in the same medium reaction. Furthermore, adherence of peptide on tips or 
vials potentially caused irreproducible losses of compound, contributing 
towards variation within and between the replicates. In addition, this cyclic 
peptide appeared to be more resistant against proteases. Therefore, there was 
little decrease in its peak area over the course of the experiment, making 
fluctuations more evident. 
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Replicate 1 
 
Replicate 2 
 
Replicate 3 
Figure 4.4: Stability of 13-mer cyclic peptide (3c) in 20% FCS at 37 
°C and pH 7.4 (Replicates 1, 2, 3). 
 
The t½ of the 13-mer cyclic peptide (3c) for the three replicates and its 
standard deviation (σ) were calculated using the same method that was used 
to calculate the t½ of the 13-mer linear peptide (3b) and the results are given in 
Table 4.8. 
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Table 4.8: t½ of 13-mer cyclic peptide (3c) in 20% FCS at 37 °C and pH 7.4 with 
the mean and standard deviation (σ) of the triplicate. 
No k (h−1) t½ (h) Mean of t½ (h) σ 
1 0.0025 277   
2 0.002 346.5 285 58 
3 0.003 231   
 
Although the standard deviation was quite high in the two experiments 
(Table 4.8 and Table 4.6), it could be said that there was a difference in the 
value of t½ between 13-mer cyclic peptide (3c) and its linear counterpart (3b). 
As a comparison between them, the result was the t½ of the former (285 ± 58 
h) is greater than the t½ of the latter (110 ± 18 h). This result was as expected 
because the cyclic peptide has no free terminus (N and C−terminus) and so 
was not a suitable substrate for the exoprotease enzymes. Therefore, the cyclic 
peptide (3c) hydrolysis was delayed in comparison to its linear counterpart (3b) 
which has the two free termini, thus being a suitable substrate for exoprotease 
enzymes, and the hydrolysis was faster than the cyclic compound (3c) giving a 
lower value of t½. Although the 13-mer cyclic peptide (3c) was not a substrate 
for the exopeptidases, it could still, however, be a substrate for endopeptidases. 
Thus, the measurement t½ of the two peptides (3b, 3c) was evidence of the 
validity of the hypothesis that the cyclic peptide might be a poorer substrate for 
endopeptidases. Therefore, 3c was more resistant against the two types of 
enzymes (endo and exopeptidase) in comparison to its linear counterpart (3b). 
Consequently, it could be said that 13-mer cyclic peptide (3c) may stand a 
greater chance of reaching a target in vivo than its linear counterpart (3b). 
Although t½ (165 ± 15 h) of 15-mer linear peptide (2b) is greater than t½ 
(110 ± 18 h) of 13-mer linear peptide (3b) considering the magnitude of the 
standard deviations the results must be interpreted with caution. Potentially, the 
length of 2b (15 residues) caused the increase in stability of the compound 
against the endo and exopeptidase enzymes by providing a degree of folding. 
Therefore, the termini of the peptide and the peptide bonds were potentially 
more shielded from the enzymes resulting in slower hydrolysis than the shorter 
and less structured 13-mer linear peptide (3b). 
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It is worth noting that the process of cyclisation for the 15-mer linear 
peptide (2b) led to a decrease in the t½ of the peptide (See Table 4.2 and Table 
4.4). This observation implies that the constricted conformation of the cyclic 
peptide (2c) made the compound more accessible as a substrate for the 
protease enzymes, thus compound 2c has less chance of reaching the target 
as a comparison to its linear counterpart (2b). However, the cyclisation process 
to form compound 3c from precursor 3b led to an increase in the t½ of 3c as a 
comparison with the t½ of 3b. Therefore, the constricted conformation of this 
cyclic peptide (3c) made the peptide less accessible as a substrate to protease 
enzyme giving a high t½. value. Consequently, compound 3c has more chance 
to reach a biological target than its linear counterpart (3b).  
According to these results, peptide cyclisation does not necessarily 
provide greater resistance to enzymatic hydrolysis but instead the effect will 
depend on the length and sequence of the peptide. 
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 Conclusion 
 Conclusion 
 Synthesis of peptides 
A Bax peptide (IMGWTLDFL) that has the ability to activate CD8+ T−cells2 was 
circularly permuted to obtain the sequence FLIMGWTLD. The purpose of this 
change was to obtain a sequence that has an aspartic acid residue at the 
C−terminus of the peptide allowing the peptide to be anchored to a solid support 
through its side chain for head-to-tail cyclisation. Cyclisation restores the 
original Bax sequence. Therefore, the backbone and sequence of the cyclic 
peptide (1c) were the same as its linear counterpart (1b), thus allowing a direct 
comparison of the two peptides for evaluation of the effect of cyclisation. 
There was no problem during synthesis of the 9-mer linear peptide allyl 
ester (1a) and converting it to 9-mer linear peptide (1b). Changing parameters 
such as reaction temperature, shaker RPM and coupling time during synthesis 
of the 9-mer linear peptide allyl ester (1a) did not yield significantly different 
results. In addition, identification of the two compounds (1a, 1b) by HPLC and 
LCMS was successful. The solubility of the linear compounds in the solvents of 
the HPLC and LCMS was enhanced by the polar termini. Additionally, these 
two peptides were not long sequences which may have reduced their 
propensity to aggregate in the aqueous solvent mixtures used during 
chromatography. 
The conversion of the linear peptide (1b) to cyclic peptide (1c) faced 
several problems that prevented sufficient quantity of the compound being 
obtained for further studies. The first main problem confronting synthesis of the 
cyclic peptide (1c) was failure of the cyclisation reaction. Possibly the length 
and sequence of the peptide resulted in conformations that failed to bring the 
termini sufficiently close together thus resulting in a sluggish cyclisation 
reaction. This problem could be overcome to an extent by using DEPBT as the 
coupling reagent. The second problem encountered was in the purification of 
the cyclic peptide (1c) by HPLC. Unfortunately, the solubility of this cyclic 
compound (1c) was very poor in the HPLC solvent, especially in water. Despite 
the cyclic peptide (1c) being dissolved in acetonitrile and a small amount of 
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DMSO then added to increase the solubility, the majority of 1c precipitated 
during collection due to water being one of the HPLC solvents. Although many 
gradient methods were used for the HPLC solvents (water and acetonitrile) in 
addition to different organic solvents (methanol, isopropanol), a large amount 
of the cyclic peptide (1c) was lost. Consequently, the yield was very low. 
The third problem was observed on two occasions when small amounts 
of 1c had been successfully purified and lyophilised. This small amount was 
dissolved in DMSO, and then stored in a freezer at −20 °C. After 15 days there 
was more than one peak besides the cyclic peptide peak in the HPLC and 
LCMS chromatograms suggesting that the peptide had decomposed during 
storage. Possible strain due to the cyclisation might have been responsible for 
an increased rate of hydrolysis. Further purification of the compound was not 
deemed to be worthwhile due to the inevitable losses that this would entail. 
Therefore, it was necessary to search for a linker that could be inserted 
into the sequence of the cyclic Bax peptide to increase its solubility without 
interfering with the residues that contact the HLA and TCR. 
The length of the peptide was increased from a 9 to 15-mer by insertion 
of the residues RELIRT which form the flanking sequence from the Bax protein. 
This longer sequence was expected to be more flexible, increasing the 
likelihood of the termini colliding during the cyclisation reaction. The presence 
of the two Arg residues was expected to increase the positive charge of the 
compound and its ability to form hydrogen bonding. 
The synthesis of the 15-mer cyclic peptide (2c) was successful using the 
same reagents and conditions as used for the 9-mer cyclic peptide (1c). The 
solubility of 2c was acceptable in water and acetonitrile. Consequently, 
insertion of the fragment of RELIRT was a successful idea. Thus, sufficient 
quantity of the 15-mer purified cyclic peptide (2c) was obtained to perform 
enzymatic degradation studies and stability studies in FCS. However, the yield 
of 2c was still very low. A possible reason for this low yield was an inefficient 
cyclisation reaction. In addition to that, the purification was wasteful, as it had 
to be repeated several times to obtain material of sufficient quality, losing an 
amount of 2c each time.  
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The retention time of the 15-mer cyclic peptide (2c) was less than the 
retention time of the 9-mer cyclic peptide (1c) in the HPLC chromatogram with 
the same method for the two compounds. It is concluded from this result that 
the polarity of 2c was greater than the polarity of 1c. This result was clear 
evidence for improvement of the properties of the cyclic peptide. 
The second fragment that was inserted into the sequence of the Bax 
peptide was KSSK. The motivation for the insertion of this fragment was that 
the two high hydrophilic residues (Lys) would increase the hydrophilicity of the 
peptide, and thus, increase solubility of the 13-mer cyclic peptide (3c) in HPLC 
and LCMS solvents. 
Synthesis and purification of this cyclic peptide (3c) was superior to the 
15-mer cyclic peptide (2c), and the evidence for this was that the yield (crude 
and purified) was greater than 2c. Potentially, the cause for this improvement 
is that the solubility of 3c in the HPLC solvents (water and acetonitrile) was 
greater than 2c. In addition to that, the cyclic peptide required fewer HPLC runs 
to purify than compound 2c. Consequently, loss of the cyclic compound (3c) 
during purification was reduced. However, the total yield was still very low. 
Possibly this was due to factors mentioned in synthesis of 2c (inefficient 
cyclisation reaction, repeated purification, lyophilisation step). 
It was concluded from this result that the insertion of the fragment (KSSK) 
in the Bax peptide sequence was a more successful proposal than the insertion 
of the RELIRT fragment. There is a possibility that the length of the peptide (13-
mer) assisted in allowing the termini of the peptide to approach closer together. 
Also, the two protected lysine residues might form more intramolecular 
hydrogen bonds with carbonyl groups of the peptide bonds to draw the termini 
of the peptide closer together.  
The storage of the two cyclic peptides (2c, 3c) for six months inside a 
freezer at −20 °C without any hydrolysis was an indicator that the two 
compounds have acceptable stability and are better than compound 1c. 
Probably, the two cyclic peptides (2c, 3c) adopt a strain free conformation in 
solution that is not predisposed to hydrolysis. Therefore, in the solution, they 
were stable for a far greater time in comparison to compound 1c. 
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No issues occurred in the synthesis, identification, purification, and 
lyophilisation of the linear peptides (2b, 3b). This may be due to their 
acceptable solubility in the HPLC solvents because they have more than one 
free polar side group, in addition to the two free polar termini.  
It was noticed that the retention time of the 15-mer cyclic peptide (2c) in 
the HPLC was very close to the retention time of its linear counterpart (2b). It 
is deduced from this value that the restricted conformation and lack of termini 
of the cyclic peptide (2c) had no significant effect on the polarity of the 
compound, while the difference between 13-mer cyclic peptide (3c) and its 
linear counterpart (3b) was observed clearly. The retention time of the cyclic 
compound (3c) was greater than the retention time of its linear counterpart (3b). 
It was concluded from this result that the loss of the termini and constricted 
conformation of 3c had reduced its polarity relative to 3b. 
It was concluded from the study of the MS2 mass spectra of compound 
1c and its linear counterpart (1b), that the main difference between them was 
a peak of 946.4 m/z in the spectrum of 2c for the fragments of b8 and b8−H2O. 
These fragments represented four different isobaric sequences, three for the 
fragment of b8−H2O and one for the fragment of b8, all of which included the 
peptide bond between Phe and Asp. As was expected, this fragment was not 
observed in the MS2 mass spectrum of compound 1b because there was no 
peptide bond between Phe (N−terminus) and Asp (C−terminus). This difference 
could be considered as evidence that the cyclic peptide (1c) had formed. 
The main difference between the MS2 spectrum of the cyclic peptide (2c) 
and its linear counterpart (2b) was a peak of 915.0 m/z. This mass was 
observed in the MS2 mass spectrum of 2c and was not observed in the MS2 
mass spectrum of its linear counterpart (2b) for the same reason that was 
mentioned in 1b. This fragment represented five sequences, one of which 
(MH2−NH3) included the peptide bond between Phe and Asp. Therefore, this 
result was potential evidence for formation of the cyclic peptide (2c). 
The main difference between the third cyclic peptide (3c) and its linear 
counterpart (3b) was the observed mass of 617.0 m/z. This mass was observed 
in the MS2 mass spectrum of compound 3c, whereas it was not observed in the 
MS2 mass spectrum of its linear counterpart (3b) for the same reason that was 
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mentioned in 1b. This mass represented two sequences (b5, y5) and because 
they included the peptide bond between Phe and Asp residues this result was 
potential evidence for formation of the cyclic peptide (3c).  
 Enzymatic degradation and kinetic study 
It was noted that the chymotrypsin enzyme exhibited the same selectivity 
towards the two predicted cleavage sites (Trp−Thr and Phe−Leu) in the two 
compounds (2b, 2c), leading to the cleaving of the peptide bond between Trp 
and Thr, but no cleavage between Phe and Leu. Potentially, the peptide bond 
of Phe−Leu did not hydrolyse due to the presence of the charged amino group 
on the N−terminal Phe residue that may have negatively affected the 
interactions with the enzyme. 
The retention time of the peptide produced by chymotrypsin catalysed 
hydrolysis of 2c was greater than the retention time of 2c. This result was not 
expected because hydrolysis of compound 2c generates two new polar groups 
at the termini. Possibly, the cause was the restricted conformation of 2c 
enhancing the overall polarity of the compound by aligning polar groups. On 
the other hand, the free orientation of the polar groups in the linear peptide 
hydrolysis product (15-mer) may have resulted in the adoption of conformations 
that lowered the overall polarity of the molecule. 
The retention times of all the peptides produced by hydrolysis of linear 
peptide 2b were less than the retention time of 2b. This result was expected 
because the generated peptides were polar (having two free polar termini in 
addition to internal polar side groups), in addition to the mass of these produced 
peptides being less than the mass of 2b. 
Surprisingly, the t½ of 2c towards chymotrypsin hydrolysis was less than 
the t½ of 2b. The cyclisation of peptide (2c) was potentially drawing compound 
2c into a conformation that was a more acceptable substrate for the 
chymotrypsin than its linear counterpart (2b).  
The expected result was observed from hydrolysis of the peptide bond 
between Arg and Thr in compound 2b by trypsin to afford a peptide with lower 
retention time and m/z than compound 2b. The second susceptible peptide 
bond (Arg−Glu) did not hydrolyse; there was a possibility that the presence of 
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charged carboxyl group on the Glu residue might have negatively affected 
interactions with the enzyme. 
 The two susceptible peptide bonds (Arg−Thr, Arg−Glu) of 2c were 
hydrolysed by trypsin. Two peptides products were observed. The first one had 
a lower retention time than 2c, which was expected because this compound 
has more polar groups and lower mass than 2c. The second peptide eluted 
with retention time greater than the retention time of the cyclic compound (2c), 
which was not predicted as it also has more polar groups and lower mass. 
Potentially, the cause was the conformation of this peptide. It was concluded 
that the second peptide bond (Arg−Glu) in the cyclic peptide (2c) was more 
suitable as a substrate for the enzyme than in linear peptide (2b). 
The t½ of 2c against trypsin was greater than the t½ of 2b indicating greater 
stability of the cyclic peptide. There is the possibility that the cause was the 
constricted conformation of the cyclic compound (2c) preventing the compound 
occupying the active site of the enzyme. Consequently, relative to its linear 
counterpart (2b) it is predicted that the cyclic compound (2c) will stand an 
increased chance in vivo of reaching the target antigen presenting cells. 
Hydrolysis of the peptide bond between Trp and Thr by chymotrypsin in 
the 13-mer linear and cyclic peptides (3b, 3c) and non−hydrolysis of the peptide 
bond between Phe and Leu, were indicators that the effect of the chymotrypsin 
on the two compounds (3c, 3b) was the same. It was possible that the 
constricted conformation of 2c did not significantly change the orientation of the 
two peptide bonds in comparison with its linear counterpart. 
As was expected, the peptide produced by chymotrypsin hydrolysis of 3b 
had a retention time that was less than the retention time of 3b as it was polar 
and lower molecular weight. The second peptide formed by hydrolysis of 3b 
was not detected, possibly due to its high hydrophilicity leading to lack of 
retention on the chromatography column. 
The linear peptide produced by hydrolysis of compound 3c by 
chymotrypsin has the same length but a permutated sequence in comparison 
to 3b; also, it has greater retention time than 3b. The rate of enzymatic 
hydrolysis of the two compounds (3b, 3c) by chymotrypsin was similar, since 
the t½ of 3b was close to the t½ of 3c. It is concluded from this result that the 
   
 
157 
 
conversion of the compound 3b to 3c did not significantly affect the stability of 
the peptide against chymotrypsin. The restricted conformation of the cyclic 
peptide (3c) appears to have made little difference to its ability to interact with 
the enzyme. 
Regarding the stability of the two compounds (3b, 3c) against trypsin, the 
cyclic peptide (3c) was very stable, while its linear counterpart was rapidly 
hydrolysed. It is deduced from this result that the restricted conformation of the 
cyclic peptide (3c) significantly changed the orientation of the peptide bond 
(Lys−Ile) to be in a conformation that was unsuitable as a substrate for trypsin. 
It is concluded that the conversion of compound 3b to 3c led to significant 
enhancement in the stability of the peptide. It is important to note that the 
second peptide bond (Lys−Ser) did not hydrolyse in either of the two 
compounds (3b, 3c). Probably, this peptide bond was in a certain conformation 
that prevented it from occupying the active site of the enzyme. 
 Stability of the peptides (2b, 2c, 3b, 3c) in fetal calf 
serum (FCS) 
Some conclusions can be drawn from the study of the stability of the cyclic 
peptides (2c, 3c) and their linear counterparts (2b, 3b) in FCS. 
Conversion of the 15-mer linear peptide (2b) to cyclic structure (2c) 
resulted in a decrease in the stability of the peptide. However, this decrease 
was not statistically significant. Therefore, there is no evidence that the 
constricted conformation of the cyclic peptide (2c) had boosted the stability of 
the peptide against the protease enzymes. It is deduced from this result that 
within experimental error the two peptides (2c, 2b) have the same resistance 
against the protease enzymes in the FCS pool. Consequently, the cyclic 
compound (2c) has the same chance of its linear counterpart (2b) to reach the 
target cell. 
Converting the 13-mer linear peptide (3b) to cyclic peptide (3c) increased 
the stability of the peptide. It is tentatively concluded from this result that the 
restricted conformation of the cyclic peptide (3c) was unsuitable as a substrate 
for the active site of the protease enzymes (greater resistance to the protease 
degradation). Therefore, it is possible that this cyclic peptide (3c) has a greater 
   
 
158 
 
chance of reaching the target cells than its linear counterpart (3b) thus leading 
to activation of CD8+ T−cells. 
  Future work 
Firstly, synthesis of an alternative compound to 9-mer cyclic peptide (1c), could 
be attempted using another method such as click reaction. The presence of a 
triazole group in the sequence of the cyclic peptide may increase the solubility 
of the peptide in HPLC solvents resulting in a higher yield. Also, synthesis of 9-
mer cyclic peptide (1c) using another coupling reagent that yields a long lived 
active ester may increase the yield. 
Preparation of larger amounts of 13-mer cyclic peptide (3c) and 15-mer 
cyclic peptide (2c) and their linear counterparts (2b, 3b) is desirable to study 
their ability to activate T cells in vitro. In addition to that, synthesis of more 
derivatives of the 9-mer cyclic peptide (1c) with insertion of new fragments that 
conferring high aqueous solubility and cell permeability would facilitate study of 
the enzymatic degradation and stability in the serum, followed by T cell activity. 
Furthermore, study of the stability of the cyclic peptides (2c, 3c) in the FCS 
could be performed for a longer time such as weeks or months, with additional 
studies of the stability of these two cyclic peptides in human serum. Following 
the fate of a cyclic peptide once it has been taken up by an antigen presenting 
cell would be another significant area of interest. The products of intracellular 
peptide cleavage could be investigated by mass spectrometry and the sub-
cellular location of fluorescently labelled peptides tracked by confocal 
microscopy. 
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 Methods 
 Analytical methods 
 RP−HPLC  
HPLC analysis was performed on a Merck−Hitachi LaChrom D−7000 
instrument with a Merck (Germany) Chromolith RP−C18E, 4.6 × 10 mm 
column, a 50 μL injection and a flow rate of 1 cm3 min−1. The detector 
wavelength was set at 220 nm. The column oven temperature was set at 30 
°C. Unless stated otherwise, solvent A was H2O with 0.1% TFA and solvent B 
was MeCN with 0.1% TFA. 
 LC−MS 
Mass spectrometry analysis was predominantly conducted on a Bruker 
Amazon SL ion trap system (Bruker Daltonics), instrument including a Thermo 
Ultimate 3000, ACQUITY UPLC, and using a Waters BEH C18 1.7 µm, 2.1 × 
100 mm column, with a 10 µL injection and flow rate 0.5 cm3 min−1. The 
temperature was set at 40 °C. 
Mass spectrometry of BSA samples was performed by Dr Thomas 
Williams on a Waters Synapt G2-Si instrument with Acquity H class UPLC 
System and Waters BEH C18 Column, 130 Å, 1.7 µm, 2.1 mm × 50 mm, 40 °C, 
flow rate 0.25 ml/min. 
For both systems, solvent A was H2O with 0.1% formic acid and solvent 
B was MeCN with 0.1% formic acid. 
 Glass and plasticware 
Table 6.1: Names of the suppliers of glassware and plasticware. 
Supplier Glass and plastics 
Fisher Scientific 
Disposable sterile centrifuge tube (15, 
50 mL), beakers (25, 100, 250, 1000 
mL), conical flask (100, 250 mL) 
Kinesis Autosampler vial (1.5 mL, 250 µL) 
Eppendorf Microcentrifuge vial (1.5, 2.5 mL) 
   
 
161 
 
 Chemicals 
Table 6.2: Names of the chemical suppliers. 
Supplier Material 
Fisher Scientific HPLC water, HPLC acetonitrile, TFA, LiCl, DIPEA 
Novabiochem 
All Fmoc−amino acids, Fmoc−Trp(Boc)−Thr(psiMe, 
Mepro)−OH, Fmoc−Asp(Resin)−Allyl 
Sigma Aldrich Trypsin, chymotrypsin, chloroform, ether, methanol 
Acros Organics DEPBT, piperidine, Parafilm 
Alfa Aesar 
Pd(PPh3)4, 4−methylmorpholine, sodium dimethyl 
dithiocarbamate hydrate 
AGTC Bioproducts N−methylpyrrolidone, PyBOP, HOBt (anhydrous)  
 Instruments 
Table 6.3: Suppliers of instruments. 
Supplier Instrument 
Kern ALS 220−4N balance 
Grant  Ultrasonic bath  
Sorval  Microcentrifuge 
Eppendorf Heat block  
Hettich  Rotina 38 R centrifuge  
Medline Scientific Ltd. Shaker 
Prestige Medical Autoclave 
Thermo Electron Corporation Freeze dryer 
Shimadzu Corporation 2401PC UV visible 
spectrometer 
 
 Method to synthesise the cyclic peptide and their linear 
counterparts 
 Method to synthesise the linear peptide allyl esters (1a, 
2a, 3a)  
Resin preloaded with Fmoc−Asp−OAllyl (catalogue number 8560250001) (0.1 
g, 0.02 mmol) was placed into a 5 mL filter tube and peptide synthesis grade 
NMP (3−4 mL) was added. The resin was left for 1 h to swell. Meanwhile, 
suitable amounts of reagents PyBOP (51 mg, 0.1 mmol) and HOBt (15 mg, 0.1 
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mmol) were added to eight Eppendorf tubes, and into each tube the required 
amount of amino acid (five molar equivalents excess relative to the resin) was 
added, taking into account the sequence of the amino acids. An excess amount 
(3−4 mL) of 20% piperidine in NMP was added to the filter tube containing the 
swollen resin, the resin was agitated for 10 min using the vortex mixer and 
filtered. The piperidine treatment was performed three times to cleave the Fmoc 
protecting group. The resin was then washed NMP (3 × 3 mL) by shaking it 
gently for 3 min to remove the remainder of the piperidine. NMP (500 μL) and 
DIPEA (38 μL) were added to the next amino acid in sequence in the Eppendorf 
tube, and this was mixed strongly by vortexing the tube. This mixture was 
added to the resin in the filter tube. The mixture was agitated for 1 h at 25 °C 
in a shaker. The solution was filtered using vacuum filtration, and the resin 
washed with NMP (3 × 3 mL) for 3 min to remove the excess activated amino 
acid, HOBt, and DIPEA. The process of deprotection of the Fmoc group by 
piperidine, the activation and coupling of the next amino acid in the sequence, 
and the washing with NMP was repeated for all the remaining amino acids. 
After addition of the final amino acid, its Fmoc group was left attached until 
immediately before the cyclisation step was performed. 
Once the resin-bound linear peptide allyl ester had been synthesised, a 
few mg of resin was removed for analysis of the cleaved and deprotected allyl 
ester peptides 1a, 2a and 3a. The Fmoc deprotection reaction was performed 
on this sample after washing with 3 × 1 mL portions of NMP, chloroform, 
ethanol, and diethyl ether for 3 min. After drying the diethyl ether using nitrogen 
gas, the small sample was placed inside a vacuum oven at 30 °C for 15 min. 
Finally, the cleavage reaction was conducted by adding 1 µL of water, 1 µL of 
triisopropyl silane, and 100 µL of TFA, then leaving for 1 hour at room 
temperature. After evaporating more than half of the TFA by nitrogen blow-
down, 250 µL of acetonitrile or water was added to the sample then it was 
vortexed, centrifuged and analysed by HPLC and LC−MS. 
 Method to deprotect the allyl ester from the C−terminus 
The resin loaded with the peptide allyl ester was soaked in 3−2 mL of 
chloroform for 10 min, during which time a solution of catalytic Pd(PPh3)4 (70 
mg, 0.06 mmol), in chloroform (950 μL), glacial acetic acid (100 μL) and 
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N−methyl morpholine (50 μL) was prepared in a small pear−shaped flask. This 
solution was then freeze−pump−thaw degassed. The filter tube containing the 
peptide−loaded resin was closed with a rubber septum and was flushed with 
nitrogen for 5 min. The solution of Pd(PPh3)4 was transferred to the resin by 
syringe and needle. This was left with gentle agitation for 2 h in the shaker at 
20 °C, using a rubber septum to exclude air. The resin was washed with 3 × 1 
mL portions of NMP, chloroform, ethanol, sodium diethyldithiocarbamate 
solution (1 g/100 mL in NMP) and diethyl ether for 3 min. A few mg of resin was 
removed to produce samples of linear peptides (1b, 2b, 3b) for analysis. The 
Fmoc deprotection reaction was performed. After the washing with 3 × 1 mL 
portions of NMP, chloroform, ethanol, and diethyl ether for 3 min, a cleavage 
reaction was conducted, as was mentioned in the synthesis of linear peptide 
allyl ester; then, a sample was taken for analysis by HPLC and LC−MS.  
 Cyclisation of the linear peptide (1c, 2c, 3c)  
After deprotection of the allyl group, the final Fmoc protecting group was 
removed using three portions of 20% piperidine in NMP (3 mL), each for 10 
min. The resin was then washed with 3 × 1 mL portions of NMP for 3 min. 
Further washing was carried out with 3 × 1 mL 10% DIPEA in NMP and then 3 
× 1 mL portions of LiCl (339 mg, 0.8 M in NMP) for 3 min. A solution of DEPBT 
(25 mg, 0.084 mmol) and DIPEA (35 μL) in NMP (500 μL) was added to the 
resin and gently agitated for 2 h in the shaker at 20 °C. The solution was then 
drained and another identical portion of the coupling reagent solution was 
added; this was then left overnight, and finally the resin was washed with 3 × 3 
mL NMP; a small amount of resin was then removed, and a Fmoc deprotection 
reaction was performed prior to washing with 3 × 1 mL portions of NMP, 
chloroform, ethanol, and diethyl ether for 3 min. Finally, a cleavage reaction 
was conducted, as was described in the synthesis of linear peptide allyl ester, 
and a sample taken for analysis by HPLC and LC−MS. 
 Method to synthesise linear peptide (1b, 2b, 3b) 
Three steps were used in the synthesis of the three compounds (1b, 2b, 3b). 
The assembly of the peptide chain was as in the procedure for the synthesis of 
linear peptide allyl ester (2.6.1); then the second step was as in the procedure 
for the deprotection of allyl group (6.2.2); the cleavage and side chain 
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deprotection followed the same procedure as cleavage of the cyclised peptide 
(2.6.5). 
 Cleavage of the cyclised peptide  
The peptide−loaded resin was firstly washed with an excess amount (3−4 mL) 
of chloroform, methanol and diethyl ether. Next, the resin was dried in a vacuum 
oven for 15 min to evaporate the ether. Water (25 μL), ethane−1,2−dithiol (25 
μL), triisopropyl silane (10 μL) and TFA (950 μL) were then added to the 
Eppendorf vial containing the resin by micropipette using a disposable tip. Any 
apparatus and all the tips that had touched the mixture were immediately put 
into a beaker (500 mL) of bleach and left for at least 12 h to oxidise the mixture 
for neutralisation purposes. The reaction was left for 2 h with gentle agitation. 
At this point, 2 × 12 mL of diethyl ether was put into centrifuge tubes (15 mL) 
and placed into an ice bath to cool. After the reaction had taken place, the 
solution of the peptide was poured into the first tube of ice cold diethyl ether (12 
mL). The peptide was then obtained as a milky cream precipitate, and the tube 
was centrifuged for 5 min at 19450 RCF using the second diethyl ether tube 
(12 mL) as a balance for the centrifuge. After this, the ether was eliminated 
through careful decantation into a waste beaker. The process of adding diethyl 
ether and its removal was repeated one further time; then, 2 mL of water was 
added to dissolve the peptide. The solution was also vortexed to ensure the 
pellet of peptide had completely dissolved. The solution was stored at 4 °C and 
LC−MS and HPLC analyses were run. 
 HPLC purification of the peptides 
The cyclic peptides (1c, 2c, 3c) were purified using a Merck (Germany) 
Chromolith RP−C18E, 100 × 4.6 mm column, via a 100 μL injection and a flow 
rate of 1 mL min−1. The column oven was set at 30 °C. Unless stated otherwise, 
solvent A was H2O with 0.1% TFA and solvent B was MeCN with 0.1% TFA. 
The method which was used to purify the 9-mer cyclic peptide (1c) has 
retention time 17.23 min as shown in Table 6.4. 
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Table 6.4: HPLC method for purification of 9-mer cyclic peptide (1c), which has 
retention time 17.23 min. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
25 5 95 
30 5 95 
33 95 5 
 
The fraction containing the cyclic peptide (1c) was lyophilised to remove 
the HPLC solvents. The solid sample was then weighed and dissolved in 
dimethylsulfoxide (DMSO) to prepare a concentration of 10 mg/mL as a stock 
solution. 1 µL was taken from the stock solution and added to 50 µL of 
acetonitrile for analysis. Finally, HPLC and LC−MS analyses were performed, 
and the stock solution was stored at −20 °C. Compound 2c, which has retention 
time 12.29 min, was purified (three times) using the method as shown in Table 
6.5. Using the same method as for the 9-mer cyclic peptide (1c), the 15-mer 
cyclic peptide (2c) was dried, weighed, re−dissolved, analysed and stored.  
Table 6.5: HPLC method for purification of 15-mer cyclic peptide (2c), which has 
retention time 12.29 min. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
20 5 95 
23 5 95 
24 95 5 
25 95 5 
 
The method which was used to collect the 15-mer linear peptide (2b), 
which has retention time 12.67 min, is the same as the method used for the 15-
mer cyclic peptide (2c). Again, the 15-mer linear peptide (2b) was dried, 
weighed, re−dissolved, analysed and stored. The method used to purify the 13-
mer cyclic peptide (3c), which has retention time 14.49 min, is described in 
Table 6.6. 
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Table 6.6: HPLC method for the purification of 13-mer cyclic peptide (3c), which 
has retention time 14.49 min. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
25 5 95 
30 5 95 
34 95 5 
35 95 5 
 
The 13-mer cyclic peptide (3c) was purified (two times), dried using the 
same method that was utilised in the 9-mer cyclic peptide: weighed, 
re−dissolved, analysed by HPLC and LC−MS and stored. 
Finally, the method used to collect the 13-mer linear peptide (3b), which 
has retention time 10.68 min, is the same as the method employed for the 13-
mer cyclic peptide (3c) and the 9-mer cyclic peptide. Then, the same final five 
steps for the 13-mer cyclic peptide (3c) were undertaken for its linear 
counterpart (3b). 
 Fragmentation of the peptides 
The same samples of the cyclic peptides (9, 13, 15-mer) and their linear 
counterparts, which were used to run MS analysis, were used to run the MS2 
analysis via the LC−MS. The selection of the precursor ion for fragmentation 
by the MS2 method for all the peptides depended on the peak observed in the 
MS scan. Therefore, the precursor ions were as described in Table 6.7. 
Collision induced dissociation was used for fragmentation, with the collision 
energy set automatically by the instrument control software. 
Table 6.7: Precursor ion m/z for the MS2 analysis which were obtained from MS 
scan. 
Peptide Precursor ion (m/z) 
9-mer linear peptide (1b) 1095.7 
9-mer cyclic peptide (1c) 1077 
15-mer linear peptide (2b) 933.0 
15-mer cyclic peptide (2c) 923.5 
13-mer linear peptide (3b) 509.6 
13-mer cyclic peptide (3c) 754.9 
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 Preparation of the buffer solution 
Ammonium bicarbonate (NH4HCO3) was used as a buffer solution in the 
enzyme degradation experiments and for checking the stability of the peptides 
in FCS. NH4HCO3 (39.5 mg) was dissolved in 50 mL of distilled water to prepare 
a 0.01 M concentration of the buffer solution, the pH of which was then adjusted 
by 3−5 drops of the concentrated ammonia solution until a pH of 8.6 was 
achieved. The buffer was then stored at room temperature.  
 Calculating the concentration of the peptides (2b, 2c, 3b, 
3c)  
 The 13-mer cyclic peptide (3c) 
2.7 mg of the 13-mer purified cyclic peptide (3c) was dissolved in 270 µL of 
DMSO solvent to obtain a 10 mg/mL stock solution. 1 µL of the stock solution 
was added to 999 µL of the ammonium bicarbonate buffer solution inside the 
UV cuvette. After mixing the solution, the absorbance was measured at 
wavelengths from 200−600 nm at a temperature of 25 °C. This measurement 
was repeated twice and the concentration of the cyclic peptide in the cuvette 
was calculated at the wavelength 280 nm by the following equation:  
C = A/ε 
ε(Trp) = 5690 M−1cm−1 
Then the concentration of the stock solution (270 µL) was calculated by the 
following equation: 
C1 × V1 = C2 × V2 
 The 13-mer linear peptide (3b)  
0.74 mg of the linear peptide was dissolved in 74 µL of dimethyl sulfoxide 
(DMSO) to obtain a 10 mg/mL stock solution. 10 µL of this stock solution was 
added to 990 µL of the ammonium bicarbonate buffer solution, inside a 
spectrophotometer cuvette. After mixing the solution, the absorbance was 
measured at wavelengths between 200−600 nm at a temperature of 25 °C. This 
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measurement was repeated twice, and the concentration of the linear peptide 
was calculated using the absorbance at 280 nm using the equation mentioned 
previously. 
 The 15-mer cyclic peptide (2c) and its linear 
counterpart (2b) 
The same method as for the previous peptide (3b) was applied to prepare the 
stock solution (10 mg/mL) and compute the concentration of the 15-mer cyclic 
peptide (2c) and its linear counterpart (2b). 
 Calculation of the percentage yield of the peptides (2b, 
2c, 3b, 3c) 
The general method that was used to calculate the percentage for the yield of 
the synthesised peptide is as follows: 
Resin substitution (mmol/g) = 0.2 
Amount of resin (g) = 0.1 
Meq of resin (mmol) = 0.2 × 0.1 = 0.02 
Yield of the synthesised peptide (mmol) = mass (by UV method)/ MW 
% of the peptide = 100 × yield of the synthesised peptide (mmol)/ Meq of resin 
(mmol)  
 Calculation of the concentration of the enzymes 
1 mg of each enzyme, trypsin and chymotrypsin, was dissolved in 1 mL of buffer 
solution (NH4HCO3) in a 1.5 mL Eppendorf tube for use as a stock solution. A 
Bradford assay for the quantity of the protein in the solution was used to 
measure the absorbance of each enzyme.197 Bovine serum albumin (BSA) was 
used as a protein standard to generate a calibration plot. An aliquot of BSA 
stock solution was diluted to a volume of 200 µL with water, then Bradford 
reagent was added to give a total volume of 1.0 mL. The absorbance at a 
wavelength of 595 nm was measured at a temperature of 25 °C. Measurements 
were performed in an identical way for the trypsin and chymotrypsin stock 
solutions. The BSA calibration graph was used to determine the amount of each 
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enzyme present in the diluted volume (200 µL), from which the stock solution 
(1.0 mL) concentration was calculated. 
 Preparation of the BSA solution 
BSA protein (2 mg, 15 × 10−3 M) was weighed and dissolved in 2 mL of buffer 
solution (NH4HCO3); then, 10 µL was taken from the solution and diluted to 500 
µL by the buffer solution to obtain BSA concentration (3 × 10−4 M) as a stock 
solution. 
 Checking the activity of the enzymes 
 Activity of the chymotrypsin 
BSA was used to check the activity of the chymotrypsin enzyme. 10 µL of 
chymotrypsin stock solution was added to 100 µL of BSA stock solution inside 
an Eppendorf tube. The reaction was incubated at 37 °C for 30 min, after which 
the reaction was stopped by heating for 5 min in a boiling water bath (100 °C) 
followed by cooling with liquid nitrogen for 1 min. MS analysis was then 
performed after centrifuging of the sample.  
 Activity of the trypsin 
10 µL of trypsin stock solution was added to 100 µL of BSA stock solution inside 
an Eppendorf tube, Then, the same methodology was used as described when 
studying the activity of chymotrypsin to examine the activity of the trypsin.  
 Enzymatic degradation and kinetics for the hydrolysis 
of peptides  
 Enzymatic degradation and calculation of the t½ of 13-
mer linear peptide (3b) in the presence of chymotrypsin  
25 µL of chymotrypsin (1.06 µM) was added to 250 µL of 3b (200 µM, pH 8.6) 
inside a 0.5 mL Eppendorf tube; this tube was then incubated inside a heat 
block at 10 °C. A small sample (25 µL) was then taken and transferred to 
another Eppendorf tube after 0, 2, 4, 6, 8, 10, 15, 20, 30 min and the reaction 
stopped by heating in a boiling water bath (100 °C) for 4 min then freezing in a 
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bath of liquid nitrogen for 1 min. Finally, LC−MS and HPLC (10 µL as injection 
volume, 30 °C column temperature and the method shown in Table 6.8) 
analysis was performed after centrifuging of the sample.  
Table 6.8: General HPLC method used to study the enzymatic degradation and 
t½ of 13-mer cyclic peptide (3c) and its linear counterpart (3b) in the presence of 
chymotrypsin and trypsin. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
25 5 95 
30 5 95 
34 95 5 
35 95 5 
 
The areas of the 13-mer linear peptide (3b) peaks in the chromatograms 
of HPLC for 0−30 min were used to calculate the t½ of compound 3b, by plotting 
ln area against the time. The LINEST function in Excel was used to obtain the 
gradient (k) and its standard error (SE). The gradient was used in the following 
equation to calculate the t½. 
t½ = ln 2 / k 
  Enzymatic degradation and calculation of the t½ of 
the 13-mer cyclic peptide (3c) in the presence of 
chymotrypsin 
25 µL of chymotrypsin (1.06 µM) was added to 250 µL of 3c (200 µM, pH 8.6) 
inside a 0.5 mL Eppendorf tube. The degradation was then achieved, using the 
same methodology as described for the enzymatic degradation of the 13-mer 
linear peptide (3b) in the presence of chymotrypsin, to perform the experiment. 
LC−MS and HPLC were again performed using the same conditions and 
solvent gradient as for 3b in the presence of chymotrypsin. 
The areas of the 13-mer cyclic peptide (3c) peaks in the chromatograms 
of HPLC for 0−30 min and the same functions in the Excel program and the 
equation, as was mentioned in the study of the t½ of the 13-mer linear peptide 
(3b) in the presence of chymotrypsin, were used to calculate the t½ of 3c. 
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 Enzymatic degradation and calculation of the t½ of the 
13-mer linear peptides (3b) in the presence of trypsin 
25 µL of trypsin (0.41 µM) was added to a 0.5 mL Eppendorf tube containing 
250 µL of 3b (200 µM, pH 6.2). The tube was then incubated inside a heat block 
at 10 °C. The experiment was then prepared in the same way as described 
previously (section 6.10.2) but with the presence of trypsin. Finally, LC−MS and 
HPLC analyses were performed with the HPLC methodology as shown in Table 
6.8. 
The same procedure was used to study the t½ of the 13-mer linear peptide 
(3b) in the presence of chymotrypsin. The areas of 3b peaks in the HPLC 
chromatograms resulting from the reaction of the 13-mer linear peptide (3b) 
with trypsin for 0−30 min were used to calculate the t½.  
 Enzymatic degradation and calculation of the t½ of the 
13-mer cyclic peptide (3c) in the presence of trypsin 
This is the same procedure, that was used in the study of the degradation of 
the linear peptide (3b) in the presence of trypsin. In addition, 3 µL of 
Fmoc−tryptophan(Boc) (2.7 × 10−2 M) was added to each sample after stopping 
the reaction (heating in a boiling water bath at 100 °C for 4 min then freezing in 
a bath of liquid nitrogen for 1 min). The ratio of peak area of peptide to internal 
standard (3c/IS) was calculated for each time point to study the stability of 3c 
against trypsin. 
 Enzymatic degradation and calculation of the t½ of the 
15-mer linear peptide (2b) in the presence of chymotrypsin 
Inside a 0.5 mL Eppendorf tube, 25 µL of chymotrypsin (1.06 µM) was added 
to 250 µL of 2b (100 µM pH 8.6). This tube was incubated inside a heat block 
at 10 °C and then a small portion of the sample (25 µL) was taken and moved 
to another Eppendorf tube after 0, 2, 4, 6, 8, 10, 15, 20, 30 min. At this point, 
the enzyme reaction was stopped by heating in a boiling water bath (100 °C) 
for 4 min followed by freezing in a bath of liquid nitrogen for 1 min. LC−MS and 
HPLC were then performed with the HPLC conditions listed in Table 6.9. 
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The areas of the 15-mer linear peptide (2b) peaks in the HPLC 
chromatograms for 0−30 min were used to calculate the t½ of 2b, using the 
same functions in the Excel program and the equation as were mentioned in 
the study of the t½ of the 13-mer linear peptide (3b) in the presence of the same 
enzyme. 
Table 6.9: General HPLC method used to study the enzymatic degradation and 
t½ of 15-mer cyclic peptide (2c) and its linear counterpart (2b) in the presence of 
chymotrypsin and trypsin. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
20 5 95 
21 5 95 
23 95 5 
 
 Enzymatic degradation and calculation of the t½ of the 
15-mer cyclic peptide (2c) in the presence of chymotrypsin 
The same procedure and conditions that were used in the hydrolysis of the 15-
mer linear peptide (2b) by chymotrypsin were then employed in this experiment 
to undertake the degradation and LC−MS, HPLC analysis of the 15-mer cyclic 
peptide (2c) with the same enzyme.  
The areas of the 15-mer cyclic peptide (2c) peaks in the chromatograms 
of HPLC for 0−30 min were used to calculate the t½ of 2c, using the same 
methodology applied for determining t½ of the 13-mer linear peptide (3b) in the 
presence of chymotrypsin. 
 Enzymatic degradation and calculation of the t½ of the 
15-mer linear peptide (2b) in the presence of trypsin 
25 µL of trypsin (0.41 µM) was added to a 0.5 mL Eppendorf tube containing 
250 µL of 2b (100 µM pH 6.2). The tube was then incubated inside a heat block 
at 10 °C. The experiment was then prepared in the same way as described 
previously (section 6.10.5) but in the presence of trypsin. Finally, LC−MS and 
HPLC analyses were performed with the HPLC method shown in Table 6.9. 
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Using the method described previously, the t½ of the 15-mer linear peptide 
(2b) was calculated from the areas of 2b peaks in the HPLC chromatograms 
for 0−30 min of reaction between trypsin and compound 2b.  
 Enzymatic degradation and calculation of the t½ of the 
15-mer cyclic peptide (2c) in the presence of trypsin 
The same procedure and conditions that were used in the hydrolysis of 2b by 
trypsin and the conditions of the LC−MS and HPLC (Table 6.9) analysis were 
used in this experiment to study the degradation of 2c with the same enzyme. 
The t½ of 2c was determined from the areas of 2c peaks in the HPLC 
chromatograms of HPLC for 0−30 min reaction time using the previously 
described method. 
 General procedures to study the stability of the 
peptides (2b, 3b, 2c, 3c) in fetal calf serum (FCS) 
 Preparation of 20% FCS solution  
The stored frozen serum (supplied by Sigma−Aldrich) was prepared by 
centrifugation at 9450 RCF at 8 °C, for 10 min. Then 200 µL of the clear solution 
was taken by micropipette and added to 800 µL of the HEPES buffer solution 
(1 M in H2O, pH 7.4) inside a 1.5 mL Eppendorf tube to obtain 20% serum 
solution. 
 Studying the stability of the 13-mer linear peptide (3b) 
in the presence of FCS 
226 µL of 3b (0.7 mM) was added to 226 µL of serum (20%) inside a 0.5 mL 
Eppendorf tube; this tube was then incubated inside a heat block at 37 °C. 
Aliquots (24 µL) were taken after 0, 2, 6, 12, 24, 48 h, following which, the 
enzymatic reaction was stopped by heating the sample in a boiling water bath 
(100 °C) for 5 min followed by freezing in a bath of liquid nitrogen for 1 min. 1 
µL of benzoic acid (8.1 mmole), used as an internal standard, was then added, 
followed by vortexing and centrifugation of the sample. HPLC analysis was 
performed with a 10 µL injection volume and column temperature of 30 °C. The 
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solvent gradient used in the HPLC analysis is shown in Table 6.10. This 
experiment was repeated a further two times. 
Table 6.10: General HPLC method used to study the stability of 13-mer cyclic 
peptide (3c) and its linear counterpart (3b) in 20% FCS. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
12 5 95 
30 5 95 
33 95 5 
 
Table 6.11: General HPLC method used to study the stability of 15-mer cyclic 
peptide (2c) and its linear counterpart (2b) in 20% FCS. 
Time (min) % Water % Acetonitrile 
0 95 5 
1 95 5 
12 5 95 
23 5 95 
 
 Studying the stability of the 13-mer cyclic peptide (3c) 
in the presence of FCS 
226 µL of 3c (0.7 mM) was added to 226 µL of serum (20%) inside a 0.5 mL 
Eppendorf tube. The experiment was then achieved using the same 
methodology as described in the study of the stability of 3b. 
 Studying the stability of the 15-mer linear peptide (2b) 
in the presence of FCS 
226 µL of 2b (0.7 mM) was added to 226 µL of 20% serum inside a 0.5 mL 
Eppendorf tube. The enzymatic degradation was then allowed to occur as 
previously described. However, the HPLC conditions required for this peptide 
were different and are described in Table 6.11. 
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 Studying the stability of the 15-mer cyclic peptide (2c) 
in the presence of FCS 
226 µL of 2c (0.7 mM) was added to 226 µL of serum (20%) inside a 0.5 mL 
Eppendorf tube. Using the same methodology as previously described, the 
sample was analysed with the same injection volume, temperature and HPLC 
method (Table 6.11). 
 General procedure to calculate the t½ of the peptides 
(2b, 2c, 3b, 3c) in the presence of FCS  
The ratio of the area of the peptide peak (2b, 2c, 3b, 3c) in the HPLC 
chromatogram at 0, 2, 6, 12, 24, 48 h to the internal standard peak (benzoic 
acid) was used to calculate the t½ of each peptide. Ln (area of peptide peak/area 
of the internal standard peak) was plotted against time and a linear trendline 
fitted using the Excel software. The first order rate constant, k, is the negative 
of the gradient of the trendline. The equation that was used to calculate the t½ 
of the peptide is as mentioned in the calculation of the t½ of 13-mer linear 
peptide (3b) in the presence of chymotrypsin (section 6.10.1). The mean of the 
t½ values for the three replicates was calculated, in addition to the standard 
deviation (σ) by the Excel program. 
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 Appendix A 
Table A.1: Suggested structures produced by fragmentation of the precursor ion 
9-mer cyclic peptide (1c) [M+H]+ m/z 1077 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
MH-H2O (m/z = 1059.5) 
1) Cleavage of the amide bond between D and F in 1c. 2) Loss of H2O 
molecule from T. 
2 
 
b8 (m/z = 962.5) 
1) Cleavage of the amide bond between F and D in 1c. 2) Cleavage of 
the amide bond between L and D in the linear fragment (loss of D). 
3 
 
1-b8-H2O (m/z = 946.4) 
1) Cleavage of the amide bond between D and L in 1c. 2) Cleavage of 
the amide bond between T and L in the linear fragment (loss of L). 3) 
Loss of H2O molecule from T. 
   
 
191 
 
 
2-b8-H2O (m/z = 946.4) 
1) Cleavage of the amide bond between M and I in 1c. 2) Cleavage of 
amide bond between L and I in the linear fragment (loss of I). 3) Loss 
of H2O molecule from T. 
 
 
3-b8-H2O (m/z = 946.4) 
1) Cleavage of the amide bond between L and I in 1c. 2) Cleavage of 
the amide bond between F and L in the linear fragment (loss of L). 3) 
Loss of H2O molecule from T. 
 
 
4-b8 (m/z = 946.5) 
1) Cleavage of the amide bond between G and M in 1c. 2) Cleavage of 
the amide bond between I and M in the linear fragment (loss of M). 
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4 
 
b7-H2O (m/z = 831.4) 
1) Cleavage of the amide bond between F and D in 1c. 2) Cleavage of 
the amide bond between T and L in the linear fragment (loss of the 
fragment of LD). 3) Loss of H2O molecule from T. 
5 
 
b6 (m/z = 748.4) 
1) Cleavage of the amide bond between F and D in 1c. 2) Cleavage of 
the amide bond between W and T in the linear fragment (loss of the 
fragment of TLD). 
6 
 
b6 (m/z = 704.3) 
1) Cleavage of the amide bond between M and I in 1c. 2) Cleavage of 
the amide bond between D and F in the linear fragment (loss of the 
fragment of FLI). 
7 
 
b5-H2O (m/z = 555.3) 
1) Cleavage of the amide bond between D and F in 1c. 2) Cleavage of 
the amide bond between M and G in the linear fragment (loss of the 
fragment of FLIM. 3) Loss of H2O molecule from T. 
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Table A.2: Suggested structures produced by fragmentation of the precursor ion 
9-mer linear peptide (1b) [M+H]+ m/z 1096 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
MH-H2O (m/z = 1077.5) 
Loss of H2O molecule from D, without any cleavage in the amide 
bonds of the linear compound (1b). 
2 
 
b8 (m/z = 962.5) 
Cleavage of the amide bond between L and D in 1b (loss of D). 
3 
 
b8-H2O (m/z = 944.5) 
1) Cleavage of the amide bond between L and D in 1b (loss of D). 2) 
Loss of H2O molecule from T. 
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4 
 
b7 (m/z = 849.4) 
Cleavage of the peptide bond between T and L in 1b (loss of the 
fragment of LD). 
5 
 
b7-H2O (m/z = 831.4) 
1) Cleavage of the amide bond between T and L in 1b (loss of the 
fragment of LD). 2) Loss of H2O molecule from T. 
6 
 
b6 (m/z = 748.4) 
Cleavage of the amide bond between W and T in 1b (loss of the 
fragment of TLD). 
7 
 
y6 (m/z = 722.3) 
Cleavage of the amide bond between M and I in 1b (loss of the 
fragment of FLI). 
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Table A.3: Suggested structures produced by fragmentation of the precursor ion 
15-mer cyclic peptide (2c) [M+2H]2+ m/z 924 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
b11 (m/z = 1300.7) 
1) Cleavage of the amide bond between L and E in 2c. 2) Cleavage 
of the amide bond between D and F in the linear fragment (loss of 
the fragment of FLRE). 
2 
 
1-MH2-NH3 (m/z = 915.0) 
1) Cleavage of the amide bond between W and G in 2c. 2) Loss of 
NH3 molecule from one of the two R residues. 
 
2-y8-NH3 (m/z = 915.5) 
1) Cleavage of the amide bond between G and W in 2c. 2) Cleavage 
of the amide bond between R and E in the linear fragment (loss of 
the fragment of WTLDFLR). 3) Loss of NH3 molecule from R. 
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3-a8-NH3 (m/z = 914.5) 
1) Cleavage of the amide bond between R and I in 2c. 2) Cleavage 
of the amide bond between L and D in the linear fragment (loss of the 
fragment of DFLRELI). 3) Loss of NH3 molecule from R. 
 
 
4-a8-NH3* (m/z = 914.5) 
1) Cleavage of the amide bond between L and I in 2c. 2) Cleavage of 
the amide bond between T and L in the linear fragment (loss of the 
fragment of LDFLREL). 2) Loss of NH3 molecule from R. 
 
 
5-b8 (m/z = 914.5) 
1) Cleavage of amide bond between R and E in 2c. 2) Cleavage of 
the amide bond between G and W in the linear fragment (loss of the 
fragment of WTLDFLR). 
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3 
 
b5 (m/z = 659.4) 
1) Cleavage of the amide bond between F and D in 2c. 2) Cleavage 
of the amide bond between L and I in the linear fragment (loss of the 
fragment of IRTIMGWTLD). 
4 
 
b4 (m/z = 546.3) 
1) Cleavage of the amide bond between F and D in 2c. 2) Cleavage 
of the amide bond between E and L in the linear fragment (loss of the 
fragment of LIRTIMGWTLD). 
5 
 
b3 (m/z = 417.3) 
1) Cleavage of the amide bond between F and D in 2c. 2) Cleavage 
of the amide bond between R and E in the linear fragment (loss of 
the fragment of ELIRTIMGWTLD). 
6 
 
b3 (m/z = 330.2) 
1) Cleavage of the amide bond between T and W in 2c. 2) Cleavage 
of the amide bond between D and F in the linear fragment (loss of 
the fragment of FLRELIRTIMGW). 
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Table A.4: Suggested structures produced by fragmentation of the precursor ion 
15-mer linear peptide (2b) [M+2H]2+ m/z 933 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
y12 (m/z = 1447.8) 
Cleavage of the amide bond between G and R in 2b (loss of the 
fragment of FLR). 
2 
 
b10-NH3 (m/z = 1256.7) 
Cleavage of the amide bond between M and G in 2b (loss of the 
fragment of GWTLD). 
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3 
 
 
 
b9-NH3 (m/z = 1125.7) 
Cleavage of the amide bond between M and I in 2b (loss of the 
fragment of MGWTLD). 
4 
 
MH2-H2O (m/z = 923.5) 
Loss of H2O molecule from D residue in 2b. 
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5 
 
y7 (m/z = 835.4) 
Cleavage of the amide bond between T and I in 2b (loss of the 
fragment of FLRELIRT). 
6 
 
b10 (m/z = 637.4) 
Cleavage of the amide bond between G and M in 2b (loss of the 
fragment of GWTLD). 
7 
 
b4 (m/z = 546.3) 
Cleavage of the amide bond between L and E in 2b (loss of the 
fragment of LIRTIMGWTLD). 
8 
 
b3 (m/z = 417.3) 
Cleavage of the amide bond between R and E in 2b (loss of the 
fragment of ELIRTIMGWTLD). 
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Table A.5: Suggested structures produced by fragmentation of the precursor ion 
13-mer cyclic peptide (3c) [M+2H]2+ m/z 755 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
MH (m/z = 1507.8) 
Cleavage of the amide bond between F and D in 3c without losing any 
fragment. 
2 
 
y12+H2O (m/z = 1378.7) 
1) Cleavage of the amide bond between F and D in 3c. 2) Cleavage of 
the amide bond between F and L in the linear fragment (loss of F). 
3 
 
b10 (m/z = 1178.6) 
1) Cleavage of the amide bond between F and D in 3c. 2) Cleavage of 
the amide bond between W and T in the linear fragment (loss of the 
fragment of TLD). 
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4 
 
y8 (m/z = 963.5) 
1) Cleavage of the amide bond between F and D in 3c. 2) Cleavage 
of the amide bond between K and S in the linear fragment (loss of 
the fragment of FLKSS). 
5 
 
b6, (m/z = 717.4) 
1) Cleavage of the amide bond between S and K in 3c. 2) Cleavage 
of the amide bond between T and L in the linear fragment (loss of the 
fragment of LDFLKSS). 
6 
 
1-y5 (m/z = 617.4) 
1) Cleavage of the amide bond between S and K in 3c. 2) Cleavage 
of the amide bond between T and L in the linear fragment (loss of the 
fragment of SSKIMGWT). 
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2-b5 (m/z = 617.4) 
1) Cleavage of the amide bond between T and L in 3c. 2) Cleavage 
of the amide bond between K and S in the linear fragment (Loss of 
the fragment of SSKIMGWT). 
7 
 
b5-H2O (m/z = 545.3) 
1) Cleavage of the amide bond between F and D in 3c. 2) Cleavage 
of the amide bond between S and K in the linear fragment (Loss of 
the fragment of KIMGWTLD. 3) Loss of H2O molecule from T. 
8 
 
y3 (m/z = 330.2) 
1) Cleavage of the amide bond between F and D in 3c. 2) Cleavage 
of the amide bond between W and T in the linear fragment (loss of 
the fragment of FLSSKLIMGW). 
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Table A.6: Suggested structures produced by fragmentation of the precursor ion 
13-mer linear peptide (3b) [M+3H]3+ m/z 510 using MS2. 
No Structure of the fragment and site of cleaved peptide bond 
1 
 
b12 (m/z = 696.9) 
Cleavage of the amide bond between F and D in 3b (loss of D). 
2 
 
b11 (m/z = 640.3) 
Cleavage of the amide bond between T and L in 3b (loss of the 
fragment of LD). 
3 
 
b10 (m/z = 589.8) 
Cleavage of the amide bond between W and T in 3b (loss of the 
fragment of TLD). 
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4 
 
b4-NH3 (m/z = 459.3) 
1) Cleavage of the amide bond between S and S in 3b (loss of the 
fragment of SKIMGWTLD. 2) Loss of NH3 molecule from K. 
5 
 
y3 (m/z = 348.2) 
Cleavage of the amide bond between W and T in 3b (loss of the 
fragment of FLKSSKIMGW). 
6 
 
y2 (m/z = 247.1) 
Cleavage of the amide bond between T and L in 3b (loss of the 
fragment of FLKSSKIMGWT). 
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 Appendix B 
 
Figure B.1: Total ion chromatogram of bovine serum albumin (BSA), 
column C18, solvent A: H2O + 0.01% TFA, solvent B: MeCN + 0.01% TFA, 
temperature: 40 °C. Method: 0.00-1.00 min A:B is 95:5, 40.00 min A:B is 
5:95. 
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Figure B.2: Mass spectrum of bovine serum albumin (BSA), column C18, 
solvent A: H2O + 0.01% TFA, solvent B: MeCN + 0.01% TFA, temperature: 
40 °C. Method: 0.00-1.00 min A:B is 95:5, 40.00 min A:B is 5:95. 
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Figure B.3: Total ion chromatogram of bovine serum albumin (BSA) 
hydrolysed by chymotrypsin at 37 °C and pH 7.4 for 15 min. Column 
C18, solvent A: H2O + 0.01% TFA, solvent B: MeCN + 0.01% TFA, 
temperature: 40 °C. Method: 0.00-1.00 min A:B is 95:5, 40.00 min A:B is 
5:95.  
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Figure B.4: Total ion chromatogram of the bovine serum albumin (BSA) 
hydrolysed by trypsin at 37 °C and pH 7.4 for 15 min. Column C18, solvent 
A: H2O + 0.01% TFA, solvent B: MeCN + 0.01% TFA, temperature: 40 °C. 
Method: 0.00-1.00 min A:B is 95:5, 40.00 min A:B is 5:95.  
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Chymotrypsin + 2b at 0 min                      Chymotrypsin + 2b at 2 
min 
  
Chymotrypsin + 2b at 4 min             Chymotrypsin + 2b at 6 min 
 
Chymotrypsin + 2b at 8 min              Chymotrypsin + 2b at 10 min 
   
Chymotrypsin + 2b at 15 min             Chymotrypsin + 2b at 20 min 
  
Chymotrypsin + 2b at 30 min             Blank (acetonitrile + water) 
Figure B.5: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 8.6 for 0, 
2, 4, 6, 8, 10, 15, 20, 30 min. 
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Figure B.6: MS2 mass spectrum of the precursor ion 348.1 m/z (2b1) 
produced by enzymatic hydrolysis of 15-mer linear peptide (2b) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
Table B.1: The expected mass of the peptides (m/z) produced by enzymatic 
hydrolysis of 15-mer linear peptide (2b) in the presence of chymotrypsin at 10 °C 
and pH 8.6 for 20 min. 
 
  
  
F-L-R-E-L-I-R-T-I-M-G-W-T-L-D 
No Site of the cleaved 
peptide bond 
m/z of the expected peptide 
1 F−L (166.1)1+, (1716.9)1+, (859)2+, (573)3+ 
2 W−T (348.2)1+, (1534.9)1+, (767.9)2+, 
(512.3)3+ 
3 F−L, W−T (166.1)1+, (348.2)1+, (1387.8)1+, 
(694.4)2+, (463.3)3+ 
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Table B.2: Suggested structures for observed peaks (fragments) in the MS2 mass 
spectrum of precursor ion 348.1 m/z (2b1) produced by enzymatic hydrolysis of 
15-mer linear peptide (2b) in the presence of chymotrypsin at 10 °C and pH 8.6 
for 20 min. 
No Structure of the fragment and site of the cleaved 
peptide bond in 2b1 (T-L-D) 
1 
 
b2 (m/z = 215.1) 
Cleavage of the peptide bond between L and D in 
2b1 (loss of D). 
2 
 
y2 (m/z = 247.1) 
Cleavage the peptide bond between T and L in 2b1 
(loss of T). 
3 
 
MH (m/z = 348.2) 
No cleavage at any of the peptide bonds of the 
precursor ion (2b1). 
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Chymotrypsin + 2c at 0 min                   Chymotrypsin + 2c at 2 min
  
Chymotrypsin + 2c at 4 min                    Chymotrypsin + 2c at 6 min 
 
Chymotrypsin + 2c at 8 min                    Chymotrypsin + 2c at 10 min 
  
Chymotrypsin + 2c at 15 min                  Chymotrypsin + 2c at 20 min 
  
Chymotrypsin + 2c at 30 min                Blank (Acetonitrile and water) 
Figure B.7: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 2c (100 µM) at 10 °C and pH 8.6 for 0, 
2, 4, 6, 8, 10, 15, 20, 30 min. 
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Figure B.8: MS2 mass spectrum of the precursor ion 924.0 m/z (2c1) 
produced by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
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Table B.3: Suggested structures for observed peaks (fragments) in the MS2 mass 
spectrum of precursor ion 924.0 m/z (2c1) produced by enzymatic hydrolysis of 
15-mer cyclic peptide (2c) in the presence of chymotrypsin at 10 °C and pH 8.6 
for 20 min. 
No Structure of the fragment and site of the cleaved peptide bond in 
2c1 (T-L-D-F-L-R-E-L-I-R-T-I-M-G-W) 
1 
 
y7 (m/z = 876.5) 
Cleavage of the peptide bond between L and I in 2c1 (loss of the 
fragment of TLDFLREL). 
2 
 
b5 (m/z = 590.3) 
Cleavage of the peptide bond between L and R in 2c1 (loss of the 
fragment of RELIRTIMGW).  
3 
 
b5-H2O (m/z = 572.3) 
1) Cleavage of the peptide bond between L and R in 2c1 (loss of 
the fragment of RELIRTIMGW). 2) Loss of H2O molecule from T. 
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4 
 
a5 (m/z = 562.3) 
Cleavage of the peptide bond between L and R in 2c1 (loss of the 
fragment of RELIRTIMGW). 
5 
 
b4 (m/z = 477.2) 
Cleavage of the peptide bond between F and L in 2c1 (loss of the 
fragment of LRELIRTIMGW).  
6 
 
b3 (m/z = 330.2) 
Cleavage of the peptide bond between D and F in 2c1 (loss of the 
fragment of FLRELIRTIMGW).  
7 
 
b2-H2O (m/z = 197.1) 
1) Cleavage of the peptide bond between L and D in 2c1 (loss of 
the fragment of DFLRELIRTIMGW). 2) Loss of H2O molecule from 
T. 
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Table B.4: The expected mass of the peptides (m/z) produced by enzymatic 
hydrolysis of 15-mer cyclic peptide (2c) in the presence of chymotrypsin at 10 °C 
and pH 8.6 for 20 min. 
  
 
No Site of cleaved 
peptide bond 
m/z of the expected peptide 
1 F−L (1864.0)1+, (932.5)2+, (622)3+ 
2 W−T (1864.0)1+, (932.5)2+, (622.5)3+ 
3 W−T, F−L (495.2)1+, (1387.8)1+, (694.4)2+, (463.3)3+ 
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Trypsin + 2b at 0 min                           Trypsin + 2b at 2 mi
 
Trypsin + 2b at 4 min                           Trypsin + 2b at 6 min 
 
Trypsin + 2b at 8 min                          Trypsin + 2b at 10 min 
 
Trypsin + 2b at 15 min                         Trypsin + 2b at 20 min 
 
HPLC Chromatogram of 2b                    Blank (water + acetonitrile) 
Figure B.9: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 2b (100 µM) at 10 °C and pH 6.2 for 0, 2, 4, 6, 8, 
10, 15, 20 min.  
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Figure B.10: MS2 mass spectrum of the precursor ion 936.6 m/z (2b4) 
produced by enzymatic hydrolysis of 15-mer linear peptide (2b) in the 
presence of trypsin at 10 °C and pH 8.6 for 20 min. 
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Table B.5: Suggested structures for observed peaks (fragments) in the MS2 mass 
spectrum of precursor ion 936.6 m/z (2b4) produced by enzymatic hydrolysis of 
15-mer linear peptide (2b) in the presence of trypsin at 10 °C and pH 8.6 for 20 
min.  
No Structure of the fragment and site of the cleaved peptide bond in 2b4 
(T-I-M-G-W-T-L-D) 
1 
 
MH-H2O (m/z = 918.4) 
Loss of H2O molecule from one of the two T residues in 2b4.  
2 
 
b7 (m/z = 803.4) 
Cleavage of the peptide bond between L and D in 2b4 (loss of D). 
3 
 
b7-H2O (m/z = 785.4) 
1) Cleavage of the peptide bond between L and D in 2b4 (loss of D). 
2) Loss of H2O molecule from one of the two T residues. 
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4 
 
b7-2H2O (m/z = 767.4) 
1) Cleavage of the peptide bond between L and D in 2b4 (loss of D). 
2) Loss of 2 H2O molecules from the two T residues. 
5 
 
y6 (m/z = 722.3) 
1) Cleavage of the peptide bond between I and M in 2b4 (loss of the 
fragment of TI). 
6 
 
b6 (m/z = 690.3) 
1) Cleavage of the peptide bond between T and L in 2b4 (loss of the 
fragment of LD). 
7 
 
b6-H2O (m/z = 672.3) 
1) Cleavage of the peptide bond between T and L in 2b4 (loss of the 
fragment of LD). 2) Loss of H2O molecule from T. 
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8 
 
y5-H2O (m/z = 573.3) 
1) Cleavage of the peptide bond between M and G in 2b4 (loss 
of the fragment of TIM). 2) Loss of H2O molecule from T. 
 
Table B.6: The expected mass of the peptides (m/z) produced by enzymatic 
hydrolysis of 15-mer linear peptide (2b) in the presence of trypsin at 10 °C and 
pH 8.6 for 20 min. 
  F-L-R-E-L-I-R-T-I-M-G-W-T-L-D 
No Site of cleaved 
peptide bonds 
m/z of the expected peptide 
1 R-T (936.4)1+, (946.6)1+, (473.8)2+, (316.2)3+ 
2 R-E (435.5)1+, (218.1)2+ (1447.8)1+, (724.4)2+ 
3 R-T, R-E (435.5)1+, (218.1)2+, (530.3)1+, (265.7)1+, (936.4)1+ 
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Trypsin + 2c at 0 min                          Trypsin + 2c at 2 min 
 
Trypsin + 2c at 4 min                           Trypsin + 2c at 6 min 
 
Trypsin + 2c at 8 min                           Trypsin + 2c at 10 min 
 
Trypsin + 2c at 15 min                         Trypsin + 2c at 20 min 
 
Trypsin + 2c at 30 min                              Chromatogram of 2c  
Figure B.11: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.58 µM) and 250 µL of 2c (100 µM) at 10 °C and pH 6.2 over 0, 2, 4, 6, 8, 
10, 15, 20, 30 min.  
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Figure B.12: MS2 mass spectrum of the precursor ion 676.6 m/z (2c2) 
produced by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the 
presence of trypsin at 10 °C and pH 8.6 for 20 min. 
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Table B.7: Suggested structures for observed peaks (fragments) in the MS2 mass 
spectrum of precursor ion 676.6 m/z (2c2) produced by enzymatic hydrolysis of 
15-mer cyclic peptide (2c) in the presence of trypsin at 10 °C and pH 8.6 for 20 
min.  
No Structure of the fragment and site of the cleaved peptide bond in 2c2 
(T-I-M-G-W-T-L-D-F-L-R) 
1 
 
b10 (m/z = 1178.6) 
Cleavage of the peptide bond between L and R in 2c2 (loss of R).  
2 
 
b10-H2O (m/z = 1160.6) 
1) Cleavage of the peptide bond between L and R in 2c2 (loss of R). 2) 
Loss of H2O molecule from one of the two T residues.  
3 
 
y9 (m/z = 1138.6) 
Cleavage of the peptide bond between I and M in 2c2 (loss of the 
fragment of TI). 
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4 
 
y9-NH3 (m/z = 1121.5) 
1) Cleavage of the peptide bond between I and M in 2c2 (loss of the 
fragment of TI). 2) Loss of NH3 molecule from R.  
5 
 
y8 (m/z = 1007.5) 
Cleavage of the peptide bond between M and G in 2c2 (loss of the 
fragment of TIM). 
6 
 
y7 (m/z = 950.5) 
Cleavage of the peptide bond between G and W in 2c2 (loss of the 
fragment of TIMG). 
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7 
 
b7 (m/z = 803.4) 
Cleavage of the peptide bond between L and D in 2c2 (loss of the 
fragment of DFLR). 
8 
 
b7-H2O (m/z = 785.4) 
1) Cleavage of the peptide bond between L and D in 2c2 (loss of 
the fragment of DFLR). 2) Loss of H2O molecule from one of 
the two T residues. 
 
9 
 
y6 (m/z = 764.4) 
Cleavage of the peptide bond between W and T in 2c2 (loss 
of the fragment of TIMGW). 
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Figure B.13: MS2 mass spectrum of the precursor ion 247.0 m/z produced 
by enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the presence of 
trypsin at 10 °C and pH 8.6 for 20 min. 
 
 
Figure B.14: MS2 mass spectrum of the precursor ion 622 m/z produced by 
enzymatic hydrolysis of 15-mer cyclic peptide (2c) in the presence of 
trypsin at 10 °C and pH 8.6 for 10 min. 
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Chymotrypsin + 3b at 0 min                 Chymotrypsin + 3b at 2 min 
 
Chymotrypsin + 3b at 4 min                  Chymotrypsin + 3b at 6 min 
 
Chymotrypsin + 3b at 8 min                  Chymotrypsin + 3b at 10 min 
 
Chymotrypsin + 3b at 15 min                Chymotrypsin + 3b at 20 min 
 
Chymotrypsin + 3b at 30 min 
Figure B.15: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 3b (200 µM) at 10 °C and pH 8.6 
over 0, 2, 4, 6, 8, 10, 15, 20, 30 min. 
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Figure B.16: MS2 mass spectrum of the precursor ion 399.6 m/z (3b1) 
produced by enzymatic hydrolysis of 13-mer linear peptide (3b) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
Table B.8: Suggested structures for observed peaks (fragments) in the MS2 
mass spectrum of precursor ion 399.6 m/z (3b1) produced by enzymatic 
hydrolysis of 13-mer linear peptide (3b) in the presence of chymotrypsin at 10 °C 
and pH 8.6 for 20 min. 
No Structure of the fragment and site of the cleaved peptide bond in 3b1 
(F-L-K-S-S-K-I-M-G-W) 
1 
 
a3-NH3 (m/z = 344.2) 
1) Cleavage of the peptide bond between K and S in 3b1 (loss of the 
fragment of SKIMGW). 2) Loss of NH2 molecule from S. 
2 
 
a3 (m/z = 361.3) 
Cleavage of the peptide bond between K and S in 3b1 (loss of the 
fragment of SSKIMGW). 
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3 
 
b3 (m/z = 389.3) 
Cleavage of the peptide bond between K and S in 3b1 (loss of the 
fragment of SSKIMGW).  
4 
 
b4 (m/z = 476.3) 
Cleavage of the peptide bond between S and S in 3b1 (loss of the 
fragment of SKIMGW).  
5 
 
b5-NH3 (m/z = 546.3) 
1) Cleavage of the peptide bond between S and K in 3b1 (loss of the 
fragment of KIMGW). 2) Loss of NH3 molecule from K.  
6 
 
a6-NH3 (m/z = 646.4) 
1) Cleavage of the peptide bond between K and I in 3b1 (loss of 
the fragment of IMGW). 2) Loss of NH3 molecule from one of 
the two K residues. 
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7 
 
a6 (m/z = 663.4) 
Cleavage of the peptide bond between K and I in 3b1 (loss of the 
fragment of IMGW). 
8 
 
a7-NH3 (m/z = 759.5) 
1) Cleavage of the peptide bond between I and M in 3b1 (loss of the 
fragment of MGW). 2) Loss of NH3 molecule from one of the two K 
residues. 
9 
 
a7 (m/z = 776.5) 
Cleavage of the peptide bond between I and M in 3b1 (loss of the 
fragment of MGW). 
10 
 
MH-NH3 (m/z = 1179.6) 
Loss of NH3 molecule from one of the two K residues in 3b1. 
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Chymotrypsin + 3c at 0 min                 Chymotrypsin + 3c at 2 min 
 
Chymotrypsin + 3c at 4 min                Chymotrypsin + 3c at 6 min 
 
Chymotrypsin + 3c at 8 min                Chymotrypsin + 3c at 10 min 
 
Chymotrypsin + 3c at 15 min             Chymotrypsin + 3c at 20 min 
Figure B.17: HPLC chromatograms of the reaction between 25 µL of 
chymotrypsin (1.06 µM) and 250 µL of 3c (200 µM) at 10 °C and pH 8.6 over 
0, 2, 4, 6, 8, 10, 15, 20 min. 
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Figure B.18: MS2 mass spectrum of the precursor ion 763.5 m/z (3c1) 
produced by enzymatic hydrolysis of 13-mer cyclic peptide (3c) in the 
presence of chymotrypsin at 10 °C and pH 8.6 for 20 min. 
 
Table B.9: Suggested structures for observed peaks (fragments) in the MS2 
mass spectrum of precursor ion 763.5 m/z (3c1) produced by enzymatic 
hydrolysis of 13-mer cyclic peptide (3c) in the presence of chymotrypsin at 10 °C 
and pH 8.6 for 20 min. 
No Structure of the fragment and site of the cleaved peptide bond in 
peptide 3c1 (T-L-D-F-L-K-S-S-K-I-M-G-W) 
1 
 
y2 (m/z = 262.1) 
Cleavage of the peptide bond between M and G in 3c1 (loss of the 
fragment of TLDFLKSSKIM). 
2 
 
b3 (m/z = 330.2) 
Cleavage of the peptide bond between D and F in 3c1 (loss of the 
fragment FLKSSKIMGW). 
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3 
 
b4 (m/z = 477.2) 
Cleavage of the peptide bond between F and L in 3c1 (loss of the 
fragment of LKSSKIMGW). 
4 
 
b5-H2O (m/z = 572.3) 
1) Cleavage of the peptide bond between L and K in 3c1 (loss of 
the fragment of KSSKIMGW). 2) Loss of H2O molecule from T. 
5 
 
y7 (m/z = 808.4) 
Cleavage of the peptide bond between K and S in 3c1 (loss of the 
fragment of TLDFLK). 
6 
 
b8-NH3 (m/z = 875.5) 
1) Cleavage of the peptide bond between S and K in 3c1 (loss of the 
fragment of KIMGW). 2) Loss of NH3 molecule from K. 
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7 
 
y8 (m/z = 936.5) 
Cleavage of the peptide bond between L and K in 3c1(loss of the 
fragment of TLDFL). 
8 
 
b9 (m/z = 1020.6) 
Cleavage of the peptide bond between K and I in 3c1 (loss of the 
fragment of IMGW). 
9 
 
b10 (m/z = 1133.7) 
Cleavage of the peptide bond between I and M in 3c1 (loss of the 
fragment of MGW). 
10 
 
b11 (m/z 1264.7) 
Cleavage of the peptide bond between M and G in 3c1 (loss of the 
fragment of GW). 
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Trypsin + 3b at 0 min                            Trypsin + 3b at 2 min 
 
Trypsin + 3b at 4 min                            Trypsin + 3b at 6 min 
 
Trypsin + 3b at 8 min                           Trypsin + 3b at 10 min 
 
Trypsin + 3b at 15 min                         Trypsin + 3b at 20 min 
Figure B.19: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 3b (200 µM) at 10 °C and pH 6.2 for 0, 2, 4, 6, 8, 
10, 15, 20 min. 
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Figure B.20: MS2 mass spectrum of the precursor ion 835.5 m/z (3b4) 
produced by enzymatic hydrolysis of 13-mer linear peptide (3b) in the 
presence of trypsin at 10 °C and pH 6.2 for 20 min. 
 
Table B.10: Suggested structures for observed peaks (fragments) in the MS2 
mass spectrum of precursor ion 835.5 m/z (3b4) produced by enzymatic 
hydrolysis of 13-mer linear peptide (3b) in the presence of trypsin at 10 °C and 
pH 6.2 for 20 min. 
No Structure of the fragment and site of the cleaved peptide bond in 3b4 
(I-M-G-W-T-L-D) 
1 
 
y3-H2O (m/z = 330.2) 
1) Cleavage of the peptide bond between W and T in 3b4 (loss of the 
fragment of IMGW). 2) Loss of H2O molecule from T. 
2 
 
b4 (m/z = 488.2) 
Cleavage of the peptide bond between W and T in 3b4 (loss of the 
fragment of TLD). 
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3 
 
y5-H2O (m/z = 573.3) 
1) Cleavage of the peptide bond between M and G in 3b4 (loss of the 
fragment of IM). 2) Loss of H2O molecule from T. 
4 
 
b5 (m/z = 589.3) 
1) Cleavage of the peptide bond between T and L in 3b4 (loss of the 
fragment of LD).  
5 
 
b6-H2O (m/z = 684.4) 
1) Cleavage of the peptide bond between L and D in 3b4 (loss of D 
residue). 2) Loss of H2O molecule from T. 
6 
 
y6-H2O (m/z = 704.3) 
1) Cleavage of the peptide bond between I and M in 3b4 (loss of I 
residue). 2) Loss of H2O molecule from T.  
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7 
 
MH-H2O (m/z = 817.4) 
Loss of H2O molecule from T in 3b4.  
 
Table B.11: Expected mass of the peptides (m/z) produced by enzymatic 
hydrolysis of 3b3 which one of the two peptides was produced by enzymatic 
hydrolysis of 13-mer linear peptide (3b) in the presence of trypsin. 
  F-L-K-S-S-K 
No Sequence Expected m/z 
1 F-L-K-S-S-K (709.4)1+, (355.2)2+, (237.1)3+ 
2 F-L-K (407.3)1+, (204.1)1+ 
3 S-S-K (321.2)1+, (161.1)2+  
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Trypsin + 3c + IS at 0 min                  Trypsin + 3c + IS at 2 min 
 
Trypsin + 3c + IS at 4 min                     Trypsin + 3c + IS at 6 min 
 
Trypsin + 3c + IS at 8 min                    Trypsin + 3c + IS at 10 min 
 
Trypsin + 3c + IS at 15 min                  Trypsin + 3c + IS at 20 min 
 
Trypsin + 3c + IS at 30 min                                 3c + IS 
Figure B.21: HPLC chromatograms of the reaction between 25 µL of trypsin 
(0.41 µM) and 250 µL of 3c (200 µM) over 0, 2, 4, 6, 8, 10, 15, 20, 30 min at 
10 °C and pH 6.2. 
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 Appendix C 
 
  
 
2b + FCS + IS, 0 h                               2b + FCS + IS, 2 h 
 
2b + FCS + IS, 6 h                               2b + FCS + IS, 12 h 
 
2b + FCS + IS, 24 h                             2b + FCS + IS, 48 h 
 
2b                                                    2b + IS 
Figure C.1: HPLC chromatograms of 15-mer linear peptide (2b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
1. 
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2b + FCS + IS, 0 h                               2b + FCS + IS, 2 h 
 
 
2b + FCS + IS, 6 h                               2b + FCS + IS, 12 h 
 
 
2b + FCS + IS, 24 h                             2b + FCS + IS, 48 h 
Figure C.2: HPLC chromatograms of 15-mer linear peptide (2b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
2. 
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2b + FCS + IS, 0 h                               2b + FCS + IS, 2 h 
 
 
2b + FCS + IS, 6 h                               2b + FCS + IS, 12 h 
 
 
2b + FCS + IS, 24 h                            2b + FCS + IS, 48 h 
Figure C.3: HPLC chromatograms of 15-mer linear peptide (2b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
3. 
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Table C.1: Areas of HPLC peaks for 15-mer linear peptide (2b) during its 
incubation in 20% FCS over 0, 2, 6, 12, 24, 48 h, in addition to areas of internal 
standard peaks (IS). Three replicates. 
Time (h) 0 2 6 12 24 48 
1-2b area 1060353 1152794 921894 1096403 1144630 824034 
2-2b area 1216151 1076991 786427 1174472 1044862 811560 
3-2b area 1091345 1010859 857342 1157014 1053747 829166 
       
1-IS area 337382 391568 323417 418947 460375 332907 
2-IS area 463892 412304 304971 490114 442073 371319 
3-IS area 387259 355134 320334 501109 408962 371213 
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2c + FCS + IS, 0 h                                     2c + FCS + IS, 2 h 
 
 
2c + FCS + IS, 6 h                                     2c + FCS + IS, 12 h 
 
 
2c + FCS + IS, 24 h                                   2c + FCS + IS, 48 h 
 
  
FCS + IS 
Figure C.4: HPLC chromatograms of 15-mer cyclic peptide (2c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
1. 
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2c + FCS + IS, 0 h                               2c + FCS + IS, 2 h  
 
2c + FCS + IS, 6 h                               2c + FCS + IS, 12 h
 
2c + FCS + IS, 24 h                            2c + FCS + IS, 48 h  
Figure C.5: HPLC chromatograms of 15-mer cyclic peptide (2c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
2. 
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2c + FCS + IS, 0 h                                   2c + FCS + IS, 2 h  
 
 
2c + FCS + IS, 6 h                                   2c + FCS + IS, 12 h  
 
2c + FCS + IS, 24 h                                 2c + FCS + IS, 48 h  
Figure C.6: HPLC chromatograms of 15-mer cyclic peptide (2c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
3. 
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Table C.2: Areas of HPLC peaks for 15-mer cyclic peptide (2c) during its 
incubation in 20% FCS over 0, 2, 6, 12, 24, 48 h, in addition to areas of internal 
standard peaks (IS). Three replicates. 
Time (h) 0 2 6 12 24 48 
1-2c area 676318 945920 1012279 740087 710622 795148 
2-2c area 103559 909394 954278 859237 709379 682021 
3-2c area 796171 1001370 917499 797369 730446 778714 
       
1-IS area 300203 466554 463299 417952 401657 445004 
2-IS area 466436 455357 503516 439796 425282 429319 
3-IS area 380832 474202 468205 440702 431867 544811 
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3b + FCS + IS, 0 h                               3b + FCS + IS, 2 h 
 
 
3b + FCS + IS, 6 h                              3b + FCS + IS, 12 h 
  
 
3b + FCS + IS, 24 h                               3b + FCS + IS, 48 h 
 
 
3b 
Figure C.7: HPLC chromatograms of 13-mer linear peptide (3b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
1. 
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3b +FCS + IS, 0 h                                3b + FCS + IS, 2 h 
 
 
3b + FCS + IS, 6 h                               3b + FCS + IS, 12 h 
 
 
3b + FCS + IS, 24 h                            3b + FCS + IS, 48 h 
Figure C.8: HPLC chromatograms of 13-mer linear peptide (3b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
2. 
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3b + FCS + IS, 0 h                               3b + FCS + IS, 2 h 
    
 
3b + FCS + IS, 6 h                              3b + FCS + IS, 12 h 
 
 
3b + FCS + IS, 24 h                            3b + FCS + IS, 48 h 
Figure C.9: HPLC chromatograms of 13-mer linear peptide (3b) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
3. 
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Table C.3: Areas of HPLC peaks for 13-mer linear peptide (3b) during its 
incubation in 20% FCS for 0, 2, 6, 12, 24, 48 h, in addition to areas of internal 
standard peaks (IS). Three replicates. 
Time(h) 0 2 6 12 24 48 
1-3b area 126132 119566 115087 113814 141978 114460 
2-3b area 110195 125733 113038 133019 137947 105792 
3-3b area 114453 108317 126577 128848 124263 950324 
       
1-IS area 585737 574695 582656 617520 708190 733461 
2-IS area 541253 640569 607461 674307 735035 711365 
3-IS area 498432 514838 616992 595893 679315 622519 
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3c + FCS + IS, 0 h                                3c + FCS + IS, 2 h 
 
 
3c + FCS + IS, 6 h                               3c + FCS + IS, 12 h 
 
 
3c + FCS + IS, 24 h                             3c + FCS + IS, 48 h 
Figure C.10: HPLC chromatograms of 13-mer cyclic peptide (3c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
1. 
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3c + FCS + IS, 0 h                                3c + FCS + IS, 2 h 
 
 
3c + FCS + IS, 6 h                                3c + FCS + IS, 12 h 
 
 
3c + FCS + IS, 24 h                              3c + FCS + IS, 48 h 
Figure C.11: HPLC chromatograms of 13-mer cyclic peptide (3c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
2. 
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3c + FCS + IS, 0 h                               3c + FCS + IS, 2 h 
 
 
3c + FCS + IS, 6 h                               3c + FCS + IS, 12 h 
 
 
3c + FCS + IS, 24 h                             3c + FCS + IS, 48 h 
Figure C.12: HPLC chromatograms of 13-mer cyclic peptide (3c) during its 
incubation in 20% FCS at 37 °C and pH 7.4 for 2, 6, 12, 24, 48 h. Replicate 
3. 
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Table C.4: Areas of HPLC peaks for 13-mer cyclic peptide (3c) during its 
incubation in 20% FCS for 0, 2, 6, 12, 24, 48 h, in addition to areas of internal 
standard peaks (IS). Three replicates. 
Time (h) 0 2 6 12 24 48 
1-3c area 104506 102887 103335 109229 145597 108236 
2-3c area 120395 131932 100142 985131 127776 131245 
3-3c area 114401 960511 147288 129664 721572 143802 
       
1-IS area 487721 534109 563335 539081 756118 610875 
2-IS area 576304 709146 460786 449606 615745 656197 
3-IS area 540835 436066 659662 491577 299432 789580 
 
 
 
 
 
